Contribution Agreement with Frontier Renewable



 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

Exhibit 10.19 
 CONTRIBUTION AGREEMENT 
 THIS CONTRIBUTION AGREEMENT is made and entered
into as of December 2, 2011, by and among Frontier Renewable Resources, LLC, a Delaware limited liability company (the “Frontier Member” ), Diamond Alternative Energy, LLC, a Delaware limited liability company (the
“Valero Member” ), Mascoma Corporation, a Delaware corporation ( “Mascoma” ), Valero Services, Inc., a Delaware corporation ( “Valero Services” ), Valero Marketing and Supply Company, a Delaware
corporation ( “VMSC” ), JML Heirs, LLC, a Michigan limited liability company ( “JML” ), and Kinross Cellulosic Ethanol LLC, a Delaware limited liability company (the “Company” ). 

WHEREAS, the Frontier Member and the Valero Member have formed the Company and have entered into that certain Limited Liability Company
Agreement, dated as of the date hereof, by and among the Company, the Frontier Member and the Valero Member (the “JV Agreement” ), for the purpose of engaging in the Business; 

WHEREAS, the parties hereto desire to set forth their agreement with respect to the contribution of certain cash amounts and other
property and the execution and/or delivery of certain agreements and other documentation, and the timing thereof, among other things, in order to facilitate the construction of the Facility and the operation of the Business, all upon the terms and
subject to the conditions contained in this Agreement; and 
 WHEREAS, each capitalized term used but not otherwise defined
herein shall have the meaning ascribed thereto in the JV Agreement; 
 NOW, THEREFORE, in consideration of the mutual covenants
contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 

ARTICLE I. 

DEFINITIONS 
 1.1 Defined Terms. As used herein, the following terms shall have the following meanings, unless the context otherwise requires: 

“Agreement” means this Contribution Agreement, as amended or modified from time to time in accordance with the terms
hereof. 
 “Ancillary Agreement” means each of the Development Agreement, Technology License Agreement,
Subgrant Agreement, Construction Management Agreement, Ethanol Marketing Agreement, Fee and Royalty Agreement, Enzyme Agreements, Warrant Purchase Agreement, Tranche 2-A Warrant, O&M Agreement, Valero Parent Guaranty, Frontier Member Assignment,
Valero Member Assignment, Frontier Member License Agreement, Valero Member License Agreement, and the Insurance Program Agreement. 
 “Charter Documents” means the limited liability company agreement, limited partnership agreement, certificate or articles of incorporation, certificate of formation, certificate of
limited 

  
 1 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

partnership, bylaws or other governing documents, as applicable, of the Person in question, as may be in effect from time to time. 

“Claim” means any claim, action, suit, inquiry, indictment, demand, hearing, investigation, legal proceeding or
administrative enforcement proceeding by or before any Governmental Entity or any arbitration proceeding as to which a Contract applies. 
 “Closing” has the meaning set forth in Section 2.1. 

“Closing Date” has the meaning set forth in Section 2.1. 

“Commitment” has the meaning set forth in Section 6.3(b). 

“Construction Management Agreement” means a Construction Management Agreement in form and substance agreed to by the
Valero Member and the Frontier Member, each in their sole discretion. 
 “Contract” means any contract, lease,
license, note, mortgage, indenture, arrangement or other agreement or obligation (including any amendments and other modifications thereto) to which the applicable Person or any of its subsidiaries is a party that are in effect and are legally
binding, whether written or oral. 
 “Deed” means a covenant deed, substantially in the form of Exhibit D, with
such changes as may be reasonably agreed. 
 “Development Agreement” means a Development Agreement in form and
substance agreed to by the Valero Member and the Frontier Member, each in their sole discretion. 
 “Enzyme
Agreements” means agreements for the manufacture and supply of enzymes to the Facility (including any associated research and development agreements) in form and substance agreed to by the Valero Member and the Frontier Member, each in
their sole discretion. 
 “Ethanol Marketing Agreement” means an Ethanol Marketing Agreement in form and
substance agreed to by VMSC and the Frontier Member, each in their sole discretion. 
 “Existing Reports” has
the meaning set forth in Section 6.6(b). 
 “Fee and Royalty Agreement” means the Fee and Royalty
Agreement in the form attached hereto as Exhibit A. 
 “Frontier Member Assignment” means an assignment
agreement providing for, among other things, (i) the assignment of certain assets that have been and/or will be developed by the Frontier Member that relate to the construction of the Facility and the operation of the Business and
(ii) representations and warranties regarding such assets with indemnities and limitations of liability related thereto, such agreement in form and substance agreed to by the Valero Member and the Frontier Member, each in their sole discretion.


  
 2 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

“Frontier Member License Agreement” means a License Agreement between the Company and the Frontier Member in form and
substance agreed to by the Valero Member and the Frontier Member, each in their sole discretion. 
 “Frontier
Parties” means the Frontier Member, Mascoma and JML. 
 “Hazardous Materials” has the meaning set
forth in Section 4.4(g). 
 “Indemnitee” has the meaning set forth in Section 8.1.

 “Indemnitor” has the meaning set forth in Section 8.1. 

“Insurance Program Agreement” means an agreement that sets forth the program for insurance for the Company and its
members in form and substance agreed to by the Valero Member and the Frontier Member, each in their sole discretion. 

“JV Agreement” has the meaning set forth in the recitals. 

“Knowledge” means an individual will be deemed to have “Knowledge” of a particular fact or other matter if
such individual is actually aware of such fact or other matter. A Frontier Party will be deemed to have “Knowledge” of a particular fact or other matter if William Brady, Stephen Hicks, Justin van Rooyen, or Emily MacDonald has Knowledge
of such fact or matter. A Valero Party shall be deemed to have Knowledge of a particular fact or other matter if George Stutzmann, Lee Morris or Robert Buchek has Knowledge of such fact or matter. JML will be deemed to have “Knowledge” of
a particular fact or other matter if Stephen J. Hicks or Art Abramson has Knowledge of such fact or matter. 

“Lien” means any lien, encumbrance, pledge, mortgage, deed of trust, security interest, claim, lease, charge, option,
right of first refusal, easement, servitude, proxy, voting trust or agreement, transfer restriction under any shareholder or similar agreement, encumbrance or any other restriction or limitation whatsoever, direct or indirect, whether accrued,
absolute, contingent, or otherwise. 
 “Losses” means any and all Claims, assessments, costs, disbursements,
losses, diminution in value, liabilities, obligations, fines, charges, penalties, awards, damages and expenses (including reasonable attorneys’ fees and expenses), but shall not include any punitive damages arising from the actions of the Party
incurring such Losses. 
 “Material Adverse Effect” means a material adverse effect on (i) the near-term
or long-term projected business, assets, properties, results of operations, condition (financial or otherwise) or prospects of the Company or (ii) with respect to any of the Frontier Parties or any of the Valero Parties, as applicable, its
ability to consummate the transactions contemplated by this Agreement or perform any of its obligations under this Agreement or the Ancillary Agreements to which it is a party. 

“Michigan Grant Cash Amount” means an amount in cash received from the Michigan Grant Program to be agreed by the
Frontier Member and the Valero Member. 

  
 3 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

“Notice” has the meaning set forth in Section 8.3. 

“O&M Agreement” means an Operating, Maintenance and Management Agreement in form and substance agreed to by the
Valero Member and the Frontier Member, each in their sole discretion. 
 “Permit” means any license, permit,
authorization, franchise, concession, certificate of authority, approval, registration, qualification or similar document or authority that has been issued or granted by any Governmental Entity, or other similar right, including any related
financial security in the form of a surety bond, letter of credit, cash collateral or similar instrument made a condition of or relating to such authorizations. 
 “Permitted Exceptions” has the meaning set forth in Section 6.4(a). 
 “Permitted Liens and Encumbrances” means (a) liens for current taxes not yet due and payable, (b) easements, restrictions, encroachments, protrusions and other similar minor
title defects affecting the Real Property (none of which is material in adverse effect, materially detracts from the value of the Real Property, or materially impairs the use of the Real Property for the Business), and (c) zoning laws and other
land use restrictions that do not impair the use of the Real Property for the Business. 
 “Property
Inspection” has the meaning set forth in Section 6.6(a). 
 “Property Taxes” means all
property taxes, whether real or personal, attributable to the Real Property plus any taxable personal property located thereupon, whether or not such real or personal property is on the ad valorem property tax rolls. Property Taxes do not include
any special assessment or portion thereof. Property Taxes do not include any taxes, fees, assessments or any other obligations arising from or payable under the Michigan Business Tax Act (Act 36 of 2007) or the Michigan Income Tax Act of 1967 (Act
281 of 1967, as amended, including but not limited to Act 38 of 2011), including any amendment to, or replacement for, those acts. 
 “Real Property” means the real property described on Schedule 1 attached hereto. 
 “Subgrant Agreement” means a Subgrant Agreement in form and substance agreed to by the Valero Member and the Frontier Member, each in their sole discretion. 

“Survey” has the meaning set forth in Section 6.3(a). 

“Technology License Agreement” means the Technology License and Supply Agreement in the form attached hereto as
Exhibit B. 
 “Title and Survey Objections” has the meaning set forth in Section 6.4(a).

 “Title and Survey Review Period” means the thirty (30) day period commencing upon the Company’s
receipt of the latest to be received of the Commitment, the Title Documents and the Survey. 

  
 4 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

“Title Company” means a Copper Range Abstract & Title Agency, Inc. as agent for Commonwealth Land Title
Insurance Company. 
 “Title Documents” has the meaning set forth in Section 6.3(b). 

“Title Policy” has the meaning set forth in Section 6.3(b). 

“Third Party Claim” has the meaning set forth in Section 8.4. 

“Third Party Claim Notice” has the meaning set forth in Section 8.4(a). 

“Tranche 2-A Warrant” means the Tranche 2-A Warrant in the form attached to the Warrant Purchase Agreement. 

“Valero Cash Amount” means an amount in cash equal to the Michigan Grant Cash Amount. 

“Valero Member Assignment” means an assignment agreement providing for, among other things, (i) the assignment of
certain assets that have been and/or will be developed by the Valero Member that relate to the construction of the Facility and the operation of the Business and (ii) representations and warranties regarding such assets with indemnities and
limitations of liability related thereto, such agreement in form and substance agreed to by the Valero Member and the Frontier Member, each in their sole discretion. 
 “Valero Member License Agreement” means a License Agreement between the Company and the Valero Member in form and substance agreed to by the Valero Member and the Frontier Member, each in
their sole discretion. 
 “Valero Member’s Experts” has the meaning set forth in
Section 6.6(a). 
 “Valero Parent Guaranty” means a guarantee from Valero Parent to and for the
benefit of the Frontier Member and the Company in form and substance agreed to by the Valero Parent and the Frontier Member, each in their sole discretion. 
 “Valero Parties” means the Valero Member, Valero Services and VMSC. 
 “Warrant Purchase Agreement” means the Warrant Purchase Agreement in the form attached hereto as Exhibit C. 
 ARTICLE II. 
 CLOSING; DELIVERABLES 

2.1 Closing Date. Except with respect to the execution and delivery of the JV Agreement, which shall be executed and delivered
concurrent with the execution and delivery of this Agreement, the closing of the transactions contemplated by this Agreement (the “Closing” ) shall take place electronically and/or via courier service on the third Business Day after
the conditions set forth in Article V have been satisfied or waived by the party entitled to do so, or at such other date, time and/or place as may mutually be agreed upon by the parties hereto. The 

  
 5 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

parties anticipate that the Closing would be held no later than February 21, 2012 The date on which the Closing is held is referred to in this
Agreement as the “Closing Date.” 
 2.2 Items to Be Delivered Concurrent with the Execution of this
Agreement. Concurrently with the execution of this Agreement, the Company, the Valero Member and the Frontier Member shall execute and deliver to each other the JV Agreement. 

2.3 Items to Be Delivered by the Valero Member at Closing. Simultaneously with the Closing, the Valero Member shall execute and/or
deliver, for itself and/or as Manager of the Company, or cause to be executed and delivered: 
 (a) to the Company, (I) the
Valero Parent Guaranty, (II) the Valero Member Assignment, (III) the O&M Agreement, (IV) the Valero Member License Agreement, (V) the Insurance Program Agreement, and (VI) the Valero Cash Amount; 

(b) to the Frontier Member, (I) the Development Agreement, (II) the Subgrant Agreement (III) the Valero Parent Guaranty, (IV) the
Frontier Member License Agreement, and (V) the Insurance Program Agreement; 
 (c) to Mascoma, (I) the Technology
License Agreement, (II) the Subgrant Agreement, (III) the Fee and Royalty Agreement, (IV) the Warrant Purchase Agreement, and (V) the Tranche 2-A Warrant. 
 (d) to Valero Services, the Construction Management Agreement; 
 (e) to the Valero
Member, (I) the O&M Agreement and (II) the Valero Member License Agreement; 
 (f) to VMSC, the Ethanol Marketing
Agreement; and 
 (g) to the Company and the Frontier Member, the certificate contemplated by Section 5.2(c).

 2.4 Items to Be Delivered by the Frontier Member at Closing. Simultaneously with the Closing, the Frontier Member
shall execute and deliver or cause to be executed and delivered: 
 (a) to the Company, (I) the Michigan Grant Cash Amount,
(II) the Frontier Member Assignment, (III) the Subgrant Agreement, (IV) the Development Agreement, (V) the Frontier Member License Agreement, and (VI) the Insurance Program Agreement; 

(b) to the Valero Member, the Insurance Program Agreement; 
 (c) to Mascoma, the Subgrant Agreement; and 
 (d) to the Company and the
Valero Member, the certificate contemplated by Section 5.1(c). 

  
 6 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

2.5 Items to Be Delivered by Mascoma at Closing. Simultaneously with the Closing. Mascoma shall execute and deliver or cause to be
executed and delivered: 
 (a) to the Company, (I) the Technology License Agreement, and (II) the Subgrant Agreement;

 (b) to the Valero Member, (I) the Fee and Royalty Agreement, (II) the Warrant Purchase Agreement, and (III) the
Tranche 2-A Warrant; 
 (c) to the Frontier Member, the Subgrant Agreement; 

(d) to the Company and the Valero Member, the certificate contemplated by Section 5.1(d); and 

2.6 Items to Be Delivered by Valero Services at Closing. Simultaneously with the Closing, Valero Services shall execute and
deliver or cause to be executed and delivered: 
 (a) to the Company, the Construction Management Agreement; and 

(b) to the Company and the Frontier Member, the certificate contemplated by Section 5.2(d). 

2.7 Items to Be Delivered by VMSC at Closing. Simultaneously with the Closing, VMSC shall execute and deliver or cause to be
executed and delivered: 
 (a) to the Company, the Ethanol Marketing Agreement; and 

(b) to the Company and the Frontier Member, the certificate contemplated by Section 5.2(e). 

2.8 Items to Be Delivered by JML at Closing. Simultaneously with the Closing, JML shall execute and/or deliver or cause to be
executed and/or delivered with respect to the contribution of the Real Property (which is being made by JML for the account of the Frontier Member), to the Company and the Title Company, as applicable, (I) the Deed, (II) an Affidavit of JML
certifying that JML is not a “foreign person” as defined in the Federal Foreign Investment and Real Property Tax Act of 1980, and the 1984 Tax Reform Act, as amended, (III) the Title Policy, and (IV) such other documents and instruments as
are reasonably required by the Title Company in connection with the issuance of its title insurance policy to the Company. 

ARTICLE III. 
 REPRESENTATIONS AND WARRANTIES OF THE VALERO PARTIES 
 Through the delivery
of the certificates contemplated in Section 5.2, the Valero Parties will, effective as of the Closing Date and not as of the date of this Agreement, represent and warrant to the Company and the Frontier Member that: 

3.1 Existence and Good Standing; Ownership. Each of the Valero Parties is duly formed, validly existing and in good standing under
the Applicable Laws of its jurisdiction of 

  
 7 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

incorporation or organization and is duly qualified to do business, and is in good standing, in each jurisdiction in which the character of the properties
owned or leased by it or in which the conduct of its business requires it to be so qualified, except where the failure to be so qualified or to be in good standing would not have a Material Adverse Effect. Each of the Valero Parties has all
requisite power and authority to own, lease and operate its properties and assets and to carry on its business as currently conducted in all material respects. 
 3.2 Authorization of Agreement. Each of the Valero Parties has all requisite corporate or similar entity power and authority to enter into this Agreement and has all requisite corporate or similar
entity power and authority to perform all of its obligations hereunder. The Valero Member has all requisite corporate or similar entity power and authority to enter into the JV Agreement and has all requisite corporate or similar entity power and
authority to perform its obligations thereunder. At or prior to the Closing, each of the Valero Parties will have all requisite corporate or similar entity power and authority to enter into each Ancillary Agreement to which it is a party and will
have all requisite corporate or similar entity power and authority to perform all of its obligations thereunder. Each of the Valero Parties has taken all action necessary to authorize the execution, deliver and performance of this Agreement and the
JV Agreement (to the extent a party thereto). At or prior to the Closing, each of the Valero Parties will have taken all action necessary to authorize the execution, delivery and performance of each of the Ancillary Agreements to which it is a
party. 
 (b) This Agreement has been, and each of the Ancillary Agreements shall be at or prior to the Closing, duly executed
and delivered by each of the Valero Parties (to the extent a party thereto) and, assuming the due authorization, execution and delivery by the other parties hereto and thereto, constitutes, and each of the Ancillary Agreements when so executed and
delivered shall constitute, a legal, valid and binding obligation of each of the Valero Parties (to the extent a party thereto), enforceable in accordance with its terms, subject to (i) bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium and other similar Applicable Laws relating to or affecting the rights of creditors generally, and (ii) limitations imposed by Applicable Law or equitable principles upon the enforceability of any of the remedies,
covenants or other provisions of this Agreement or such Ancillary Agreements and upon the availability of injunctive relief or other equitable remedies. 
 3.3 Conflicts; Consents of Third Parties. 
 (a) The execution, delivery and
performance of this Agreement and the JV Agreement do not, and the execution, delivery and performance of any of the Ancillary Agreements to which any of the Valero Parties is a party will not, conflict with or result in a violation of (i) the
Charter Documents of the Valero Parties, (ii) any Applicable Law, order or Permit applicable to the Valero Parties or any of their assets and properties, or (iii) currently or with the passage of time, any Contract or Permit to which any
of the Valero Parties is a party or by which any of its properties or assets are bound (or result in the creation or imposition of a Lien upon any material property or assets of the Valero Parties), other than, in the case of clauses (ii) and
(iii), any conflict, violation or Lien that would not have a Material Adverse Effect. There are no Claims pending or, to the Knowledge of the Valero Parties, threatened against the Valero Parties relating to or affecting the Valero Parties or any of
their assets and properties that could reasonably be expected to result in the issuance of an order (i) restraining, enjoining or otherwise 

  
 8 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

prohibiting or making illegal the consummation of any of the transactions contemplated by this Agreement or any of the Ancillary Agreements to which any
of the Valero Parties is a party or (ii) that would be likely to result in a Material Adverse Effect. 
 (b) The execution
and delivery of this Agreement and the JV Agreement do not, and the execution and delivery of each of the Ancillary Agreements to which any of the Valero Parties is a Party will not, require the Valero Parties to obtain any approval or consent of,
or make any notice to or filing with, any Person or Governmental Entity, other than approvals, consents, notices and filings obtained or made prior to the Closing Date or as may be listed on Schedule 3.3(b) which may be delivered by the
Valero Parties to the Company prior to the Closing and attached hereto. 
 ARTICLE IV. 

REPRESENTATIONS AND WARRANTIES OF THE FRONTIER PARTIES 
 Through the delivery of the certificates contemplated in Section 5.1, each of the Frontier Parties will, effective as of the Closing Date and not as of the date of this Agreement, represent
and warrant to the Company and the Valero Member the matters set forth in Section 4.1, Section 4.2 and Section 4.3 below. Each of the Frontier Parties will make such representations and warranties only with
respect to itself. Through the delivery of the certificate contemplated in Section 5.1, the Frontier Member and/or JML, as the case may be, will, effective as of the Closing Date and not as of the date of this Agreement, represent and
warrant to the Company and the Valero Member the matters set forth in Section 4.4 below. For the avoidance of doubt, representations and warranties with respect to the Frontier Member, JML and the Real Property set forth in
Section 4.4 shall be deemed made solely by the Frontier Member and/or JML, as the case may be, and Mascoma shall not have responsibility therefor. 
 4.1 Existence and Good Standing; Ownership. Each of the Frontier Parties is duly formed, validly existing and in good standing under the Applicable Laws of its jurisdiction of incorporation or
organization and is duly qualified to do business, and is in good standing, in each jurisdiction in which the character of the properties owned or leased by it or in which the conduct of its business requires it to be so qualified, except where the
failure to be so qualified or to be in good standing would not have a Material Adverse Effect. Each of the Frontier Parties has all requisite power and authority to own, lease and operate its properties and assets and to carry on its business as
currently conducted in all material respects. 
 4.2 Authorization of Agreement. 

(a) Each of the Frontier Parties has all requisite corporate or similar entity power and authority to enter into this Agreement and has
all requisite corporate or similar entity power and authority to perform all of its obligations hereunder. The Frontier Member has all requisite corporate or similar entity power and authority to enter into the JV Agreement and has all requisite
corporate or similar entity power and authority to perform its obligations thereunder. At or prior to the Closing, each of the Frontier Parties will have all requisite corporate or similar entity power and authority to enter into each Ancillary
Agreement to which it is a party and will have all requisite corporate or similar entity power and authority to perform all of its obligations thereunder. Each of the Frontier Parties has taken all action necessary to authorize the execution,


  
 9 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

deliver and performance of this Agreement and the JV Agreement (to the extent a party thereto). At or prior to the Closing, each of the Frontier Parties
will have taken all action necessary to authorize the execution, delivery and performance of each of the Ancillary Agreements to which it is a party. 
 (b) This Agreement has been, and each of the Ancillary Agreements shall be at or prior to the Closing, duly executed and delivered by each of the Frontier Parties (to the extent a party thereto) and,
assuming the due authorization, execution and delivery by the other parties hereto and thereto, constitutes, and each of the Ancillary Agreements when so executed and delivered shall constitute, a legal, valid and binding obligation of each of the
Frontier Parties (to the extent a party thereto), enforceable in accordance with its terms, subject to (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Applicable Laws relating to or affecting the
rights of creditors generally, and (ii) limitations imposed by Applicable Law or equitable principles upon the enforceability of any of the remedies, covenants or other provisions of this Agreement or such Ancillary Agreements and upon the
availability of injunctive relief or other equitable remedies. 
 4.3 Conflicts; Consents of Third Parties. 

(a) The execution, delivery and performance of this Agreement and the JV Agreement do not, and the execution, delivery and performance of
any of the Ancillary Agreements to which any of the Frontier Parties is a party will not, conflict with or result in a violation of (i) the Charter Documents of the Frontier Parties, (ii) any Applicable Law, order or Permit applicable to
the Frontier Parties or any of their assets and properties, or (iii) currently or with the passage of time, any Contract or Permit to which any of the Frontier Parties is a party or by which any of its properties or assets, including the Real
Property, are bound (or result in the creation or imposition of a Lien upon any material property or assets of the Frontier Parties, including the Real Property), other than, in the case of clauses (ii) and (iii), any conflict, violation or
Lien that would not have a Material Adverse Effect. There are no Claims pending or, to the Knowledge of the Frontier Parties, threatened against the Frontier Parties relating to or affecting the Frontier Parties or any of their assets and properties
that could reasonably be expected to result in the issuance of an order (i) restraining, enjoining or otherwise prohibiting or making illegal the consummation of any of the transactions contemplated by this Agreement or any of the Ancillary
Agreements to which any of the Frontier Parties is a party or (ii) that would be likely to result in a Material Adverse Effect. 
 (b) The execution and delivery of this Agreement and the JV Agreement do not, and the execution and delivery of each of the Ancillary Agreements to which any of the Frontier Parties is a Party will not,
require the Frontier Parties to obtain any approval or consent of, or make any notice to or filing with, any Person or Governmental Entity, other than approvals, consents, notices and filings obtained or made prior to the Closing Date or as may be
listed on Schedule 4.3(b) which may be delivered by the Frontier Parties to the Company prior to the Closing and attached hereto. 

  
 10 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

4.4 Real Property. 
 (a) JML represents and warrants that JML has good and marketable title to the Real Property, subject to no Liens of any kind in, to or on said Real Property, except for the Permitted Exceptions, Permitted
Liens and Encumbrances and as may otherwise be shown on the Commitment. 
 (b) No Claims are pending or, to the Knowledge of the
Frontier Member and JML, threatened, against the Real Property, or to the Knowledge of JML threatened against JML, which could reasonably be expected to have a material adverse effect on development or use of the Real Property for the anticipated
Facility. 
 (c) The Frontier Member represents and warrants that it has not received any written notice of nor, to the
Knowledge of the Frontier Member, is there any pending or contemplated condemnation, eminent domain or similar proceeding affecting the Real Property or any part thereof. JML represents and warrants that it has not received any written notice of
nor, to the Knowledge of JML, is there any pending or threatened condemnation, eminent domain, or similar proceeding affecting the Real Property or any part thereof. 
 (d) JML represents and warrants with respect to itself and the Frontier Member represents and warrants with respect to itself that it has complied and is in compliance in all material respects with all
Applicable Laws and all restrictive and/or protective covenants applicable to the Real Property, except such noncompliance that could not reasonably be expected to have a material adverse effect on development or use of the Real Property for the
anticipated Facility. 
 (e) Except for an Access Agreement dated as of June 24, 2010, with the Frontier Member or as
disclosed herein or provided to the Company in writing pursuant to this Agreement, (i) JML represents and warrants that there are no contracts, arrangements or commitments of JML in connection with the Real Property and there are no leases or
any other parties in possession of the Real Property or having any rights to possession of the Real Property, and (ii) the Frontier Member represents and warrants that there are no contracts, arrangements or commitments of the Frontier Member
in connection with the Real Property and that there are no leases or any other parties in possession of the Real Property or having any rights to possession of the Real Property. No party has any option to acquire or lease all or any part of the
Real Property except as contemplated in this Agreement. 
 (f) (i) There are no unpaid assessments (governmental or otherwise)
for sewer, water, paving, electrical power, improvements or otherwise incurred or levied or otherwise affecting the Real Property except as may otherwise be shown on the Commitment; (ii) to the Knowledge of JML, no such assessments are
threatened; (iii) to the Knowledge of the Frontier Member, no such assessments are threatened; and (iv) JML represents and warrants with respect to itself and the Frontier Member represents and warrants with respect to itself that it has
made no commitments (other than payment of taxes) to any government authority, utility company, religious body, home-owners group or association, or any other entity relating to the Real Property which would impose an obligation on the Company or
its successors or assigns to make any contribution or dedication of money or land or to construct or maintain any improvements of a 

  
 11 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


public or private nature on or off of the Real Property, except such commitments as may be contemplated by the Renaissance Zone Development Agreement: Renewable Energy Facility, dated
December 7, 2010, among the Michigan Strategic Fund, Longyear Realty Corporation (a party related to JML) and the Frontier Member, as it may be modified (“RZDA”), the Michigan Grant Program, this Agreement or the JV Agreement.

 (g) To the Knowledge of JML, the Real Property is free from and has not been used for the storage, holding, existence,
manufacture, release, treatment, abatement, removal, disposition, handling, transportation, or disposal of any Hazardous Materials from, under, into, or on the Real Property, other than the use, handling, storage, or sale of any such materials in
not significant quantities in the ordinary course of business and in accordance with all Applicable Laws. To the Knowledge of the Frontier Member, the Real Property is free from and has not been used for the storage, holding, existence, manufacture,
release, treatment, abatement, removal, disposition, handling, transportation, or disposal of any Hazardous Materials from, under, into, or on the Real Property, other than the use, handling, storage, or sale of any such materials in not significant
quantities in the ordinary course of business and in accordance with all Applicable Laws. “Hazardous Materials” means (i) any “hazardous waste” as defined by the Resource Conservation and Recovery Act of 1976 (42
U.S.C. Section 6901 et seq.), as amended from time to time, and the regulations promulgated thereunder (“RCRA”); (ii) any “hazardous substance” as defined by the Comprehensive Environmental
Response, Compensation and Liability Act of 1980 (42 U.S.C. Section 9601 et seq.) (“CERCLA”), as amended from time to time, and the regulations promulgated thereunder; (iii) any petroleum-based products;
(iv) any substance which by any applicable governmental requirements requires special handling or notification of any federal, state or local governmental entity in its collection, storage, treatment, or disposal; and (vi) any other
substances which are now classified or considered to be hazardous or toxic under applicable governmental requirements. 

ARTICLE V. 

CONDITIONS TO CLOSING 
 5.1 Conditions Precedent to Obligations of the Valero Parties. The obligations of the Valero Parties to consummate the transactions contemplated by this Agreement are subject to the fulfillment,
prior to or on the Closing Date, of each of the following conditions (any or all of which may be waived expressly in writing by the Valero Parties in whole or in part to the extent permitted by Applicable Law): 

(a) each of the representations and warranties of the Frontier Parties contained in Article IV and qualified as to materiality
shall be true and correct as of the Closing Date, and all representations and warranties of the Frontier Parties contained in Article IV and not qualified as to materiality shall be true and correct in all material respects as of the Closing
Date; 
 (b) the Frontier Parties shall have performed and complied in all material respects with all obligations and covenants
required by this Agreement to be performed or complied with by them on or prior to the Closing Date; 

  
 12 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

(c) the Company and the Valero Member shall have been furnished with a certificate (dated the Closing Date and in form and substance
reasonably satisfactory to the Valero Member) executed by the chief executive officer of the Frontier Member certifying as to the fulfillment of the conditions specified in Sections 5.1(a) and 5.1(b) that are applicable to the Frontier
Member; 
 (d) the Company and the Valero Member shall have been furnished with a certificate (dated the Closing Date and in
form and substance reasonably satisfactory to the Valero Member) executed by the chief executive officer of Mascoma certifying as to the fulfillment of the conditions specified in Sections 5.1(a) and 5.1(b) that are applicable to
Mascoma; 
 (e) the Company and the Valero Member shall have been furnished with a certificate (dated the Closing Date and in
form and substance reasonably satisfactory to the Valero Member) executed by the chief executive officer of JML certifying as to the fulfillment of the conditions specified in Sections 5.1(a) and 5.1(b) that are applicable to JML;

 (f) the Frontier Member shall have executed and/or delivered to the Company and, if applicable, the Valero Member at the
Closing all of the documents required to be executed and/or delivered by the Frontier Member pursuant to Section 2.4; 
 (g) Mascoma shall have executed and/or delivered to the Company and, if applicable, the Valero Member at the Closing all of the documents required to be executed and/or delivered by Mascoma pursuant to
Section 2.5; 
 (h) JML shall have executed and/or delivered to the Company at the Closing all of the documents
required to be executed and/or delivered by JML pursuant to Section 2.8; 
 (i) The respective executive management
and/or boards (or other governing bodies) of Valero Energy Corporation, Valero Services, VMSC, and the Valero Member shall have approved, which approval may be given or not given in each such executive management’s and/or board’s sole
discretion, the Ancillary Agreements; 
 (j) no Claim shall have been instituted or threatened or Claim made against any of the
Frontier Parties, the Valero Parties or the Company seeking to restrain or prohibit or obtain substantial damages with respect to the consummation of the transactions contemplated hereby or by the JV Agreement, and there shall not be in effect any
order by a Governmental Entity of competent jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the transactions contemplated hereby or by the JV Agreement; 

(k) the Title and Survey Review Period shall have ended; 
 (l) the Company and other appropriate parties shall have executed and delivered at the Closing the Enzyme Agreements; 
 (m) the U.S. Department of Energy and Mascoma shall have entered into at or prior to the Closing a Cooperative Agreement and associated Special Terms and Conditions in form and substance agreed to by the
Valero Member, in its sole discretion; 

  
 13 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

(n) the Valero Member shall have received (i) bids for the engineering, procurement, and construction of the Facility that are
satisfactory in the sole discretion of the Valero Member and (ii) the form of the EPC Contract, in form and substance agreed by the Valero Member in its sole discretion; 
 (o) the business plan contained in the Project Execution Plan shall have been completed to the satisfaction of the Valero Member in its sole discretion; 

(p) the Valero Member shall be satisfied, in its sole discretion, that the RZDA is in full force and effect and is valid and enforceable
in accordance with its terms; and 
 (q) the Valero Member shall be fully and finally satisfied, in its sole discretion, with
all legal, accounting, tax, commercial, operational and other diligence with respect to (i) the Frontier Parties, (ii) each of the Frontier Parties’ respective assets to be utilized by the Company, (iii) the Facility, and
(iv) the proposed development and operation of the Business. 
 5.2 Conditions Precedent to Obligations of the Frontier
Parties. The obligations of the Frontier Parties to consummate the transactions contemplated by this Agreement are subject to the fulfillment, prior to or on the Closing Date, of each of the following conditions (any or all of which may be
waived expressly in writing by the Frontier Member in whole or in part to the extent permitted by Applicable Law): 
 (a) each
of the representations and warranties of the Valero Parties contained in Article III and qualified as to materiality shall be true and correct as of the Closing Date, and all representations and warranties of the Valero Parties contained in
Article III and not qualified as to materiality shall be true and correct in all material respects as of the Closing Date; 
 (b) the Valero Parties shall have performed and complied in all material respects with all obligations and covenants required by this Agreement to be performed or complied with by them on or prior to the
Closing Date; 
 (c) the Company and the Frontier Member shall have been furnished with a certificate (dated the Closing Date
and in form and substance reasonably satisfactory to the Frontier Member) executed by an officer of the Valero Member certifying as to the fulfillment of the conditions specified in Sections 5.2(a) and 5.2(b); 

(d) the Company and the Frontier Member shall have been furnished with a certificate (dated the Closing Date and in form and substance
reasonably satisfactory to the Frontier Member) executed by an officer of Valero Services certifying as to the fulfillment of the conditions specified in Sections 5.2(a) and 5.2(b); 

(e) the Company and the Frontier Member shall have been furnished with a certificate (dated the Closing Date and in form and substance
reasonably satisfactory to the Frontier Member) executed by an officer of VMSC certifying as to the fulfillment of the conditions specified in Sections 5.2(a) and 5.2(b); 

  
 14 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

(f) the Valero Member shall have executed and/or delivered to the Company and, if applicable, the Frontier Member and/or Mascoma at the
Closing all of the documents required to be executed and/or delivered by the Valero Member pursuant to Section 2.3; 

(g) Valero Services shall have executed and/or delivered to the Company and, if applicable, the Frontier Member at the Closing all of the
documents required to be executed and/or delivered by Valero Services pursuant to Section 2.6; 
 (h) VMSC shall
have executed and/or delivered to the Company and, if applicable, the Frontier Member at the Closing all of the documents required to be executed and/or delivered by VMSC pursuant to Section 2.7; and 

(i) The respective executive management and/or boards (or other governing bodies) of the Frontier Parties (as applicable) shall have
approved, which approval may be given or not given in each such executive management’s and/or board’s sole discretion, the Ancillary Agreements; 
 (j) no Claim shall have been instituted or threatened or Claim made against any of the Frontier Parties, the Valero Parties or the Company seeking to restrain or prohibit or obtain substantial damages
with respect to the consummation of the transactions contemplated hereby or by the JV Agreement, and there shall not be in effect any order by a Governmental Entity of competent jurisdiction restraining, enjoining or otherwise prohibiting the
consummation of the transactions contemplated hereby or by the JV Agreement; 
 (k) the U.S. Department of Energy and Mascoma
shall have entered into at or prior to the Closing a Cooperative Agreement and associated Special Terms and Conditions in form and substance agreed to by the Frontier Member, in its sole discretion; 

(l) the Frontier Member shall have received (i) bids for the engineering, procurement, and construction of the Facility that are
satisfactory in the sole discretion of the Frontier Member and (ii) the form of the EPC Contract, in form and substance agreed by the Frontier Member in its sole discretion; 

(m) the business plan contained in the Project Execution Plan shall have been completed to the satisfaction of the Frontier Member in its
sole discretion; and 
 (n) the Frontier Member shall be fully and finally satisfied, in its sole discretion, with all legal,
accounting, tax, commercial, operational and other diligence with respect to (i) the Valero Parties, (ii) each of the Valero Parties’ respective assets to be utilized by the Company, (iii) the Facility, and (iv) the proposed
development and operation of the Business. 
 ARTICLE VI. 

REAL PROPERTY MATTERS 
 6.1 Direct Deeding of Real Property. The Frontier Member and Valero Member acknowledge that the JV Agreement contemplates a contribution of the Real Property by the Frontier Member to the Company.
As a matter of convenience, the parties agree that the conveyance of title to the Real Property may be made directly by JML to the Company but such 

  
 15 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


conveyance is for the account of the Frontier Member and, for purposes of the JV Agreement, shall be deemed to have occurred so that ownership of the Real Property (including all beneficial
rights and incidents thereto) had been transferred at the Closing by JML to the Frontier Member and concurrently thereafter by the Frontier Member to the Company. 
 6.2 Property Taxes, Utilities and Other Expenses. 
 (a) All Property Taxes
and installments of special assessments, if any, that relate to tax periods on or before the Closing Date, regardless of when due and payable, will be paid by JML. All Property Taxes and installments of special assessments, if any, that relate to
tax periods after the Closing Date, regardless of when due and payable, will be paid by the Company. All Property Taxes, if any, for the year in which the Closing occurs shall be prorated between the Company and JML based on days of ownership for
the year in which the Closing occurs. If the current year’s Property Taxes are not known as of Closing, the parties shall, upon Closing, enter into a proration agreement which shall provide that the Property Taxes subject to proration shall be
based on the previous year’s millage rate applied against the most recent assessed valuation, with an adjustment being made between the Company and JML when the current year’s Property Taxes are known. If this transfer or the
Company’s use of the Real Property after Closing results in the requirement to pay recapture or other additional Property Taxes for periods prior to Closing as a result of the Real Property being enrolled in or benefiting from any commercial
forest, agricultural, or similar program, such recapture or other additional Property Taxes shall be the obligation of JML. If JML’s or the Frontier Member’s breach of the RZDA prior to Closing results, at any time, in the obligation to
pay Property Taxes not otherwise payable under the RZDA, such Property Taxes shall be the obligation of JML or the Frontier Member, as the case may be. 
 (b) All utility expenses and other charges related to the Real Property will be prorated between the Company and the Frontier Member on a per diem basis (the Frontier Member will be responsible for
pre-Closing periods and the Company will be responsible for post-Closing periods). 
 6.3 Title and Survey. 

(a) Survey(s). Within forty-five (45) days after the date hereof, JML will deliver to the Company, the Valero Member and the
Title Company a survey (herein the “Survey”) of the Real Property, prepared by UP Engineers and Architects, in such form and content as to permit the deletion of the “survey exception” for all matters other than shortages
in area of the land from the Title Policy. The Survey shall contain a certificate specifically addressed to the Company, the Valero Member and the Title Company that certifies that the Survey was made in accordance with the Minimum Standard Detail
Requirements for ALTA/ACSM Land Title Surveys jointly established and adopted by ALTA, ACSM and NSPS in 2011, including Items 1-4, 6(a), 8, 11(a), 13, 14, 16, 18, 19, and 21 ($1,000,000) from Optional Table A thereof. The Survey shall, at minimum,
include, the boundary lines of the Real Property, the location of all paved or unpaved roadways and alleys (both those roads on the Real Property and those adjacent thereto), all visible or recorded easements, and rights-of-way affecting the Real
Property (setting forth book and page number of the recorded instruments), together with visible improvements, signs, fences, drainage ditches, waterways, streams, rivers, creeks, railroad tracks,


  
 16 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


building set-back lines, encroachments, protrusions, landfill, and electric telephone, sewer, water, other above-ground utility facilities on or immediately adjacent to the Real Property. In
addition, the Survey shall also depict the wetland delineation data provided to the surveyor. 
 (b) Title Commitment.
The Valero Member acknowledges receipt of a commitment for Title Insurance from the Title Company (Commitment No. 08-22954, effective date 11/21/11) (herein the “Commitment”), together with complete and legible copies of all
instruments that create or evidence exceptions to title (herein the “Title Documents”). JML shall request the Title Company to modify such Commitment to require the Title Company to provide the Company, at the Closing, with a fully
paid Owner’s Policy of Title Insurance (the “Title Policy”) covering the Real Property in the amount of the Land Contribution Amount, which Title Policy shall further permit the Company, at its expense, to increase the amount
thereof to include the cost of improvements subsequently made to the Real Property or to purchase a new Owner’s Policy of Title Insurance covering the Real Property for the aggregate amount of the Title Policy plus the cost of such improvements
(provided that the premium for such new Owner’s Policy of Title Insurance shall be based only upon the incremental increase in the amount thereof above the amount of the Title Policy or at a minimum benefit from a re-issue credit), subject to
the preprinted exceptions set forth therein. 
 6.4 Title and Survey Objections. 

(a) On or before the expiration of the Title and Survey Review Period, the Valero Member may object to any items related to the
Commitment and Survey that could interfere with the anticipated use of the Real Property by the Company for the Business (a “Defect”). If the Valero Member fails to object to any Defect by written notice to the Frontier Member and
JML prior to expiration of the Title and Survey Review Period, the Valero Member shall be deemed to have elected not to object to such item. The Valero Member shall give the Frontier Member and JML written notice of its objections to a Defect
(herein the “Title and Survey Objections”) prior to expiration of the Title and Survey Review Period. All of the exceptions set forth on the Commitment or the Survey not objected to or which are deemed not objected to by the Valero
Member on or before the expiration of the Title and Survey Review Period shall constitute the “Permitted Exceptions.” 
 (b) If the Valero Member duly and timely objects to any Defect, the Valero Member may terminate this Agreement unless the Frontier Member or JML, prior to the Closing, agrees in writing to endeavor to
cure the Valero Member’s objections to such Defect and in fact cures such item by the Closing (without any obligation on the part of the Frontier Member or JML to do so). In addition, the Valero Member shall have five (5) Business Days
from receipt of any updates or continuations of the Commitment identifying new encumbrances to notify the Frontier Member and JML of any objections to any Defect not previously contained in the Commitment, in the same manner as provided above, and
the Title and Survey Objection Period will be extended, to the extent necessary, so that the Title and Survey Objection Period ends not sooner than five (5) Business Days after the Valero Member’s receipt of any such update or continuation
of the Commitment which identifies a new encumbrance. 

  
 17 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

6.5 [Intentionally Omitted]. 
 6.6 Inspections. 
 (a) Prior to the Closing, the Valero Member and its
authorized agents, employees, contractors, and experts (“Valero Member’s Experts”) may, at the expense of the Company, conduct such soil, environmental and/or other studies or tests or reviews that the Valero Member or the
Valero Member’s Experts deem advisable, and if this Agreement is not consummated, the Valero Member shall ensure that the Real Property is returned to substantially the same condition existing prior to such studies, at the Valero Member’s
expense (herein the “Property Inspection”). The Valero Member shall not permit the Property Inspection to be conducted in any manner that creates any unsafe or hazardous condition on the Real Property or that unreasonably disturbs,
interrupts, or interferes with any persons, including, without limitation, tenants or other occupants of neighboring properties, or their employees, customers or invitees. JML hereby grants to the Valero Member and the Valero Member’s Experts a
license to enter upon the Real Property for the purposes of performing the Property Inspection. 
 (b) Within five (5) days
of the date hereof, JML and/or the Frontier Member will deliver to the Valero Member copies of the following items, to the extent the same are within the custody, control, or possession of JML or any of JML’s affiliates or the Frontier Member
(“Existing Reports”): any actual or proposed lease, license or contract pertaining to the Real Property currently in effect or under negotiation; utility capacity letters from the electric, water and sewer service providers serving
the Real Property; all environmental, soil, topography, hydrology, vegetation, traffic, archeological, karst, or endangered species reports, studies, notices, and assessments relating to the Real Property; reports or notices from any governmental
agencies affecting the Real Property; any agreement with third parties encumbering or affecting the current or future development of the Real Property; any and all present, pending or threatened claims against the Real Property that are known to JML
or the Frontier Member; and any other report, agreement, writing or instrument relating to or affecting the use of the Real Property. 
 6.7 Project Expenses. The Title Commitment and Title Policy costs shall be at the expense of JML or the Frontier Member, provided that the cost of (i) increasing the amount of the Title Policy
to include the cost of improvements subsequently made to the Real Property or obtaining a new Owner’s Policy of Title Insurance covering the Real Property for the aggregate amount of the Title Policy plus the cost of such improvements (to the
extent that the premium for such new Owner’s Policy of Title Insurance shall be based only upon the incremental increase in the amount thereof above the amount of the Title Policy) (ii) the deletion of the survey exception and
(iii) any other endorsement, if requested by the Valero Member, will be at the Company’s expense. The Company shall be responsible for all recording fees, survey costs, environmental inspection costs, transfer taxes, and any other fees of
the Title Company. 
 ARTICLE VII. 
 TERMINATION 
 7.1 Termination of Agreement. This Agreement may be
terminated by written notice at any time prior to the Closing: 

  
 18 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

(a) by the Valero Parties if satisfaction of any of the conditions set forth in Section 5.1(a) – (o) is or becomes
impossible (other than through the failure of a Valero Party to comply with its obligations under this Agreement) and the Valero Parties have not waived the condition on or before the Closing Date. 

(b) by the Frontier Parties if satisfaction of any of the conditions set forth in Section 5.2(a) – (m) is or
becomes impossible (other than through the failure of a Frontier Party to comply with its obligations under this Agreement) and the Frontier Parties have not waived the condition on or before the Closing Date. 

(c) by the Valero Member in accordance with Section 6.4. 

(d) by either the Frontier Member or the Valero Member if the Closing has not occurred (other than through the failure of the party
seeking to terminate this Agreement to comply fully with its obligations under this Agreement) on or before April 30, 2012 (as such date may be extended by mutual written agreement of the Valero Member and the Frontier Member). 

(e) By either the Valero Member or the Frontier Member, if the Company is dissolved by the Valero Member and the Frontier Member.

 (f) by the Valero Parties if satisfaction of the condition set forth in Section 5.1(q) is or becomes impossible
in the sole discretion of the Valero Parties. 
 (g) by the Frontier Parties if satisfaction of the condition set forth in
Section 5.2(n) is or becomes impossible in the sole discretion of the Frontier Parties. 
 7.2 Effect of
Termination. If this Agreement is terminated in accordance with Section 7.1 and the transactions contemplated hereby are not consummated, (i) each party shall redeliver all documents, work papers and other materials of the other
parties hereto, and all copies of any such materials, relating to the transactions contemplated hereby or by the JV Agreement, whether obtained before or after the execution hereof, to the party furnishing the same, and (ii) none of the parties
shall have any liability or further obligation to any other party to this Agreement resulting from such termination. If this Agreement is terminated, the JV Agreement shall terminate and the Frontier Member and Valero Member will voluntarily
dissolve the Company. 
 ARTICLE VIII. 
 SURVIVAL OF REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION 
 In no event
shall any of the parties hereto be deemed to make any of the representations and warranties in Article III or Article IV unless and until the Closing occurs. The representations and warranties of the parties contained in
Section 3.1, Section 3.2, Section 4.1 and Section 4.2 shall survive the Closing indefinitely; the representations and warranties in Section 4.4(a) shall not survive the Closing (and the
Company shall look solely to the Title Policy for any claims relating to title to the Real Property, other than claims made with respect to the warranty of title set forth in the Deed) and all other representations and warranties in Article
III or Article IV shall survive the Closing for a period of eighteen (18) months. 

  
 19 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

8.1 Indemnification by Frontier Parties. A Frontier Party shall indemnify and hold harmless the Company, the Valero Parties, and
their respective Affiliates, directors, officers, employees, agents, successors and assigns, harmless from, against, and in respect of any and all Losses arising out of or resulting from (a) any misrepresentation, nonfulfillment or breach of
any representation or warranty made by it contained in this Agreement or (b) any failure by it to observe any of its covenants contained in this Agreement. 
 8.2 Indemnification by the Valero Parties. The Valero Parties shall indemnify and hold the Company, the Frontier Member and Mascoma, and their respective Affiliates, directors, officers, employees,
agents, successors and assigns, harmless from, against, and in respect of any and all Losses arising out of or resulting from (a) any misrepresentation, nonfulfillment or breach of any representation or warranty of the Valero Parties contained
in this Agreement or (b) any failure to observe any covenant of the Valero Parties contained in this Agreement. 
 8.3
Procedure for Claims between Parties. If a Claim for Losses is to be made by a Person entitled to indemnification hereunder (an “Indemnitee”), the Indemnitee shall give written notice (a “Notice”) to the
party from whom indemnification is to be sought hereunder (the “Indemnitor”) as soon as practicable after the Indemnitee becomes aware of any fact, condition or event which may give rise to Losses for which indemnification may be
sought under this Article VIII. Any failure to provide any such Notice in a timely manner to the Indemnitor shall not relieve the Indemnitor of any liability hereunder, except to the extent (and only to the extent) the Indemnitor is
materially prejudiced by such failure. Each Notice shall set forth (a) the specific representation, and warranty or covenant alleged to have been breached or other basis for indemnification, (b) the nature and amount of the Claim asserted,
together with sufficient facts relating thereto so that the Indemnitor may reasonably evaluate such Claim and (c) a calculation or good faith estimate, if such can be reasonably calculated, of the aggregate Losses to which the Indemnitee
believes it is entitled in connection with the Claim. If the Indemnitor, within twenty (20) Business Days after receipt of the Notice, does not give written notice to the Indemnitee stating its intent to contest such Claim, the Claim shall be
deemed accepted and the amount of the Claim shall be deemed a valid Claim. If the Indemnitor shall contest the assertion of a Claim by giving such written notice to the Indemnitee within such 20-Business Day period, then such dispute will be
resolved in accordance with the terms, conditions, rules and procedures set forth in Section 12.20 of the JV Agreement. 

8.4 Defense of Third Party Claims. The following procedures shall be applicable with respect to the indemnification obligations of
a party hereunder in respect of any Claim asserted or brought by any third party or parties (such Claim being referred to herein as a “Third Party Claim”): 
 (a) Promptly after receipt by an Indemnitee of written notice of the assertion or the commencement of any Third Party Claim with respect to any matter within the scope of this Article VIII, the
Indemnitee shall give written notice thereof (a “Third Party Claim Notice”) to the Indemnitor and shall thereafter keep the Indemnitor reasonably informed with respect thereto; provided, however, that the failure of
the Indemnitee to give the Indemnitor prompt notice as provided herein shall not relieve the Indemnitor of its indemnification obligations hereunder, unless such failure results in (i) a default judgment, (ii) the expiration of the time to
answer a complaint or (iii) material prejudice to the Indemnitor’s defense of such Third Party Claim. In 

  
 20 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


case any such Third Party Claim is brought against any Indemnitee, the Indemnitor shall be entitled to assume the defense thereof by giving the Indemnitee written notice of its intention to do so
within thirty (30) days after receipt of the Third Party Claim Notice, with counsel reasonably satisfactory to the Indemnitee at the Indemnitor’s own expense; provided, however, that the Indemnitor shall not be entitled to
assume the defense if the named parties to any such Third Party Claim (including any impleaded parties) include both the Indemnitee and the Indemnitor, and the Indemnitor shall have been advised by such counsel that there is one or more legal
defenses available to it that are in addition to or in conflict with those available to the Indemnitee. If the Indemnitor shall assume the defense of such Third Party Claim, it shall not settle such Third Party Claim without the prior written
consent of the Indemnitee, which consent shall not be unreasonably withheld, conditioned or delayed, unless such settlement includes an unconditional release of the Indemnitee from all liability arising out of such Third Party Claim. Notwithstanding
the assumption by the Indemnitor of the defense of any Third Party Claim as provided in this Section 8.4, the Indemnitee shall be permitted to join in the defense of such Third Party Claim and to employ counsel at its own expense.

 (b) If the Indemnitor shall fail to notify the Indemnitee of its desire to assume the defense of any such Third Party Claim
within the prescribed period of time, or shall not be entitled to assume the defense of any such Third Party Claim, then the Indemnitee shall control and conduct the defense of any such Third Party Claim at the reasonable cost and expense of the
Indemnitor, in which event it may do so in such manner as it may deem appropriate; provided, however, that it shall not settle any Third Party Claim which would give rise to material liability on the part of the Indemnitor without the
prior written consent of the Indemnitor, which shall not be unreasonably withheld, conditioned or delayed. The Indemnitor shall be permitted to join in the defense of such Third Party Claim and to employ counsel at its own expense. 

ARTICLE IX. 

MISCELLANEOUS 
 9.1 Waiver. No failure by any party to insist upon the strict performance of any covenant, duty, agreement or condition of this Agreement or to exercise any right or remedy upon a breach thereof
shall constitute a waiver of any such breach or any other covenant, duty, agreement or condition. 
 9.2 Amendments.
Except as otherwise expressly provided herein, this Agreement may be amended, modified or waived only with the written consent of the Frontier Member and the Valero Member, of if such amendment relates to any provision concerning the Real Property,
by JML. Any such amendment, modification or waiver entered into or made in accordance with this Section 9.2 shall be binding on all parties hereto. 
 9.3 No Third Party Rights. None of the provisions contained in this Agreement shall be for the benefit of or enforceable by any third parties, including creditors of the Company. 

9.4 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and
valid under Applicable Law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any Applicable Law in any jurisdiction, such invalidity, illegality or unenforceability will not


  
 21 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


affect any other provision or the effectiveness or validity of any provision in any other jurisdiction, and this Agreement will be reformed, construed and enforced in such jurisdiction as if such
invalid, illegal or unenforceable provision had never been contained herein but only to the minimum extent necessary to circumvent such invalidity, illegality or unenforceability, and in such a manner as to preserve to the maximum extent the
original intention of this Agreement. 
 9.5 Successors and Assigns; Assignment. All covenants and agreements contained
in this Agreement shall bind and inure to the benefit of the parties hereto and their respective heirs, executors, administrators, successors, legal representatives and permitted assigns, whether so expressed or not. No assignment of this Agreement
or of any rights or obligations hereunder may be made by any of the parties hereto without the prior written consent of the other parties hereto and any attempted assignment without the required consents shall be void; provided, however, that the
Frontier Member or the Valero Member may assign this Agreement and any or all rights or obligations hereunder to any Affiliate of the Frontier Member or the Valero Member, respectively, without the prior written consent of the other parties hereto.

 9.6 Interpretive Matters. In this Agreement, unless otherwise specified or where the context otherwise requires:

 (a) the headings of particular provisions of this Agreement are inserted for convenience only and will not be construed as a
part of this Agreement or serve as a limitation or expansion on the scope of any term or provision of this Agreement; 
 (b)
words importing any gender shall include other genders; 
 (c) words importing the singular only shall include the plural and
vice versa; 
 (d) the words “include,” “includes” and “including” shall be deemed to be followed
by the words “without limitation” for all purposes outside this Section 9.6; 
 (e) the words
“hereof,” “herein” and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement; 

(f) references to “Articles,” “Sections,” “Schedules” or “Exhibits” shall be to Articles,
Sections, Schedules or Exhibits of or to this Agreement; 
 (g) references to any Person include the permitted successors and
assigns of such Person; 
 (h) except as otherwise expressly provided herein, wherever a conflict exists between this Agreement
and any other agreement referenced herein, this Agreement shall control but solely to the extent of such conflict; 
 (i)
references to any agreement or contract, unless otherwise stated, are to such agreement or contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof; and 

  
 22 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

(j) the parties hereto have participated jointly in the negotiation and drafting of this Agreement; accordingly, in the event an ambiguity
or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party hereto by virtue of the authorship of
any provisions of this Agreement. 
 9.7 Counterparts. This Agreement may be executed simultaneously in two or more
separate counterparts, any one of which need not contain the signatures of more than one party, but each of which will be an original and all of which together shall constitute one and the same agreement binding on all the parties hereto.

 9.8 Delivery by Facsimile or E-mail. This Agreement, the agreements referred to herein, and each other agreement or
instrument entered into in connection herewith or therewith or contemplated hereby or thereby, and any amendments hereto or thereto, to the extent signed and delivered by means of a facsimile machine or other form of electronic transmission
(including by e-mailed PDF) producing a facsimile of the signing party’s signature, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were
the original signed version thereof delivered in person. At the request of any party hereto or to any such agreement or instrument, each other party hereto or thereto shall re-execute original forms thereof and deliver them to all other parties. No
party hereto or to any such agreement or instrument shall raise the use of a facsimile machine or other form of electronic communication (including e-mailed PDF) to deliver a signature or the fact that any signature or agreement or instrument was
transmitted or communicated through the use of a facsimile machine or other form of electronic communication (including e-mailed PDF) as a defense to the formation or enforceability of a contract and each such party forever waives any such defense.

 9.9 Entire Agreement. This Agreement, those documents expressly referred to herein and other documents of even date
herewith embody the complete agreement and understanding among the parties and supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter
hereof in any way. As of the date hereof, other than the Ancillary Agreements, there are no other agreements between the parties relating to the subject matter hereof. 
 9.10 Arbitration. Except as necessary to enforce any arbitral award, any controversy or claim, whether based on contract, tort, statute or other legal or equitable theory (including any claim of
fraud, misrepresentation or fraudulent inducement or any question of validity or effect of this Agreement including this Section 9.10) arising out of or related to this Agreement, or the breach or termination of this Agreement, will be
resolved in accordance with the terms, conditions, rules and procedures set forth in Section 12.20 and Exhibit B of the JV Agreement. 
 9.11 Applicable Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or
provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. 

  
 23 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

9.12 Exclusive Jurisdiction. Subject to Section 9.10 and without waiving the same, each of the parties hereto hereby
submits to the exclusive jurisdiction of any federal court sitting in New York, New York, in any action arising out of or relating to this Agreement and agrees that all claims in respect of such action may be heard and determined in any such court.
Each party hereto also agrees, subject to Section 9.10 and only to the extent expressly permitted herein, not to bring any action arising out of or relating to this Agreement in any other court. Each of the parties hereto waives any
defense of inconvenient forum to the maintenance of any action so brought and waives any bond, surety, or other security that might be required of any other party with respect thereto. 

9.13 Waiver of Jury Trial. EACH OF THE PARTIES TO THIS AGREEMENT WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY DISPUTE OF ANY NATURE
WHATSOEVER THAT MAY ARISE BETWEEN THEM, INCLUDING THOSE DISPUTES RELATING TO OR INVOLVING, IN ANY WAY THE CONSTRUCTION, PERFORMANCE OR BREACH OF THIS AGREEMENT OR ANY OTHER AGREEMENT BETWEEN THE PARTIES, THE PROVISIONS OF ANY APPLICABLE LAW
NOTWITHSTANDING. By execution of this Agreement, each of the parties hereto acknowledges and agrees that such party has had an opportunity to consult with legal counsel and that such party knowingly and voluntarily waives any right to a trial by
jury of any dispute pertaining to or relating in any way to the transactions contemplated by this Agreement, the provisions of any Applicable Law notwithstanding. 
 9.14 Addresses and Notices. All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to
have been given or made when (i) delivered personally to the recipient, (ii) telecopied to the recipient with confirmation of delivery or delivered by other form of electronic transmittal customarily used for such communication that
permits retention of an electronic copy of such notice and verification of receipt (in each case with hard copy sent to the recipient by reputable overnight courier service (charges prepaid) that same day) if telecopied or so delivered
electronically before 5:00 p.m. New York, New York time on a Business Day, and otherwise on the next Business Day, or (iii) one (1) Business Day after being sent to the recipient by reputable overnight courier service (charges prepaid).
Such notices, demands and other communications shall be sent to the address for such recipient set forth below: 

If to the Company: 
 Kinross Cellulosic Ethanol LLC 
 One Valero Way 

San Antonio, Texas 78249 
 Attention: Vice President – Alternative Energy 
 Facsimile:
(210) 370-4386 

  
 24 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

With a copy to: 
 Diamond Alternative Energy, LLC 
 One Valero Way 

San Antonio, Texas 78249 
 Attention: Vice President – Alternative Energy 
 Facsimile:
(210) 370-4386 
 With an additional copy to: 

Frontier Renewable Resources, LLC 

210 N Front St Floor 1 
 Marquette, Michigan 49855 
 Attention: Stephen J. Hicks 

Facsimile: (906) 228-9499 
 If to the Frontier Member and/or Mascoma, to: 
 Frontier Renewable
Resources, LLC 
 210 N Front St Floor 1 

Marquette, Michigan 49855 
 Attention: Stephen J. Hicks 
 Facsimile: (906) 228-9499

 With a copy to: 
 J.M. Longyear, L.L.C. 
 210 N Front St Floor 1 

Marquette, Michigan 49855 
 Attention: Stephen J. Hicks 
 Facsimile: (906) 228-9499

 With an additional copy to: 

Mascoma Corporation 
 67 Etna Road, Suite 300 
 Lebanon, NH 03766 

Attention: Chief Executive Officer 

Facsimile: (603) 676-3321 
 With a copy to: 
 Goodwin Procter LLP 

Exchange Place 
 Boston, MA 02109-2881 
 Attention: Bruce Tribush, Esq. 

Facsimile: (617) 227-8591 

  
 25 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

If to the Valero Member, Valero Services and/or VMSC, to: 

Diamond Alternative Energy, LLC 
 One Valero Way 
 San Antonio, Texas 78249 

Attention: Vice President – Alternative Energy 

Facsimile: (210) 370-4386 
 With a copy to: 
 Valero Energy Corporation 

One Valero Way 
 San Antonio, Texas 78249 
 Attention: General Counsel 

Facsimile: (210) 345-2988 
 If to JML, to: 
 JML Heirs, LLC 

210 N Front St Floor 1 
 Marquette, Michigan 49855 
 Attention: Stephen J. Hicks 

Facsimile: (906) 228-9499 
 or to such other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party. 

9.15 Expenses. Except as otherwise provided in this Agreement (including Section 6.7), each party to this Agreement
will bear its respective fees, legal expenses and other expenses incurred in connection with the preparation, execution and performance of this Agreement and the fulfillment of its obligations hereunder. 

9.16 Further Action. Subject to the right of any party to terminate this Agreement at any time prior to the Closing, the parties
agree to execute and deliver all documents, provide all information and take or refrain from taking such actions as may be necessary or appropriate to achieve the purposes of this Agreement. 

9.17 Non-Recourse. 
 (a) No past, present or future director, officer, employee, incorporator, member, manager, partner, stockholder, Affiliate, agent, attorney or representative of the Frontier Member or any of its
Affiliates shall have any liability for any obligations or liabilities of the Frontier Member under this Agreement or for any claim based on, in respect of, or by reason of, the transactions contemplated hereby. 

(b) No past, present or future director, officer, employee, incorporator, member, manager, partner, stockholder, Affiliate, agent,
attorney or representative of the Valero Member or any of its Affiliates shall have any liability for any obligations or liabilities of the 

  
 26 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


Valero Member under this Agreement or for any claim based on, in respect of, or by reason of, the transactions contemplated hereby. 

[The Remainder of This Page Is Intentionally Left Blank.] 

  
 27 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

IN WITNESS WHEREOF, the undersigned have executed or caused to be executed on their behalf this Agreement as of the date first written
above. 
  

									
	JML HEIRS, LLC	 		 	FRONTIER RENEWABLE RESOURCES, LLC
					
	By:	 	/s/ Stephen J. Hicks	 		 	By:	 	/s/ Stephen J. Hicks
		 	Name: Stephen J. Hicks	 		 		 	Name: Stephen J. Hicks
		 	Title: Chief Executive Officer	 		 		 	Title: CEO

  

									
		 		 	 KINROSS CELLULOSIC ETHANOL LLC
  

By: Diamond Alternative Energy, LLC, Manager

					
		 		 		 	By:	 	/s/ George W. Stutzmann
		 		 		 		 	Name: George W. Stutzmann
		 		 		 		 	Title: Vice President

  

									
		 		 	DIAMOND ALTERNATIVE ENERGY, LLC
					
		 		 		 	By:	 	/s/ George W. Stutzmann
		 		 		 		 	Name: George W. Stutzmann
		 		 		 		 	Title: Vice President

  

									
		 		 	MASCOMA CORPORATION
					
		 		 		 	By:	 	/s/ William J. Brady
		 		 		 		 	Name: William J. Brady
		 		 		 		 	Title: CEO

  

									
		 		 	VALERO MARKETING AND SUPPLY COMPANY
					
		 		 		 	By:	 	/s/ Gene Edwards
		 		 		 		 	Name: Gene Edwards
		 		 		 		 	Title: Executive Vice President

  

									
		 		 	VALERO SERVICES, INC.
					
		 		 		 	By:	 	/s/ George W. Stutzmann
		 		 		 		 	Name: George W. Stutzmann
		 		 		 		 	Title: Vice President


  
 28 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

 
 SCHEDULES AND EXHIBITS 

 

			
	SCHEDULE 1	  	Real Property
		
	SCHEDULE 3.3(b)	  	Approvals, Consents, Notice Filings in Connection with the Execution and Delivery of the Contribution Agreement, the JV Agreement, and the Ancillary Agreements
		
	SCHEDULE 4.3(b)	  	Approvals, Consents, Notice Filings in Connection with the Execution and Delivery of the Contribution Agreement, the JV Agreement, and the Ancillary Agreements
		
	EXHIBIT A	  	Form of Fee and Royalty Agreement
		
	EXHIBIT B	  	Form of Technology License Agreement
		
	EXHIBIT C	  	Form of Warrant Purchase Agreement
		
	EXHIBIT D	  	Form of Covenant Deed








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

SCHEDULE 1 

REAL PROPERTY 
 Township
of KINROSS 
 Town 45 North, Range 01 West, Section 21 
 The Southeast 1/4 EXCEPT commencing at the North Quarter Corner of Section 21; thence S 00°18’13” E, along the North-South Quarter Line, 2640.73 feet to the Center Quarter Corner of
said Section 21, also being the Point of Beginning; thence N 89°41’48” E, along the East-West Quarter Line, 113.99 feet; thence the following two courses along a curve and a line parallel to and 20 feet Southeasterly of the
centerline of a recreational trail: 1) 169.76 feet along a 620.00 foot radius non-tangent curve to the right with a delta angle of 15°41’18” and a chord bearing S 29°08’00” W 169.23 feet; 2) thence S
36°58’38” W 50.88 feet to said North-South quarter line; thence N 00°18’13” W, along said North-South Quarter line, 187.87 feet to the Point of Beginning. 
 AND 
 All that part of the East 1/2 of the Southwest 1/4 lying in the following described parcel:
Beginning at the Quarter Corner common to Sections 21 and 28; thence S 00°23’11” W, along the North-South Quarter Line of Section 28, a distance of 2651.51 feet to the Center Quarter Corner of said Section 28; thence N
89°49’31” W, along the East-West Quarter Line of Section 28, a distance of 115.80 feet to the centerline of Gaines Highway; thence the following two courses along said centerline: 1) N 00°29’30” W 2029.65 feet; 2)
thence 2183.69 feet along a 3819.72 foot radius curve to the left with a delta angle of 32°45’19” and a chord bearing N 16°52’09” W 2154.08 feet; thence N 36°58’38” E 1268.80 feet, along a line parallel to
and 20 feet southeasterly of the centerline of a recreation trail, to the North-South Quarter Line of Section 21; thence S 00°18’13” E, along said Quarter Line 2453.50 feet to the Point of Beginning. 

Township of KINROSS 
 Town 45 North, Range 01
West, Section 28 
 The Northeast 1/4 AND 
 That part of the East 1/2 of the Northwest 1/4 lying in the following described parcel: Beginning at the Quarter Corner common to Sections 21 and 28; thence S 00°23’11” W, along the
North-South Quarter Line of Section 28, a distance of 2651.51 feet to the Center Quarter Corner of said Section 28; thence N 89°49’31” W, along the East-West Quarter Line of Section 28, a distance of 115.80 feet to the
centerline of Gaines Highway; thence the following two courses along said centerline: 1) N 00°29’30” W 2029.65 feet; 2) thence 2183.69 feet along a 3819.72 foot radius curve to the left with a delta angle of 32°45’19” and
a chord bearing N 16°52’09” W 2154.08 feet; thence N 36°58’38” E 1268.80 feet, along a line parallel to and 20 feet southeasterly of the 

  
 Schedule 1









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


centerline of a recreation trail, to the North-South Quarter Line of Section 21; thence S 00°18’13” E, along said Quarter Line 2453.50 feet to the Point of Beginning.

 SUBJECT TO the reservation of a 66 foot wide access easement for public purposes, said easement described as commencing at the South Quarter
Corner of Section 28; thence N 00°23’41” E, along the North-South Quarter Line, 2642.75 feet to the Center Quarter Corner, also being the Point of Beginning; thence N 89°49’31” W, along the East-West Quarter Line,
115.80 feet to the centerline of Gaines Highway; thence N 00°29’30” W, along said centerline, 66.00 feet; thence S 89°49’31” E 182.56 feet; thence S 00°10’29” W 66.00 feet to said East-West Quarter Line;
thence N 89°49’31” W, along said East-West Quarter Line, 66.00 feet to the Point of Beginning. 

  
 Schedule 1









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

SCHEDULE 3.3(b) 

APPROVALS, CONSENTS, NOTICE FILINGS IN CONNECTION 
 WITH THE EXECUTION AND DELIVERY OF 
 THE CONTRIBUTION AGREEMENT, THE JV AGREEMENT,

 AND THE ANCILLARY AGREEMENTS 
 None. 

  
 Schedule
3.3(b) 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

SCHEDULE 4.3(b) 

APPROVALS, CONSENTS, NOTICE FILINGS IN CONNECTION 
 WITH THE EXECUTION AND DELIVERY OF 
 THE CONTRIBUTION AGREEMENT, THE JV AGREEMENT,

 AND THE ANCILLARY AGREEMENTS 
 None. 

  
 Schedule
4.3(b) 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

EXHIBIT A 
 FORM OF
FEE AND ROYALTY AGREEMENT 

  
 Exhibit A









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

CONFIDENTIAL 

FEE AND ROYALTY AGREEMENT 
 THIS FEE AND ROYALTY AGREEMENT (this “Agreement”) is entered into as of the [            ] day of
            (the “Effective Date”), by and between Mascoma Corporation, a Delaware corporation, with its principal place of business located at 67 Etna Road, Suite 300,
Lebanon, NH 03766 (“Mascoma”), and Diamond Alternative Energy, LLC, with its principal place of business located at One Valero Way, San Antonio, TX 78249 (“Valero”). 

WHEREAS, concurrently with the execution of this Agreement, (a) Mascoma is entering into, among other agreements, that certain
Technology License and Supply Agreement with Kinross Cellulosic Ethanol LLC (“Kinross”), dated as of the date hereof, pursuant to which Mascoma is granting Kinross a license to use a proprietary Mascoma process (as defined therein,
the “Mascoma Process”) for converting woody biomass feedstocks to ethanol (the “Field”) at the Kinross facility to be located in Kinross, Michigan (the “Kinross License Agreement”); and
(b) Valero, Frontier Renewable Resources, LLC, and Kinross are entering into that certain Limited Liability Company Agreement (the “JV Agreement”). 
 WHEREAS, the parties desire to agree upon the license fee and royalty structure that would apply to a license for the right to use the Mascoma Process in the Field at any additional future cellulosic
ethanol plant site or an expansion of such future cellulosic ethanol plant site located in North America in which Valero or any of its Affiliates (as defined in the JV Agreement), whether jointly or individually, is at least a [***] equity investor
(on a fully diluted basis) (a “Valero Project Site”); for the avoidance of doubt, this Agreement shall not apply to the Kinross site. 
 NOW, THEREFORE, in consideration of the mutual covenants herein contained and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as
follows: 
  

	1.	Valero Project Sites. Upon written notification by Valero or its Affiliate delivered (as set forth in Section 10 herein) to Mascoma prior to the expiration
of the term of this Agreement (a “Valero Project Site Notification”), Mascoma will grant to each Valero Project Site a license agreement for the use of the Mascoma Process in the Field in connection with the design, construction,
operation, repair, replacement and maintenance of such Valero Project Site’s facility that is consistent with the grant of license in the Kinross License Agreement (except as modified to reflect the revised terms set forth in Agreement). Within
[***] after receipt of the Valero Project Site Notification, Mascoma shall provide written acknowledgement of its obligation to grant a license agreement with the Valero Project Site (unless it conflicts with an Excluded Area, as described below),
and the date of Valero’s receipt of such acknowledgement letter shall be the effective date of license notification (the “License Notification Date”). In the Valero Project Site Notification, Valero will state that [***].
Notwithstanding the foregoing, Mascoma will not be obligated to grant such license for any proposed Valero Project Site (or any related exclusive geographic area) located [***] (all areas excluded by clauses (a), (b), and (c) are collectively
referred to as “Excluded 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


Areas”). Within fifteen (15) days of any changes to the Excluded Areas, Mascoma will provide Valero with written notice of any Excluded Areas then existing in North America, except to
the extent disclosure thereof is prohibited by Applicable Law (including any securities law, rule or regulation). 
 If Valero
has not satisfied (i) the Initial Conditions (as hereinafter defined) within [***] following the License Notification Date, (ii) the Secondary Conditions (as hereinafter defined) within [***] following the License Notification Date, or
(iii) the Tertiary Conditions (as hereinafter defined) within [***] following the License Notification Date, then after written notice by Mascoma, Mascoma may terminate such Valero Project Site license; provided, however, that all such time
periods shall be tolled to the extent that the applicable conditions could not, in the exercise of commercially reasonable efforts, be satisfied by Valero to the extent arising out of [***] 

As used herein: 
 “Initial Conditions” means [***] 

“Secondary Conditions” means each [***] 

“Tertiary Conditions” means [***] 

Notwithstanding anything to the contrary, Mascoma will not be obligated to grant an additional license for any proposed Valero Project
Site if, at such time, there are [***] Valero Project Sites licensed for which the Initial Conditions have not yet been satisfied. 
 With respect to each such license agreement entered into between Mascoma and a Valero Project Site, all compensation to Mascoma (other than payment for support, engineering or consulting services,
organisms as contemplated below, equipment or other commodities), will be as set forth in Section 1.1, Section 1.2, and Section 1.3 (for clarity, there shall be no other fees or royalties due). 

1.1 Fees. 
 (a) License Fees. [***] 
 (b) Schedule A Package Fee. Within [***]
following Mascoma’s receipt of [***] of the Schedule A Package Fee (as defined below) for a proposed Valero Project Site, Mascoma shall prepare and deliver the Schedule A basic engineering package, which shall be consistent


  
 2 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


with the basic engineering design package delivered under the Kinross License Agreement, to Valero that has been revised for the proposed Valero Project Site. Within [***] from receipt of the
Schedule A package, Valero shall pay Mascoma the remaining [***] of the stipulated amount (the “Schedule A Package Fee”) of [***] as compensation for the Schedule A basic engineering package for the proposed Valero Project Site. For
the avoidance of doubt, the Schedule A basic engineering package will include generic preliminary engineering for Mascoma’s then current process design (sufficient for a Third Party contractor to conduct detailed engineering, procurement and
construction with respect to such process), but will not include detailed construction level engineering for the specific Valero Project Site. Valero will be responsible for retaining a qualified engineering, procurement and construction contractor
to complete the engineering of the Valero Project Site and, except for errors or omissions attributable to Mascoma (or its subcontractors), the Valero Project Site’s third party directly engaged engineer(s) shall be responsible for its
engineering, procurement and construction. 
 1.2 Base Royalties. 

(a) [***], Mascoma shall elect one of two Base Royalty scales (the “Royalty Option”, referenced below as
“Royalty Option 1” and “Royalty Option 2”) (and the Royalty Option selected will apply for all design capacity for such Valero Project Site); failure to elect a Royalty Option shall be deemed an election of Royalty
Option 1. 
 (b) The base royalties will be paid [***] (“Base Royalties”, and such royalty term, “Royalty
Term”). The Base Royalty amounts will be as follows: 
 [***] 

  
 3 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


[***] 
 (c) During the term of a license agreement with a Valero Project
Site, such license agreement shall incorporate terms and conditions substantially similar as those that are set forth in Sections 5.4 and 2.2 of the Kinross License Agreement, but taking into account any material differences between Kinross and the
new Valero Project Site. [***] 
 1.3 Profit Sharing Royalties. In addition to the Base Royalty set forth above,
the Valero Project Site will pay Mascoma an amount equal to the annual profit sharing royalty (“PSR”) multiplied by Production (as defined below) for each calendar year (or proportional share thereof) during the Royalty Term for each
increment of capacity, which is intended to provide Mascoma with a share of the upside profits after reaching a hurdle that first provides the Valero Project Site with a targeted return on investment; an example of such Profit Sharing Royalties is
attached hereto in Exhibit 1.3. The PSR will be calculated as follows with all measures based upon annual amounts or volume-weighted averages, as applicable: 
 [***] 

  
 4 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

[***] 
 However, the PSR will never be less than
zero and (a) in the case of Royalty Option 1, the PSR will never exceed the [***] and (b) in the case of Royalty Option 2, the Actual Royalty plus the PSR will never exceed [***]. 

1.4 [***] 

  
 5 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


[***] 
 Mascoma will maintain records in the ordinary course of business on all such
licenses. Valero will have the right during normal business hours and upon reasonable notice to inspect and copy such records solely for the purpose of verifying the Qualifying Project Site’s costs. Valero may retain such information as long as
reasonably necessary to verify the foregoing or enforce it rights under this Agreement. All Mascoma information obtained or made available in connection with such audit shall be deemed the Confidential Information of Mascoma under that certain
Reciprocal Confidentiality Agreement, dated January 12, 2010, by and between Mascoma and Valero (the “Mascoma NDA”), but Valero may use such information to enforce its rights under this Agreement. Only with respect to the
information disclosed under this clause (and not any other information), the term of the Mascoma NDA is hereby amended to continue until the end of the term of this Agreement (provided that Valero will maintain the confidentiality of such
information for so long as it retains such information). 
 [***] 

1.5 In addition, Mascoma will consider any request by a Valero Project Site to receive a license for the use of the Mascoma
Process to convert any non-woody biomass feedstocks to ethanol (the “Non-Woody Field”). The parties will use the Kinross License Agreement, as modified to incorporate the terms of this Agreement, as a basis for the terms of such
license in the Non-Woody Field; however, the final determination of the granting of such license and the related terms shall be subject to the mutual agreement of the Valero Project Site and Mascoma. If any such license is mutually agreed


  
 6 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


upon, [***]. 
 1.6 If, during the term
of this Agreement, Valero or any of its Affiliates, whether jointly or individually, becomes at least a [***] equity investor (on a fully diluted basis) in a project site in North America (a “Site Acquisition”) after such site had
already received a license from Mascoma to use the Mascoma Process in the Field, the royalties, profit share and other ongoing compensation under such license will continue until the earlier of (a) the expiration or termination of the
obligations to pay such compensation under such license pursuant to its terms or (b) [***] after the Site Acquisition (either (a) or (b) being referred to as the “End of Former Site License Term”). Upon the occurrence of a
Site Acquisition, Valero will send notice to Mascoma of such Site Acquisition. At the End of Former Site License Term (even if after the term of this Agreement), the Site Acquisition shall automatically receive from Mascoma: (a) a fully paid up
process license (unless such license was already granted and such grant is at least as broad as the Kinross License process grant), (b) a fully paid royalty for the existing capacity at the time of acquisition (for the avoidance of doubt, all
other royalties, compensation, fees, or profit sharing mechanisms shall be terminated; and any additional capacity added after the acquisition shall be under the terms of this Agreement), (c) a vested right to receive the last organism being
used as of the End of Former License Term for so long as the Site Acquisition requires such organism consistent with Section 5 below, and (d) the right to enter into new agreements for the supply of improved organisms consistent with
Section 5 below. And, at the End of Former Site License Term, any and all fees, damages, refunds, reimbursements, over-payments or similar compensation (if any) owed from Mascoma to Site Acquisition, shall be paid within [***] of the End of
Former Site License Term. The economics of capacity expansions for any such sites will be as set forth in Sections 1.1 though 1.4.  
 2. Mascoma Investment. For each Valero Project Site, the parties will have “good-faith” discussions on a site-by-site basis to negotiate the conditions under which, Mascoma may
have an option to invest up to [***] of the equity (on a fully diluted basis) of the Valero Project Site; however, the final determination of such right shall be subject to mutual agreement of Valero and Mascoma. To the extent mutually agreed by
Mascoma and Valero, such Mascoma investment would be made on substantially the same financial terms (including the same valuation) as those under which Valero or its Affiliate is investing in such Valero Project Site. 

 

	3.	Performance Guarantee. Similar to the method of performance guarantee set forth in the Kinross License Agreement but adjusted by the mutual agreement of the
parties based on performance of prior operating sites of Kinross and other Valero Project Sites, one or more performance guarantee tests will be conducted pursuant to which Licensor will, if the result of the final performance guarantee test fails
to meet the agreed metrics, forfeit [***]. Such damages shall be deducted on an ongoing basis from any Base Royalty and PSR payments until such time as such the damages have been paid in full. 


4. Grantback / Grant Forward of Improvements. Until the end of the license term (but limited to [***] from the effective date of the
license agreement) for each Valero Project Site, grant-back and grant-forward provisions would apply for the sharing of any process improvements with respect to such Valero Project Site, consistent with the provisions of the Kinross License
Agreement. 
 5. Organism Supply. During the term of the license agreement or, if the license agreement has been terminated then
until the end of the last-to-expire Royalty Term for each Valero Project Site, Mascoma, at 

  
 7 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


its costs and expense, will supply the Valero Project Site with Mascoma’s proprietary organisms (the Organism as defined in the Kinross License Agreement) or the most current validated
improved proprietary organisms (the Validated Organism Improvement as defined in the Kinross License Agreement) for the Mascoma Process [***], consistent with the provisions of the Kinross License Agreement. After expiration or termination of the
license agreement or such last-to-expire Royalty Term (other than for the Valero Project Site’s breach), Mascoma will perpetually supply such organisms or such validated improved proprietary organisms in use at expiration or termination (the
“Last Used Organism”) and the Valero Project Site will reimburse Mascoma for [***]. If Mascoma makes any validated improved proprietary organisms after such expiration or termination, the parties shall negotiate the supply of these
organism on terms to be mutually agreed upon, but for the avoidance of doubt, Mascoma shall still be obligated to supply the Valero Project Site with the Last Used Organism as set forth above should the site not accept the new supply terms.

 6. Engineering Design Package and Engineering Fees. As required in Section 1.1 above, for each license agreement granted
pursuant Section 1.1 above, Mascoma will prepare and deliver a Schedule A basic engineering package including all current updates and modifications to the Mascoma Process or improvements thereto (sufficient for a Third Party contractor to
conduct detailed engineering, procurement and construction with respect to such process) for the proposed Valero Project Site , for which Valero will pay Mascoma the [***]. To the extent the licensee requests engineering services beyond the Schedule
A basic engineering design package , Valero will pay Mascoma [***] to perform the engineering for such services. 
 7. Assignment.
This Agreement may not be assigned by any of the parties without the prior written consent of the other parties, except that either party may assign this Agreement to the successor in interest of substantially all of the business to which this
Agreement relates. Notwithstanding the foregoing, Valero may not assign this Agreement to any Mascoma Competitor (as defined in Exhibit 1.14 of the Kinross License Agreement) without the express approval of Mascoma (which approval shall not be
unreasonably withheld, conditioned or delayed), and in the event Valero is acquired (whether by a change of control or otherwise) by a Mascoma Competitor, “Affiliates” of Valero will be limited thereafter to the Affiliates of Valero
existing immediately prior to such acquisition. To the extent Mascoma seeks to assign, sell, transfer, encumber, or otherwise divest any portion of the rights to the Mascoma Process or any rights granted under any license agreement to Valero
(collectively a “Transfer”), Mascoma shall obtain Valero’s prior written approval, unless this Agreement remains as part of such Transfer and all of Valero’s rights hereunder are fully protected, provided that the foregoing will
not be interpreted to require Valero’s approval to any license granted by Mascoma to the Mascoma Process that is not in conflict with any rights granted to any Valero, a Valero Project Site or Kinross. Subject to the foregoing, this Agreement
shall be binding upon and inure to the benefit of any permitted successors and assigns. 
  

	8.	Start-Up Support and other Assistance. Upon the grant of a license to a Valero Project Site, Mascoma shall be obligated to provide start-up support
services for the operation of the site similar to the support listed and on substantially similar terms as those set forth in the Kinross License Agreement, including all of the support detailed in Section 2.3(e) and in the Performance
Guarantee section. 

  

	9.	Term. This Agreement shall commence on the date hereof and continue until [***]. 


  
 8 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

10. Miscellaneous. This Agreement (together with the other agreements referenced herein) contains the entire agreement among the parties
with respect to the subject matter hereof and supersedes all prior negotiations, commitments, agreements and understandings among them with respect thereto. Except as otherwise provided herein, this Agreement may be amended only by the written
agreement of each of the parties. This Agreement may be executed in any number of counterparts, each such counterpart shall be deemed to be an original instrument, and all such counterparts together shall constitute but one agreement. Facsimile or
PDF transmission of execution copies or signature pages for this Agreement shall be legal, valid and binding execution and delivery for all purposes. This Agreement shall be governed by, and construed and enforced in accordance with, the substantive
laws of Delaware without regard to its principles of conflicts of laws. Any disputes between the parties will be resolved in accordance with the dispute resolution procedures set forth in Section 12 of the Kinross License Agreement (as applied
to Mascoma and Valero, mutatis mutandis). Capitalized terms used but not defined herein (or, as noted herein, in the JV Agreement) have the meanings ascribed to them in the Kinross License Agreement. Notices delivered under this Agreement
will be deemed delivered in accordance with Section 12.9 of the JV Agreement. 
 11. Frontier Projects. Before entering into
any binding agreement with another party to develop a woody biomass cellulosic ethanol plant at a site in Michigan, Minnesota or Wisconsin (the “Frontier Region”), Frontier Renewable Resources, LLC (“Frontier”)
shall first deliver written notice (a “Frontier Region Project Notice”) that includes the Estimated Plan (as defined below) to Valero. As used herein, the term “Estimated Plan” means a description of the proposed
project that includes the location of the proposed facility, anticipated acquisition and development costs, feedstock supply sources and estimated costs, proposed offtake terms, pro forma project economics, anticipated capital needs, and general
terms on which Frontier would be willing to discuss the possibility of Valero participating in such project. The Frontier Region Project Notice shall be a good faith representation of terms that Frontier believes are commercially reasonable based
upon generally accepted industry practices. Valero shall have a period of [***] following Frontier’s delivery (as set forth in Section 10 herein) of the Frontier Region Project Notice to deliver written notice (a “Valero Interest
Notice”) to Frontier stating that Valero is interested in discussing the possibility of Valero participating in such project. If Valero timely delivers a Valero Interest Notice, Frontier shall not enter into any binding agreement with
another party to develop such proposed facility until at least [***] have elapsed since the date of delivery of the Valero Interest Notice in order to allow sufficient time for Valero and Frontier to discuss terms on which Valero might participate
on such project. Notwithstanding anything to the contrary, the final determination as to whether and on what terms Valero might participate in any woody biomass cellulosic ethanol plant project in the Frontier Region shall be subject to mutual
agreement of Valero and Frontier. If Valero fails to deliver a Valero Interest Notice within [***] following Frontier’s delivery of the Frontier Region Project Notice, or if Valero delivers a Valero Interest Notice within [***] following
Frontier’s delivery of the Frontier Region Project Notice upon the expiration of [***] following the date of the Valero Interest Notice, then Frontier may enter into a binding agreement with any other party to develop the proposed facility
without any involvement by Valero, except (a) to the extent that Valero and Frontier mutually agree otherwise or (b) as otherwise provided in the immediately following paragraph. 
 If Valero fails to deliver a Valero Interest Notice within [***] following Frontier’s delivery of the Frontier Region Project Notice, or if Valero and Frontier fail to enter into a binding agreement
within [***] after the date of the Frontier Region Project Notice, then Frontier may continue to discuss terms with a third party and may enter into an agreement for development of such proposed facility, but, however, if there is any material
reduction to the compensation or fees payable to Mascoma or Frontier, including (i) development fee(s), (ii) license fee(s), (iii) royalties and (iv) other compensation (including revenue/profit share or equity), taken as a
whole, from the last Estimated Plan delivered to Valero (a “Reduction to the Estimated Plan”), then Frontier shall deliver to Valero a second 

  
 9 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


Frontier Region Project Notice (a “Revised Frontier Region Project Notice”), which includes the revised terms of the Estimated Plan including (i) through (iv) above,
prior to entering into a binding agreement with any other party to develop the proposed facility. Valero shall have a period of [***] following Frontier’s delivery (as set forth in Section 10 herein) of the Revised Frontier Region Project
Notice to deliver a Valero Interest Notice to Frontier stating that Valero is interested in participating in such project. If Valero timely delivers a Valero Interest Notice, Frontier shall not enter into any binding agreement with another party to
develop such proposed facility until at least [***] have elapsed since the date of delivery of the Valero Interest Notice in order to allow sufficient time for Valero and Frontier to discuss terms on which Valero might participate on such project.
Notwithstanding anything to the contrary, the final determination as to whether and on what terms Valero might participate in any woody biomass cellulosic ethanol plant project in the Frontier Region shall be subject to mutual agreement of Valero
and Frontier. If Valero fails to deliver a Valero Interest Notice within [***] following Frontier’s delivery of the Revised Frontier Region Project Notice, or if Valero delivers a Valero Interest Notice within [***] following Frontier’s
delivery of the Revised Frontier Region Project Notice upon the expiration of [***] following the date of the Valero Interest Notice, then Frontier may enter into a binding agreement with any other party to develop the proposed facility without any
involvement by Valero, except (a) to the extent that Valero and Frontier mutually agree otherwise or (b) if there is a subsequent Reduction to the Estimated Plan. 
 Frontier is joining in the execution of this Agreement solely the purpose of acknowledging and agreeing to the provisions of this Section 11. 
 12. Exit of a Member from the JV Agreement. This Agreement will automatically terminate without action by any party upon the actions of either Member, as defined in the JV Agreement, to
terminate the JV Agreement in accordance with Section 10.9(b) or Section 10.9(c) of the JV Agreement, whereupon this Agreement shall be terminated as of the effective date of the dissolution of the Company (as defined in the JV Agreement).

 [Remainder of this page intentionally left blank] 

  
 10 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized representatives. 

 

	
	


					
		 	MASCOMA CORPORATION
			
		 	By:	 	 
		 		 	Name:
		 		 	 Title:

		
		 	 DIAMOND ALTERNATIVE ENERGY, LLC

			
		 	By:	 	 
		 		 	 Name:

		 		 	 Title:

		
	 	 	 For purposes of Section 11 only:


  

					
		 	 FRONTIER RENEWABLE RESOURCES, LLC

			
		 	By:	 	 
		 		 	 Name:

		 		 	 Title:



  








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

EXHIBIT 1.3

Example calculations – Base Royalties and Profit Sharing Royalties
 [***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

EXHIBIT B 
 FORM OF
TECHNOLOGY LICENSE AGREEMENT 

  
 Exhibit B









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

CONFIDENTIAL 
 TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 
 This TECHNOLOGY LICENSE AND
SUPPLY AGREEMENT (this “Agreement”), dated as of [                ] [    ], 2011 (the “Effective Date”), is made by and
between Mascoma Corporation, a Delaware corporation (“Mascoma”), and Kinross Cellulosic Ethanol LLC, a Delaware limited liability company (“Licensee”). Each of Mascoma and Licensee may be referred to herein as a
“Party” or together as the “Parties.” 
 WHEREAS, Mascoma owns and is developing proprietary
microorganisms and manufacturing processes for the production of cellulosic ethanol and other products from cellulosic biomass; 

WHEREAS, Licensee intends to develop and operate an integrated commercial scale cellulosic production facility to perform such processes
for the production of cellulosic ethanol and associated by-products and co-products; 
 WHEREAS, Licensee desires that Mascoma
provide a supply of Organisms (as defined below) for such purpose, and Mascoma is willing to provide such supply for such purpose; 
 WHEREAS, Licensee desires that Mascoma provide certain support services and Mascoma is willing to provide such services under the terms hereof; 

WHEREAS, subject to the terms and conditions of this Agreement, Licensee desires and is willing to secure from Mascoma, and Mascoma
desires and is willing to grant to Licensee, a license to use the Mascoma Process and the Organisms under the Mascoma IPRs in the Field with respect to the Kinross Facility (each as defined below). 

NOW, THEREFORE, in consideration of these premises and the mutual covenants, agreements, representations and warranties herein contained,
the Parties hereby agree as follows: 
  

	1.	Definitions. 

 The
following terms and their correlatives will have the following meanings: 
 1.1 “Applicable Law” means all
applicable laws, rules and regulations (including those of any Regulatory Agencies) that may be in effect from time to time. 

1.2 “Commercial Validation of Performance” means that the Kinross Facility has successfully completed and passed a
Performance Test (as defined in the Guarantee Agreement set forth in Exhibit 2.3(e)); with respect to any Expanded Capacity, a separate Performance Test must be completed and passed for such Expanded Capacity. 

1.3 “Control”, “Controls” or “Controlled by” means, with respect to any Intellectual
Property Rights, the possession by Mascoma, during the Term, of the ability to grant to Licensee a sublicense as provided herein to such Intellectual Property Rights, limited to Intellectual Property Rights licensed to Mascoma pursuant to
(a) New Upstream Licenses under which Licensee elects to receive a sublicense hereunder pursuant to Section 2.4(b) and (b) Third Party 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
License Agreements (as defined in Section 1.31) (it being understood that Licensee is not a party to such third party agreements, nor has any obligations to Third Party Licensors under such
agreements and is not in privity of contract with any Third Party Licensors). 
 1.4 “Development and
Operation” (and its correlatives) means engineering, planning, construction, testing, qualification, validation, production, repair and maintenance, and expansion. 
 1.5 “EPA” means the U.S. Environmental Protection Agency, and any successor agency thereto. 
 1.6 “Exclusive Area” means the land area encompassing a 150 mile land radius around the Kinross Facility (which, for the avoidance of doubt, includes land mass in the United States and
Canada). 
 1.7 “Kinross Facility” means a cellulosic ethanol production facility operated by Licensee that
(a) is located at Kinross Charter Township, Michigan, and (b) has initial design capacity for cellulosic ethanol of twenty (20) MMGY, with expanded capacity rights as set forth in Section 4.2. 

1.8 “Feedstock” means hardwood biomass of such type, grade and composition that is generally available within the
Exclusive Area. 
 1.9 “Field” means the production of cellulosic ethanol by converting Feedstock directly into
Product using an Organism(s) in a facility. 
 1.10 “Initial Project Financing” means the initial closing of a
financing transaction pursuant to which the Licensee receives proceeds sufficient to commence the construction of the Kinross Facility with cellulosic ethanol production design capacity of at least twenty (20) MMGY for the performance of the
Project at the Kinross Facility. 
 1.11 “Intellectual Property Rights” means trade secret rights, copyrights,
Patents and other intellectual property rights. 
 1.12 “Mascoma Subsidiary” means any entity which (directly
or indirectly) is controlled by Mascoma. Notwithstanding the foregoing, the term “Mascoma Subsidiary” will not include Frontier or any subsidiaries of Frontier (including Licensee). For the purposes of this Section 1.12, the
term “control” (including its correlatives) means the direct or indirect possession of the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting securities, by contract
or otherwise. 
 1.13 “Mascoma IPRs” means all Intellectual Property Rights owned or Controlled by Mascoma (in
the territory(ies) in North America in which Licensee is permitted to perform the Mascoma Process or Mascoma Process Improvements and use the Organisms or Organism Improvements hereunder) during the Term for the use of the Mascoma Process or Mascoma
Process Improvements in order to manufacture Product directly from Feedstock using Organisms or Organism Improvements in the Kinross Facility or to manufacture additional supplies of 

  
 2 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
Organisms or Organism Improvements (in each case to the extent expressly permitted hereunder). Exhibit 1.13 lists Patents that are included within the Mascoma IPRs as of the Effective Date.

 1.14 “Mascoma Process” means a process for converting a Feedstock into Product using an organism(s) via
enzymatic hydrolysis and fermentation followed by distillation, which process is described in Exhibit 1.14A and Exhibit 1.14B. 
 1.15 “Mascoma Process Improvements” means any improvements made to the Mascoma Process, whether by Mascoma, Mascoma Subsidiaries, Licensee or Third Parties. [***] 

1.16 “Mascoma Process Validated Improvements” means any Mascoma Process Improvements that have (a)(i) been tested by
Mascoma in a pilot, demonstration, or commercial scale facility and that have passed the requirements reasonably determined by Mascoma for such testing and (ii) been certified by or on behalf of Mascoma as being free from any material risk of a
Third Party intellectual property claim or (b) otherwise been generally authorized for use by Mascoma with its Third Party Mascoma Process licensees. 
 1.17 “MMGY” means million Gallons per year. 
 1.18 “North
America”, for the purposes of this Agreement, means the United States, Canada and Mexico. 
 1.19
“Organism” means the proprietary microorganisms described in Exhibit 1.18. 
 1.20 “Organism
Improvements” means any improvements made to the Organisms, whether by Mascoma, Mascoma Subsidiaries, Licensee or Third Parties. [***] 
 1.21 “Organism Validated Improvements” means any Organism Improvements that have (a)(i) been tested by Mascoma in a pilot, demonstration, or commercial scale facility and that have passed
the requirements reasonably determined by Mascoma for such testing and (ii) been certified by or on behalf of Mascoma as being free from any material risk of a Third Party intellectual property claim or (b) otherwise been generally
authorized for use by Mascoma with its Third Party Mascoma Process licensees. 
 1.22 “Patent” means a patent
or patent application, including any additions, divisions, continuations, continuations-in-part, substitutions, reissues, reexaminations, registrations and renewals. 

  
 3 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 1.23 “Product” means cellulosic ethanol and
associated co-products and by-products. 
 1.24 “Project” means the Development and Operation of the Kinross
Facility for the commercial production of Product directly from Feedstock, together with such production at such Kinross Facility. 
 1.25 “Project Construction Phase Completion” means mechanical completion of the Kinross Facility. 
 1.26 “Regulatory Agency” means any national (e.g., the EPA), supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other
governmental entity. 
 1.27 “Regulatory Approvals” means all permits (including environmental and site
permits), licenses, approvals, permissions, registrations or authorizations of any Regulatory Agencies necessary in order for Licensee to exercise any of its rights hereunder, including the performance of the Project with respect to each Kinross
Facility. 
 1.28 “Rome Facility” means Mascoma’s cellulosic ethanol facility located in Rome, New York.

 1.29 “Term” means the term of this Agreement, as described in Section 10.1. 

1.30 “Third Party” means any person or entity other than Mascoma, Mascoma Subsidiaries and Licensee. 

1.31 “Mascoma’s Obligations Under Third Party License Agreements” means the obligations of Mascoma under any
agreement pursuant to which a Third Party Licensor has licensed or licenses to Mascoma any of the Mascoma IPRs as of the Effective Date and specifically listed in Exhibit 1.31 (“Third Party License Agreements”); it being understood
that Licensee does not have any obligations to such Third Party Licensor and all such obligations rest solely with Mascoma. 

1.32 “Third Party Licensor” means any Third Party that has licensed to Mascoma any of the Mascoma IPRs. 

1.33 “Gallon” means one standard United States liquid gallon comprising 231 cubic inches at 60 degrees Fahrenheit.

 1.34 “Ethanol Yield” means Gallons of cellulosic ethanol which, when blended with denaturant will meet the
specifications set forth in ASTM D 4806-11a per bone dry ton of Feedstock. 
 1.35 “JV Agreement” means
that certain LLC Agreement between Kinross, Diamond Alternative Energy, LLC and Frontier Renewable Resources, LLC (“Frontier”) of even date herewith. 

  
 4 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
  

	2.	License. 

 2.1 Mascoma
IPRs License. Subject to the terms and conditions of this Agreement, Mascoma hereby grants to Licensee during the Term a non-transferable, non-sublicensable license, under the Mascoma IPRs, to Use (as defined below) the Mascoma Process,
including the right to use the Organism and any and all Mascoma Process Improvements and Organism Improvements, in each case at the Kinross Facility. For the avoidance of doubt, the foregoing license does not include the right to, and Licensee will
not, (a) use the Mascoma Process outside the Field, or (b) use any trademarks of Mascoma in connection with the commercialization of any Products without Mascoma’s prior written consent. Such license is exclusive in the Exclusive
Area, and grants Licensee the right to use, including the rights for the design, maintenance, construction, operation and repair of the Kinross Facility (collectively, “Use”), the Mascoma Process in the Field and for the Kinross
Facility, to use in carrying out the Mascoma Process in the Field in the Kinross Facility any apparatus or Organism therefor, and to export to, sell or use in any country the Products of the Mascoma Process. 

2.2 Exclusive Area Exclusivity. During the Term, Mascoma will not grant any other license that may use Feedstock within the
Exclusive Area. 
 2.3 Engineering Design Package; Improvements; Organism Supply. The Mascoma Process includes the full
engineering design package provided to Licensee by Mascoma. 
 (a) Ability to Disclose. Mascoma hereby represents and
warrants that it is free to disclose such engineering design package to Licensee and such engineering package will be provided without obligation to account to a Third Party therefore, other than as specifically included in Exhibit 1.31. 

(b) Clarifications; Validated Improvements. The initial engineering design package will be made in accordance with the
Mascoma’s current process design. However, the parties agree to include without limitation (i) a [***] supply of Organisms supplied by Mascoma [***] to Licensee, as described in Section 3, plus any Organism Validated Improvements made
by or on behalf of Mascoma, and (ii) [***] access to all Mascoma Process Validated Improvements [***]. Mascoma will promptly provide Licensee with notice of any Mascoma Process Validated Improvements or Organism Validated Improvements [***].
However, notwithstanding anything contained herein, Licensee will not have any rights to any Mascoma Process Validated Improvements or Organism Validated Improvements hereunder that require Third Party Intellectual Property Rights to which Licensee
elects not to take a sublicense pursuant to Section 2.4(b). 

  
 5 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 (c) Organism Escrow. The parties will enter into a
third party escrow arrangement, at no charge to Licensee, for frozen Organism stock, which will be updated with Organisms or Organism Validated Improvements at Licensee’s direction as they are developed (but no more frequently than quarterly to
the extent any Organism Validated Improvements are developed), whereby Licensee would have the right to access and use such frozen organism stock within the scope of the license granted herein. Subject to the terms of this Agreement, Licensee shall
have the right to access and use frozen Organism stock for any reason within the scope of the license granted herein in the event Mascoma is unable or unwilling to supply Organisms as set forth herein. 

(d) Engineering Design Package; Support. [***], Mascoma will deliver a basic engineering design package (sufficient for a Third
Party contractor to conduct detailed engineering, procurement and construction with respect to the Mascoma Process) covering the components specified in Exhibit 2.3(d). For any Mascoma Process Validated Improvements for which Mascoma creates an
engineering design package, Mascoma will use commercially reasonable efforts to provide Licensee, [***] an engineering design package of similar detail and quality to the initial basic engineering design package. However, if Mascoma does not provide
or create an engineering design package for such Mascoma Process Validated Improvements, Licensee may use such Mascoma Process Validated Improvements to have an engineering design package created for itself for use at the Kinross Facility. However,
for the avoidance of doubt, if Mascoma or any other party by or through Mascoma, desires to obtain such design package, Licensee will reasonably cooperate to provide such package to Mascoma or such other party [***] 

(e) Support; Performance Guarantee. Mascoma will provide all startup technical support to Licensee, [***] until Commercial
Validation of Performance in accordance with Exhibit 2.3(e). In addition, all guarantees relating to the performance of the Kinross Facility are specified in Exhibit 2.3(e). As between Mascoma and Licensee, Licensee will remain
responsible for the detailed design, procurement, construction, operation and maintenance of the Kinross Facility, except as performed by Mascoma. 
 (f) Third Party Technologies. Subject to Section 5.4, Licensee, at its sole option and expense, will have the right to elect to use any Third Party technology (as permitted herein) at the
Kinross Facility. 
 2.4 Third Party License Agreements. 

(a) Initial Third Party License Obligations. Only those obligations specifically set forth in Exhibit 1.31 shall apply to
Licensee under this Agreement. 
 (b) New Third Party License Agreements. If Mascoma receives a license under any
Intellectual Property Rights of any Third Party that are sublicensable to Licensee 

  
 6 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
hereunder, and that cover or claim improvements to the Mascoma Process or Organisms, then Mascoma will notify Licensee in writing of such event and provide Licensee with a copy of the applicable
license agreement with such Third Party (“New Upstream License”) and notify Licensee as to the pass-through obligations of such New Upstream License, in each case subject to confidentiality obligations to which Mascoma may be bound,
but in no event any more stringent than those set forth in this Agreement. Licensee will have the right to elect in writing, at any time after receipt of such notice, whether or not to include any such Third Party Intellectual Property Rights in the
Intellectual Property Rights that are Controlled by Mascoma (and therefore sublicensed to Licensee) for purposes of this Agreement. If Licensee elects to have such Third Party Intellectual Property Rights included in this Agreement, such
Intellectual Property Rights will be deemed Controlled by Mascoma and thus licensed to Licensee as part of the Mascoma IPRs, and Licensee will comply with the pass-through obligations to which it agreed [***]. 

(c) Precedence. All rights and the license granted to Licensee hereunder are and will be subject to and limited in all respects by
the terms and conditions of all New Upstream Licenses under which Licensee elects to receive a sublicense, in each case that are applicable to Licensee. 
 (d) Certain Covenants. Mascoma has not and will not enter into any agreements with Third Parties or Mascoma Subsidiaries that limit or restrict any of the rights granted to Licensee hereunder.

 2.5 Certain Restrictions. Except as permitted herein, Licensee will not and will not aid any Third Party through
Licensee’s actions, to (i) manufacture, reproduce or use any Organisms or Organism Validated Improvements, or practice any method claimed or included in the Mascoma IPRs, outside of the Field, outside of the Kinross Facility, or otherwise
in any manner not permitted hereunder, including in violation of any Applicable Law, or (ii) sell, offer for sale, export, import, distribute, disclose, disassemble, analyze the structure of or reverse engineer any Organisms or Organism
Validated Improvements. 
 2.6 No Other Licenses or Rights. Except as expressly set forth herein, Mascoma reserves all
right, title and interest in and to the Mascoma IPRs. No license or other right is or will be created or granted hereunder by implication, estoppel or otherwise. 
  

	3.	Organism Supply. 


3.1 Supply of Cell Banks. Mascoma will supply Licensee, on a semi-annual basis, at a time reasonably requested by Licensee, with a
cell bank for the Organisms from which Licensee will obtain its supply of Organisms (the “Organism Cell Banks”). [***] 

  
 7 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
[***] 
 3.2 Ongoing Maintenance. Subject to Mascoma’s
fulfillment of its obligations, Licensee will be responsible for maintaining sufficient quantities of Organisms for purposes of exercising the license granted in Section 2.1. In furtherance of the foregoing, as part of the license granted in
Section 2.1, to the extent necessary to maintain a reasonable supply of Organisms, Licensee will have the right to manufacture Organisms by propagating Organisms that are either (a) contained in the Organism Cell Banks provided by Mascoma
or (b) replicated through propagation (including through multiple generations) from the Organism Cell Banks provided by Mascoma. 
 3.3 Re-Supply. If Licensee’s inventory of Organisms becomes genetically contaminated or otherwise non-viable such that Licensee is unable to maintain sufficient quantities of Organisms
pursuant to Section 3.2, Mascoma will use commercially reasonable efforts to re-supply Licensee with Organisms (in reasonable and appropriate quantities to be determined by the Parties) [***], If Licensee requires re-supplies of Organisms more
frequently than [***]. 
 3.4 Organism Warranties. Mascoma warrants that the Organisms furnished pursuant to this
Agreement will be without defect and will meet the specifications set forth in Exhibit 1.18 (“Specifications”). Mascoma agrees to timely supply certificates of analysis (“COA”) to Licensee for quality verification of the
supplied Organisms, which COAs will include the reasonable process parameters associated with Licensee’s quality programs. Licensee may independently test any Organism batch onsite or at a mutually agreed upon Third Party location (that is
bound by obligations of confidentiality consistent with Section 7), with testing processes and procedures mutually agreed upon by the Parties in advance. If such Third Party testing demonstrates non-conformance with Specifications, then
Licensee may reject any such Organism batch by providing written notice as described in this Section 3.4. Licensee must have such testing performed within [***] after receipt and provide Mascoma with a written notice of rejection within [***]
thereafter; otherwise, the Organisms will be deemed accepted. Mascoma will have no liability or responsibility for any negligent handling of the Organism after delivery to Licensee. However, regardless of handling issues, if Licensee requests
additional or replacement Organisms, Mascoma will use commercially reasonable efforts to promptly re-supply Licensee with new Organisms in accordance with Section 3.3. If Licensee uses the Mascoma Process or any Mascoma Process Validated
Improvements with any organisms other than Organisms and Organism Validated Improvements, then Mascoma’s guarantees and indemnities with respect to the Mascoma Process or any Mascoma Process Validated Improvements do not apply to the extent of
Licensee’s use of such other organisms. 

  
 8 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 [***] 

3.6 Delivery Transfer. All Organisms are furnished on a “delivered” basis, with risk of loss to Organisms passing at the
applicable offloading point at the Kinross Facility. Mascoma specifically retains ownership of and is responsible for the Organisms throughout the transportation and off-loading process, including within the delivery vehicle. 

 

	4.	License Fee; Payments. 

 [***] 
 4.2 Expanded Capacity. Licensee will have the unilateral option to
expand the design capacity of the Kinross Facility for up to an additional 60 MMGY of cellulosic ethanol in any number and amount of increments, for a total design capacity of eighty (80) MMGY of cellulosic ethanol (the “Expanded
Capacity”), subject to the payment of US$[***] (“Expanded Capacity License Fee”) to Mascoma. Such option may be exercised by Licensee upon written notice to Mascoma (the “Expanded Capacity Notice”). Mascoma
will deliver a basic engineering design package consistent with Section 2.3(d) for such Expanded Capacity, and Licensee will pay Mascoma 

  
 9 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
US[***] (the “Expanded Capacity Engineering Fee”) within [***] after delivery of such engineering package. Licensee will pay Mascoma an amount equal to [***]. Within [***] of the
completion of the final Product Test (as described in Section 3.2 of Exhibit 2.3(e)) (as adjusted to reflect the expected performance of such Expanded Capacity including any Mascoma Process Validated Improvements and Organism Validated
Improvements) for such Expanded Capacity, Licensee will pay [***]. 
 4.3 Running Royalties. 

(a) Royalties. Licensee will pay Mascoma a running royalty [***]; provided, however, that [***] if Licensee is not producing
ethanol in any material respect in the Kinross Facility due to an Event of Force Majeure or due to any change in Applicable Law during such time periods, such time periods will be extended for the length of any such non-production. [***] 


  
 10 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 Table 4.3 
 [***] 
 [***] 
 (b) Other Feedstock. Notwithstanding anything herein to the contrary, the initial intended feedstock for the Kinross Facility is Feedstock as defined herein; however, such Feedstock definition may
be broadened, upon the mutual written agreement of the Parties (which shall not be unreasonably withheld, delayed or conditioned by Mascoma) as to the parameters for such broadening, after the completion of the Commercial Validation of Performance.
For purposes hereof, the definition of “Feedstock” would then include any lignocellulosic biomass (including but not limited to soft wood, switchgrass, and corn stover) mutually agreed upon by the Parties. Should alternative feedstock(s)
become available that Licensee desires to process, Licensee must notify Mascoma in advance of processing such alternative feedstocks and the Parties must mutually agree in advance on the parameters for Licensee’s processing such alternative
feedstocks. Mascoma agrees to negotiate with Licensee in good faith regarding the parameters for processing alternative feedstock, and that Mascoma’s permission to process alternative feedstock shall not be unreasonably withheld, delayed or
conditioned. [***] 

  
 11 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 4.4 Reporting. For as long as Licensee has an
obligation to account for running royalties to Mascoma pursuant to Section 4.3, Licensee will furnish to Mascoma a written report, within [***], accounting for such royalties during such calendar quarter, together with information in sufficient
detail for Mascoma to determine the royalties that are owed to Mascoma under this Agreement. [***]. In addition, for purposes of Mascoma fulfilling its obligations to its Third Party Licensors, Licensee will provide Mascoma with the information set
forth in Exhibit 1.31 as part of such reports. 
 4.5 Payment Terms. 

(a) Payments. 
 (i) All payments to be made by Licensee to Mascoma hereunder will be made in U.S. dollars by wire transfer to such bank account as Mascoma may designate. 

(ii) For running royalties for which Licensee is required to pay Mascoma pursuant to Section 4.4, Licensee will pay such amounts to
Mascoma concurrently with the delivery of reports accounting for such royalties described in Section 4.4. 
 (b) Books
and Records. Throughout the Term (and, in the event of any termination of this Agreement, for as long as royalties are otherwise payable hereunder), Licensee will keep adequate books and records for the purposes of calculating all amounts
payable by Licensee to Mascoma hereunder (and any amounts payable by Licensee to Mascoma pursuant to New Upstream Licenses, as applicable). For the removal of doubt, Licensee shall be required to maintain such records for [***] from the date of
their creation. Licensee will also maintain such books and records at its principal place of business and keep them open for inspection at reasonable times and upon reasonable notice by Mascoma to verify all amounts payable to Mascoma hereunder. The
information provided or made available to Mascoma in accordance with this Section 4.5(b) will be deemed “Confidential Information” of Licensee hereunder. [***] Licensee will also permit any and all Mascoma Third Party auditors, bound
under a provision of confidentiality no less stringent than those set forth in this Agreement, to inspect or audit such books and records. [***]. 
 (c) Taxes. Licensee may withhold from payments due to Mascoma amounts for payment of any withholding tax that is required by Applicable Law to be paid to any taxing authority with respect to such
payments. Licensee will provide Mascoma all relevant documents 

  
 12 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
and correspondence, including evidence from time to time as to the payment of such tax, and will also provide to Mascoma any other cooperation or assistance on a reasonable basis as may be
necessary to enable Mascoma to claim exemption from such withholding taxes. Apart from any such permitted withholding, the amounts payable by Licensee to Mascoma hereunder will not be reduced on account of any taxes, charges, duties or other levies,
but excluding any taxes based upon the income of Mascoma, Mascoma gross receipts taxes, Mascoma license registration fees and the like or any taxes related to Mascoma’s conducting business. Mascoma will reasonably cooperate with Licensee with
respect to obtaining tax exemptions or any tax credits applicable to Licensee. 
 (d) Interest Due. Licensee will pay
Mascoma interest on any undisputed payments that are not paid on or before the date such payments are due under this Agreement [***] 
 (e) [***] 
 (i) [***]


  
 13 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
[***] 
 (ii) Mascoma will maintain records in the ordinary course of
business on all such licenses. During [***], Licensee will have the right during normal business hours and upon reasonable notice to inspect and copy such records solely for the purpose of verifying that the Qualifying Project Site’s cost
[***]. Licensee may retain such information only for so long as reasonably necessary to verify the foregoing or enforce this Section 4.5(e). All Mascoma information obtained or made available in connection with such audit shall be deemed the
Confidential Information of Mascoma. 
 (iii) [***] 
 (iv) [***] 
  

	5.	Other Covenants of the Parties. 

 5.1 Equipment. Any equipment required to operate the Kinross Facility would be sourced by Licensee as follows: 
 [***] 
 [***] 

5.2 Access to Kinross Facility and Data. 

  
 14 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 (a) Mascoma Access. Upon at least [***] advance
written notice to Licensee, Mascoma will have the right to enter and have reasonable access to the Kinross Facility, under the supervision of Licensee, for the purpose of observing the operation of the Mascoma Process at the Kinross Facility.
Further, within [***] after Mascoma’s reasonable request, Licensee will provide Mascoma with a copy of relevant operating data relating to the Mascoma Process at the Kinross Facility, among other purposes, for the purpose of Mascoma’s
analysis and comparison of such operating data with operating data for the Rome Facility and Mascoma’s cellulosic ethanol facility located in Lebanon, New Hampshire. Notwithstanding the foregoing, such access may not create an unreasonable
burden on the Kinross Facility plant operations. 
 (b) Licensee Access. Prior to the date the first Commercial
Validation of Performance of the Kinross Facility, upon at least [***] advance written notice to Mascoma, Licensee will have the right to enter and have reasonable access to the Rome Facility, under the supervision of Mascoma, for the purpose of
observing the operation of the Mascoma Process at the Rome Facility to the extent substantially related to Licensee’s activities hereunder. Further, within [***] after Licensee’s reasonable request, Mascoma will provide Licensee with a
copy of relevant operating data relating to the Mascoma Process at the Rome Facility, among other purposes, for the purpose of Licensee’s analysis and comparison of such operating data with operating data for the Kinross Facility and to aid
Licensee with any construction, maintenance, repair or operational issues that pertain to the Mascoma Process. Notwithstanding the foregoing, such access may not create an unreasonable burden on the Rome Facility plant operations. 

5.3 Compliance. 
 (a) Compliance with Applicable Law. Each Party will comply with all Applicable Law and accepted industry practices in the performance of any and all of their obligations and the exercise of any and
all of their rights hereunder. 
 (b) Regulatory Approvals. Without limiting the foregoing, Licensee will obtain the
Regulatory Approvals necessary for Licensee to exercise any of its rights hereunder, including obtaining permits, licenses and permissions required to Develop and Operate the Kinross Facility; for the avoidance of doubt Mascoma shall ensure that the
Organism and any Organism Validated Improvements have full Regulatory Agency approvals for use at the Kinross Facility, including as used as part of the Mascoma Process (for example, and without limitation, Regulatory Agency approvals for commercial
use of a genetically modified organism). 
 5.4 Exclusivity. 

(a) Exclusivity Obligation. During the Term, Licensee will work exclusively with Mascoma in the Field with respect to the Mascoma
Process, Mascoma Process Validated Improvements, Organisms and Organism Validated Improvements (other than as permitted below) at the Kinross Facility. Notwithstanding the foregoing, without limiting Mascoma’s rights to the Process-Related IP
or Field-Related IP (each as defined in Section 6), Licensee will have the right to incorporate non-Mascoma Third Party technologies at the Kinross Facility 

  
 15 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
[***], provided that at the time of such incorporation, such Third Party technology does not circumvent the Mascoma Process, Mascoma Process Validated Improvements, Organisms or Organism
Validated Improvements, as applicable. 
 [***] 
 [***] 
 [***] 

  
 16 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
  

	6.	Developed Intellectual Property. 

 6.1 Process-Related IP. Without limiting clause (i) of Section 5.4(b), if not restricted or otherwise limited by other obligations or Applicable Laws, Licensee hereby assigns to Mascoma
any intellectual property created, conceived and reduced to practice by or on behalf of Licensee in the course of operating the Kinross Facility during the Term that directly relates to the Mascoma Process (or any Mascoma Process Validated
Improvements) or Organisms (or any Organism Validated Improvements) (“Process-Related IP”), provided that Licensee will retain a perpetual, irrevocable, non-exclusive, royalty-free, non-terminable, unrestricted right and license to
use and otherwise fully exploit any and all such assigned Process-Related IP and further provided that Mascoma will only be able to license (or allow the sublicense of) such assigned Process-Related IP to the Third Party licensees of Mascoma
technology that are contractually bound to permit the licensing to Licensee of intellectual property directly related to the Mascoma Process created by such Third Party licensees. Licensee will cooperate with Mascoma to effectuate and perfect the
foregoing assignment, including by executing within a reasonable period assignments and other documents consistent with such ownership by Mascoma. All Process-Related IP will be deemed the Confidential Information of Mascoma (subject to
Section 7.1(b)). To the extent that any information included in the Process-Related IP pertains to Licensee’s business or finances, such information shall be deemed Confidential Information of Licensee, provided that if Mascoma desires to
disclose any such information of Licensee, then Mascoma will request Licensee’s consent to such disclosure, and Licensee will respond within [***] after such request and specify in writing which information it desires to redact, if any,
provided further that if any such information is required for any regulatory filing, Mascoma may include such information in such filing without Licensee’s prior approval, but Mascoma will consult with Licensee prior to making any such filing.
Notwithstanding the foregoing, Mascoma shall only disclose that amount of information that is reasonably necessary to meet its obligations but in all cases, Mascoma shall remove items specifically identifying Kinross or the performance of the
Kinross Facility. 
 6.2 Responsibility; Cooperation. As between Mascoma and Licensee, Mascoma will have the sole
responsibility hereunder to procure, maintain, enforce and defend all Process-Related IP (except as set forth herein, in its sole discretion) and Mascoma IPRs and will be responsible for any and all related filings, recordings, or other means of
protection, including the payment of any and all such fees, expenses and costs, including, by way of example, any corresponding patent prosecution and maintenance fees. Licensee will use commercially reasonable efforts to cooperate with Mascoma, in
Mascoma’s procurement, maintenance, enforcement and defense of the Mascoma IPRs and Process-Related IP, at Mascoma’s 

  
 17 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
reasonable expense. Licensee shall not have the obligation to patent or otherwise protect any of the Process-Related IP, but will use commercially reasonable efforts to cooperate with Mascoma as
set forth above. 
 (a) Records. Licensee will maintain records in the ordinary course of business. To the extent such
records relate to the Process-Related IP and Field-Related IP, Mascoma will have the right, during normal business hours and upon reasonable notice, to inspect and copy any such records of Licensee. 

6.3 Field-Related IP. Subject to the terms and conditions of this Agreement, Licensee hereby grants to Mascoma a perpetual,
irrevocable, non-exclusive, royalty-free, sublicensable (through multiple tiers), non-terminable right and license to use and otherwise fully exploit any and all intellectual property, other than Process-Related IP, with applicability in the Field,
that is developed or created by or on behalf of Licensee during the Term in the course of operating the Kinross Facility (“Field-Related IP”), to the extent Licensee owns or can sublicense such intellectual property. Mascoma shall
have no right to any intellectual property developed by or on behalf of Licensee, other than the Process-Related IP and Field-Related IP. However, Mascoma shall only be able to further sublicense any Field-Related IP to the other Third Party or
Mascoma Subsidiary licensees of Mascoma in the Field who have obtained a license from Mascoma to the Mascoma Process to the extent such other licensees have agreed to permit the sublicense to Licensee in the Field of such Third Party or Mascoma
Subsidiary licensees’ Field-related intellectual property developed or created in the course of operating their licensed facilities (it being understood that Licensee will have the right to elect whether or not to license such Third Party or
Mascoma Subsidiary licensees’ Field-related intellectual property pursuant to Section 2.4(b)), to the extent such Third Party or Mascoma Subsidiary licensee owns or can sublicense such intellectual property. For the avoidance of doubt, in
order for Field-Related IP to be sublicensable to a licensee of Mascoma, such licensee must agree to allow the sublicense of its Field-related intellectual property to Licensee without cost to Licensee. 

6.4 No Representations or Warranties. Notwithstanding any of the foregoing assignment or use of Process-Related IP or
Field-Related IP, Licensee makes no representations or warranty of any kind with respect to the Process-Related IP or Field-Related IP, and any and all use of such Process-Related IP or Field-Related IP shall be at Mascoma’s sole expense and
risk. 
 6.5 Disclosure of New Intellectual Property and Assignments. To the extent permitted herein, Licensee will use
commercially reasonable efforts to (a) disclose to Mascoma Process-Related IP and Field-Related IP created, conceived and reduced to practice by or on behalf of Licensee in the course of operating the Kinross Facility, and (b) cause its
employees, agents and contractors to assign their rights, title and interests in such Process-Related IP or Field-Related IP to Licensee (for further assignment of the Process-Related IP to Mascoma as set forth above), but so long as Licensee
complies with its obligation to use such efforts, Licensee will not be obligated to ensure such disclosure or assignment occurs. 
 6.6 Enforcement of Mascoma IPRs. 

  
 18 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 (a) Notification. To the extent not violative of any
contractual commitment of Licensee, Licensee will promptly notify Mascoma, in writing, upon Licensee learning of any actual or suspected infringement by a Third Party of any Patents contained within the Mascoma IPRs (“Mascoma
Patents”) within the Exclusive Area. 
 (b) Enforcement in the Exclusive Area. During the Term, to the extent
permitted under Third Party License Agreements to which Mascoma is bound, Mascoma agrees to enforce any Mascoma Patents against Third Party infringers in the Field in the Exclusive Area (using the level of diligence commonly dedicated by a company
in the bioethanol industry to the enforcement of patents against infringement that has a materially adverse competitive effect on such company’s own commercialized product of similar commercial value, in each case taking into account issues of
geographic territory, proprietary position, the then-current competitive environment for such product and other scientific, technical and commercial factors) at no cost to Licensee. 

6.7 Joint Research Agreement. For the limited purposes pertaining to Process-Related IP developed during the Term by or on behalf
of Licensee, this Agreement will be understood to be a joint research agreement in accordance with 35 U.S.C. § 103(c)(3), provided that neither Party will not be required by this reference to have any Patent take advantage of or become subject
to such § 103(c)(3). 
  

	7.	Confidentiality. 

 7.1
Confidential Information. 
 (a) Scope. “Confidential Information” means, subject to the
exceptions set forth in the following sentence, any information or data, regardless of whether it is in tangible form, disclosed by either Party (the “Disclosing Party”) that the Disclosing Party has either marked as confidential or
proprietary, or has identified in writing as confidential or proprietary within thirty (30) days of disclosure to the other Party (the “Receiving Party”); provided, however, that [***] will be deemed Confidential Information of
the Disclosing Party even if not so marked or identified, unless any such report or information is the subject of any of the exceptions set forth in Section 7.1(b). 
 (b) Exceptions. Information and data will not be deemed Confidential Information hereunder if such information: (i) is known to the Receiving Party prior to receipt from the Disclosing Party
directly or indirectly from a source other than one having an obligation of confidentiality to the Disclosing Party; (ii) becomes known (independently of disclosure by the Disclosing Party) to the Receiving Party directly or indirectly from a
source other than one having an obligation of confidentiality to the Disclosing Party; (iii) becomes publicly known or otherwise ceases to be secret or confidential, except through a breach of this Agreement by the Receiving Party; or
(iv) is independently developed by the Receiving Party without reference to or use of the Confidential Information of the Disclosing Party. Notwithstanding the foregoing, 

  
 19 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
(i) technical information disclosed under this Agreement will not be deemed to be within the foregoing exceptions merely because such information is embraced by more general information that is
publicly known or in the Receiving Party’s possession, and (ii) any combination of features will not be deemed to be within the foregoing exceptions merely because individual features are publicly known or in the Receiving Party’s
possession, but only if the combination itself and its principle of operation are publicly known or in the Receiving Party’s possession. 
 (c) Use and Disclosure of Confidential Information. The Receiving Party will not (i) use any Confidential Information of the Disclosing Party in any way, for its own account or the account of
any other person or entity, except for the exercise of its rights and performance of its obligations under this Agreement, or (ii) disclose any such Confidential Information to any person or entity, other than furnishing such Confidential
Information to (a) its employees and consultants who are required to have access to the Confidential Information in connection with the exercise of the Receiving Party’s rights and performance of its obligations under this Agreement,
(b) existing and prospective investors and/or acquirers that are contemplating a potential investment in or acquisition of the Receiving Party and professional advisers (e.g., lawyers and accountants), or (c) in the case of Mascoma as the
Receiving Party, to a Third Party Licensor to the extent disclosed in this Agreement (but subject to the confidentiality obligations consistent with those contained in this Agreement) or to its Third Party or Mascoma Subsidiary licensees with
respect to Field-related IP pursuant to Section 6.3; provided, however, that any and all such employees, consultants, investors and acquirers and advisers, Third Party Licensors and licensees are bound by written agreements (or in the case of
such lawyers and other professional advisors, ethical duties) to treat, hold and maintain such Confidential Information in accordance with the terms and conditions of this Section 7. The Receiving Party will not allow any unauthorized person
access to the Disclosing Party’s Confidential Information, and the Receiving Party will take all action reasonably necessary to protect the confidentiality of such Confidential Information, including implementing and enforcing procedures to
minimize the possibility of unauthorized use or copying of such Confidential Information. In the event that the Receiving Party is required by Applicable Law to make any disclosure of any of the Disclosing Party’s Confidential Information, by
subpoena, judicial or administrative order or otherwise, the Receiving Party will first give written notice of such requirement to the Disclosing Party, and will permit the Disclosing Party to intervene in any relevant proceedings to protect its
interests in such Confidential Information, and shall provide reasonable cooperation and assistance to the Disclosing Party in seeking to obtain such protection. 
 (d) Terms of this Agreement. 
 (i) Each Party will not disclose any of the
terms of this Agreement to any Third Party without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may disclose such terms as are required to be disclosed (i) to its accountants and advisors who have a
“need-to-know” solely for the purpose of providing services to such Party, or (ii) to existing and potential investors, lenders and acquirers and the accountants and advisors of any of the foregoing; provided, however, that any such
recipient is bound by a written agreement (or in the case of such lawyers and other professional advisors, ethical duties) requiring such recipients to treat, hold and maintain the terms of this Agreement as Confidential Information in accordance
with the terms and conditions of this 

  
 20 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
Section 7. Further, notwithstanding the foregoing, Mascoma may disclose the terms and conditions of this Agreement to any Third Party Licensor to the extent required as a Mascoma obligation
as specified in Exhibit 1.30. 
 (ii) In addition, this Agreement and terms hereof may be disclosed by either Party only if and
to the extent required pursuant to Applicable Law (including stock market or stock exchange rules; e.g., rules or regulations of the United States Securities and Exchange Commission, the Nasdaq or the NYSE), provided that a Party proposing to
make such a disclosure as required by Applicable Law will inform the other Party of such required disclosure and provide the other Party with a copy of the text of such proposed disclosure at least [***] prior to any proposed initial disclosure (and
[***] prior to any required revisions to such disclosure) unless otherwise agreed to by the parties in writing, to afford such other Party a reasonable opportunity to review and comment upon the proposed disclosure (including, if applicable, the
redacted version of this Agreement) and will reasonably consider, consistent with Applicable Law (including interpretations thereof), the requests of the other Party regarding confidential treatment for such disclosure. 

7.2 Press Releases. No Party may issue a press release regarding this Agreement or any other related transaction absent the
express prior written approval of the other Party. 
 [***] 

 

	8.	Representations and Warranties; Disclaimers; Limitations of Liability. 


8.1 Mascoma. Mascoma hereby represents and warrants to Licensee that as of the Effective Date: 

(a) all corporate action on the part of Mascoma and on the part of each of its officers and directors necessary for the authorization,
execution and delivery of this Agreement and the performance of its obligations hereunder has been taken; 
 (b) this Agreement
is the legal, valid and binding obligation of Mascoma, enforceable against it in accordance with its terms, subject, as to enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting
creditors’ rights generally, and to general equitable principles; 
 (c) neither the execution and delivery of this
Agreement nor the performance of the obligations contemplated hereby will: (i) conflict with or result in any violation of or constitute a breach of any of the terms or provisions of, or result in the acceleration of any obligation under, or
constitute a default under any provision of any contract or any other obligation to which Mascoma is a party or under which Mascoma is subject or bound, or (ii) violate any judgment, order, injunction, decree or award of any Regulatory Agency
against, or affecting or binding upon, Mascoma or upon the assets, property or business of Mascoma, or (iii) constitute a violation by Mascoma of any Applicable Law of any jurisdiction as such Applicable Law relates to Mascoma or to the
property or business of Mascoma; 

  
 21 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 (d) it has the right to grant Licensee the license set forth
in Section 2.1 for the Use of the Mascoma Process, including the rights under the Mascoma IPRs, and Use of the Organism in the Mascoma Process; 
 (e) it is in full compliance with the terms and obligations of the Third Party License Agreements that are valid and in effect as of the Effective Date of this Agreement; and . 

(f) the Organism (including use of the Organism as part of the Mascoma Process) have full Regulatory Agency approvals for use at the
Kinross Facility. 
 8.2 Licensee. Licensee hereby represents and warrants to Mascoma that as of the Effective Date:

 (a) all corporate action on the part of Licensee and on the part of each of its officers, members, or managers necessary for
the authorization, execution and delivery of this Agreement and the performance of its obligations hereunder has been taken; 

(b) this Agreement is the legal, valid and binding obligation of Licensee, enforceable against it in accordance with its terms, subject,
as to enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting creditors’ rights generally, and to general equitable principles; and 

(c) neither the execution and delivery of this Agreement nor the performance of the obligations contemplated hereby will:
(i) conflict with or result in any violation of or constitute a breach of any of the terms or provisions of, or result in the acceleration of any obligation under, or constitute a default under any provision of any contract or any other
obligation to which Licensee is a party or under which Licensee is subject or bound, or (ii) violate any judgment, order, injunction, decree or award of any Regulatory Agency against, or affecting or binding upon, Licensee or upon the assets,
property or business of Licensee, or (iii) constitute a violation by Licensee of any Applicable Law of any jurisdiction as such Applicable Law relates to Licensee or to the property or business of Licensee. 

8.3 Disclaimer of Warranties. 
 (a) Notwithstanding anything to the contrary in this Agreement, Mascoma specifically disclaims any representation, warranty or guarantee that the Project will be an economically viable commercial
operation, and all other implied warranties, except for the warranties expressly set forth herein. 
  

	9.	Indemnification. 

 9.1
Indemnification by Licensee. [***] 
 9.2 Indemnification by Mascoma. 

(a) [***] 

  
 22 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 (b) Mascoma will defend, indemnify and hold harmless Licensee
and its directors, officers, employees and agents, and their successors, heirs and assigns (collectively, “Licensee Indemnitees”), from and against any and all Losses arising from or in connection with all Claims that may be
threatened, assessed in or become payable under any settlement, or decree or judgment by any court or Regulatory Agency, which results from such Claims to the extent arising from infringement of any Intellectual Property Rights of a Third Party
arising out of or in connection with (1) the disclosure by or through Mascoma of the Mascoma Process, Mascoma Process Validated Improvements or information provided by Mascoma, (2) possession by Licensee of the information provided by or
through Mascoma regarding the Mascoma Process, Mascoma Process Validated Improvements or information provided by Mascoma, or (3) license to Licensee or Use of the Mascoma Process, Mascoma Process Validated Improvements or any portion of the
Mascoma Process or Mascoma Process Validated Improvements, or technology provided by Mascoma hereunder, including the use or possession of the Organisms and Organism Validated Improvements. 

(c) Reserved 

(d) Notwithstanding the foregoing, Mascoma’s obligations under this Section 9.2 will not apply to Claims of a Third Party to
the extent based on (x) the combination of the Mascoma Process, Mascoma Process Validated Improvements, Organisms or Organism Validated Improvements with a third party technology or organism not provided by or through Mascoma unless Mascoma was
provided with prior written notice of such combination for purposes of its obligations in Section 9.2(b) and did not object to such combination, (y) modifications of the Mascoma Process, Mascoma Process Validated Improvements, Organisms or
Organism Validated Improvements by Licensee, unless Mascoma was provided with prior written notice of such modifications for purposes of its obligations in Section 9.2(b) and did not object to such modifications, or (z) unauthorized use of
the Mascoma Process, Mascoma Process Validated Improvements, Organisms or Organism Validated Improvements unless Mascoma was provided with prior written notice of such use for purposes of its obligations in Section 9.2(b) and did not object to
such use. 
 (e) If the Mascoma Process or any Mascoma Process Validated Improvements, Organism or Organism Validated
Improvement is subject to a Claim of a Third Party claiming that the Mascoma Process, Mascoma Process Validated Improvement, Organism or Organism Validated Improvement infringes a Third Party’s Intellectual Property Right, or in Mascoma’s
opinion is likely to become the subject of such a claim, Mascoma will have the right to either: (a) procure for Licensee the right to continue using the Mascoma Process, Mascoma Process Validated Improvement, Organism or Organism Validated
Improvement provided such procurement does not materially increase the costs or expenses for Licensee; (b) modify the Mascoma Process, Mascoma Process Validated Improvement, Organism or Organism Validated Improvement so that it becomes
non-infringing but only if approved by Licensee (such approval will not be unreasonably withheld or delayed) and provided such modification does not materially degrade, slow or increase costs or expenses for Licensee; or (c) substitute the
allegedly infringing portion of the Mascoma Process, Mascoma Process Validated Improvement, Organism or Organism Validated Improvement with other non-infringing processes or catalysts but only if approved by Licensee (such approval will not be
unreasonably withheld or delayed) 

  
 23 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 and, provided such substitution does not materially degrade, slow or increase
the costs or expenses for Licensee. 
 (f) Provided that Mascoma has complied with its obligations under Section 9.2(b) and
(e), the provisions herein are Licensee’s sole and exclusive remedy in connection with actual or alleged infringement of any Intellectual Property Rights of a Third Party. 

9.3 Process. 
 (a) If a Mascoma Indemnitee or Licensee Indemnitee (the “Indemnitee”) intends to claim indemnification under this Section 9, the Indemnitee will notify the indemnifying Party (the
“Indemnitor”) in writing promptly upon becoming aware of any Claim (it being understood and agreed, however, that the failure by an Indemnitee to give such notice will not relieve the Indemnitor of its indemnification obligation
under this Agreement except to the extent materially prejudiced thereby). 
 (b) The Indemnitor will be fully responsible for
the defense of any such Claim at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee; provided, however the Indemnitee shall have the right to be represented by advisory counsel of its own selection.
The Indemnitor will reasonably consult with the Indemnitee with respect to the defense of any Claims. The Indemnitee will render the Indemnitor all reasonable cooperation, assistance and information that may be required by the Indemnitor in the
defense of such Claim, at the Indemnitor’s reasonable costs and expense. 
 (c) The Indemnitor will not, except with the
approval of the the Indemmnitee, consent to entry of any judgment or enter into any settlement that (a) would result in injunctive or other relief being imposed against the Indemnitee, (b) does not include as a term thereof an
unconditional release for the benefit of the Indemnitee from all liability in respect to such Losses, and (c) would impose unreasonable costs on the Indemnitee. 
 9.4 Limitations of Liability. 
 NOTWITHSTANDING ANY OTHER PROVISION IN THIS
AGREEMENT, EXCEPT FOR (A) LICENSEE’S BREACH OF THE SCOPE OF THE LICENSE GRANTED HEREIN, (B) EITHER PARTY’S BREACH OF SECTION 7 OR (C) LIABILITY ARISING FROM SECTION 9, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY
CONSEQUENTIAL, INDIRECT, PUNITIVE, INCIDENTAL OR SPECIAL DAMAGES, LOSS OF PROFITS OR GOODWILL OR FOR EXEMPLARY DAMAGES, IN EACH CASE EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

10. Term and Termination. 
 10.1 Term. This Agreement will commence as of the Effective Date and will continue for a period of [***] and will continue thereafter unless (i) terminated by Licensee in writing by giving
[***] notice, or unless sooner terminated in 

  
 24 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 accordance with the terms hereof or by mutual written consent, or
(ii) until the final dissolution or winding up of the Licensee or permanent discontinuation of the operation of the Kinross Facility. 
 (a) In the event this Agreement terminates pursuant to clause (i) above (other than pursuant to Section 10.2), Licensee will continue to have the right to use the Mascoma Process and Mascoma
Process Validated Improvements (as they existed at the time of termination) pursuant to the license granted in Section 2.1 with respect to the Kinross Facility for the ethanol capacity existing at the time of termination for which the
corresponding license fee(s) under Sections 4.1 and 4.2 have been paid, and the royalties payable under Section 4.3 will continue to be payable until the expiration of their royalty term in accordance with Section 4.3 to the extent
Licensee continues to produce ethanol using Organisms or Organism Validated Improvements during such royalty term, even after such termination; for clarity, Mascoma shall continue to provide to the Kinross Facility the latest Organism or Organism
Validated Improvements as of the date of termination [***], except that if Licensee fails to pay any undisputed royalties within [***] after receipt of written notice thereof, or Licensee breaches the scope of the license granted herein, and, in
either event, Licensee fails to commence to cure such breach within [***] after receipt of written notice thereof or to continually use commercially reasonable efforts to cure such breach after such [***] period, then Mascoma will no longer have any
obligation to provide Licensee with any Organisms or Organism Validated Improvements. Following termination Kinross shall have the sole option to continue to use the Mascoma Organism, [***]. If Mascoma develops an improved organism after
termination, the parties will negotiate separate terms relating to the commercial supply thereof. 
 (b) If this Agreement
expires pursuant to clause (ii) above or is terminated pursuant to Section 10.2, the license granted in Section 2.1 shall automatically terminate, except that if this Agreement is terminated pursuant to Section 10.2, Licensee
will continue to have the right to use the Mascoma Process and Mascoma Process Validated Improvements pursuant to the terms of the license granted in Section 2.1 with respect to the Kinross Facility for the ethanol capacity existing at the time
of termination for which the corresponding license fee(s) under Sections 4.1 and 4.2 have been paid, but Licensee will have no rights to any Organisms or Organism Validated Improvements (and Licensee will not use any Organisms or Organism Validated
Improvements) absent the written consent of Mascoma. 
 (c) In any case, upon any expiration or termination of this Agreement,
Mascoma will have no further obligation to provide Licensee with access or any rights to any future improvements thereto and Licensee will have no further obligation to provide Mascoma with access or any rights to any future improvements thereto.

 10.2 Early Termination by Mascoma. Mascoma will have the right to terminate this Agreement in full immediately upon
written notice to Licensee in the event that: 
 (a) Licensee fails to pay Mascoma any amounts not disputed in good faith when
due in accordance with Article 4, and, after proper written notice to Licensee from 

  
 25 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 Mascoma, such failure to pay remains uncured through no fault of Mascoma for
more than [***]; 
 (b) the Initial Project Financing has not closed, or construction of the Kinross Facility has not commenced,
within [***] after the Effective Date (which [***] period will be tolled to the extent (i) any support provided by or through Mascoma causes any delays or (ii) the Manager (as defined in the JV Agreement) elects to delay completion of the
Phase I Project (as defined in the JV Agreement) pursuant to Section 10.9 in the JV Agreement), or if the Project Construction Phase Completion for the Kinross Facility has not been successfully achieved within [***] after such commencement of
construction (which [***] period will be tolled to the extent the Manager elects to delay completion of the Phase I Project pursuant to Section 10.9 in the JV Agreement), unless delayed by a Force Majeure Event (as defined in
Section 14.9), provided that Licensee will use commercially reasonable efforts to mitigate the Force Majeure Event and in any case if any Force Majeure Event(s) result in aggregate delays of longer than [***], such termination right will apply;

 (c) Licensee materially breaches any covenant, obligation, representation or warranty contained herein and Licensee does not
cure such breach or, if the breach cannot reasonably be cured within the required [***], commence to cure (and Mascoma agrees with the cure proposed by Licensee, which agreement will not be unreasonably withheld, delayed or conditioned) such breach
within [***] after the receipt by Licensee of written notice specifying the nature of the alleged material breach; 
 (d)
Licensee has abandoned efforts to commence commercial production of Product at the Kinross Facility using the Mascoma Process within [***] such Project Construction Phase Completion has been successfully achieved, unless the reason is an Event of
Force Majeure, provided that Licensee will use commercially reasonable efforts to mitigate the Force Majeure Event. 
 10.3
Early Termination by Licensee. Licensee will have the right to terminate this Agreement in full immediately upon written notice to Mascoma in the event that Mascoma materially breaches any covenant, obligation, representation or warranty
contained herein and Mascoma does not cure such breach or, if the breach cannot reasonably be cured within the required [***], commence to cure (and Licensee agrees with the cure proposed by Mascoma, which agreement will not be unreasonably
withheld, delayed or conditioned) such breach within [***] after the receipt by Mascoma of written notice specifying the nature of the alleged material breach. 
 10.4 Certain Effects of Termination. Upon any expiration or termination of this Agreement: 
 (a) If the license granted in Section 2.1 survives termination pursuant to Section 10.1(a), then (i) Section 10.4 (b) will not apply to any Confidential Information of Mascoma
related to the Mascoma Process, Mascoma Process Validated Improvements, Organisms or Organism Validated Improvements (but, for clarity, Licensee shall continue to be 

  
 26 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 obligated to maintain the same as confidential pursuant to Section 7),
provided that if Licensee no longer has the right to use Organisms or Organism Validated Improvements, then Section 10.4(b) will apply to Confidential Information of Mascoma related to Organisms or Organism Validated Improvements, and
(ii) Licensee will further have the non-exclusive right to produce (or have produced), or to make (or have made) the Organism and Organism Improvements for the Kinross Facility in the Exclusive Area only for as long as it continues to have the
right to use Organisms and Organism Improvements, provided that such Organism and Organism Improvements are used solely within the scope of the license granted in Section 2.1. 

(b) Upon written request after such expiration or termination, (i) all materials containing such Confidential Information of the
Disclosing Party in the Receiving Party’s possession or control will be returned by the Receiving Party or destroyed with the Disclosing Party’s prior written consent (files archived in electronic format will be deleted in the ordinary
course of business but will not be used after termination of this Agreement), and (ii) all Organisms and Organism Validated Improvements in Licensee’s possession or control will be returned to Mascoma by Licensee or destroyed with
Mascoma’s prior written consent. With respect to the foregoing clause (i), an officer of the Receiving Party will certify in writing to the Disclosing Party that the Receiving Party has complied with its obligations under such clause
(i) and, with respect to the foregoing clause (ii), an officer of Licensee will certify in writing to Mascoma that Licensee has complied with its obligations under such clause (ii). The return of any Confidential Information will not relieve
the Receiving Party of any of its obligations hereunder. Notwithstanding the foregoing, Mascoma and its Third Party or Mascoma Subsidiary licensees may retain the Field-related IP that constitutes Confidential Information of Licensee, so long as
they maintain the confidentiality of such Confidential Information in accordance with Section 7 for so long as such Confidential Information is retained and the Field-related IP is used only for the purposes as provided herein. 

(c) For clarity, upon any expiration or termination of this Agreement, Licensee will have the right to repurpose any of its equipment
used as part of the Mascoma Process, provided that Licensee will not disclose any Confidential Information of Mascoma to any Third Parties in connection with such repurposing unless protected by a confidentiality agreement consistent with the
obligations contained in this Agreement, subject in any case to Exhibit 1.14A and Exhibit 1.14B. 
 10.5
Survival. The following provisions will survive termination or expiration of this Agreement, as well as any other provision which by its terms or by the context thereof, is intended to survive such termination: 1, 6 (solely with respect to
Process-Related IP and Field-Related IP disclosed or required to be disclosed pursuant to Section 6.5 prior to termination or expiration), 7, 9, 10, 11, 12, [13] and 14; and, if the license granted in Section 2.1 survives, Sections 2.1,
2.2 (only to the extent Organisms and Organism Validated Improvements are supplied by Mascoma and only for so long as Licensee is obligated to pay and pays royalties hereunder with respect thereto), 2.3(c) (but only to the extent Organisms and
Organism Validated Improvements are supplied by Mascoma), 2.4 (only to the extent Licensee has elected to receive any New Upstream Licenses), 2.5, 2.6, 3, 4.3 (to the extent Licensee is using Organisms and Organism Validated Improvements and subject
to the royalty term), 4.4, 4.5, 5.3 , in each case subject to the other terms and conditions of this Section 10. Termination or 

  
 27 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 expiration of this Agreement will not relieve the Parties of any liability or
obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this
Agreement nor prejudice either Party’s right to obtain performance of any obligation. All other rights and obligations will terminate upon expiration or termination of this Agreement. 

10.6 Alternate Project Plan. Prior to any termination of this Agreement due to a material adverse change to the development of the
Project, Licensee and Mascoma will negotiate in good faith the terms and conditions for an alternate project plan for an alternative site located in North America based on the terms and conditions contained in this Agreement (but without obligation
on either Party to enter into an agreement), as reasonably adjusted based on the characteristics of such alternative plan. In such case, any license fee (in any form) amount which has been paid by Licensee would be transferable. Notwithstanding any
other term herein, if Licensee determines that such site is not economical, the Licensee may transfer this Agreement to another project site of Licensee’s selection located in North America, subject to any rights Mascoma may have granted before
such transfer and any rights that Mascoma is then negotiating granting under a signed letter of intent, and provided that Licensee may not transfer this Agreement to another project site (or any related exclusive geographic area) located within
[***] of a facility operated by or under a license from Mascoma. Notwithstanding anything contained herein, if Licensee elects to transfer this Agreement to another project site located in North America but outside of the United States or Canada,
then Mascoma makes no representations, warranties, guarantees or indemnities solely with respect to regulatory approvals (unless Mascoma has obtained the requisite regulatory approvals) or patent infringement for the Mascoma Process, Mascoma Process
Validated Improvements, any Organisms or any Organism Validated Improvements, provided that the parties will first discuss in good faith and agree upon (a) reimbursement of Mascoma for [***] associated with the fulfillment of its support and
supply obligations for such project site (and not any other project site, other projects, or other initiatives) located outside the United States or Canada and (b) if the type of Feedstock to be used is materially different from the Feedstock
contemplated to be used for the Kinross Facility, the parameters for the Product Test that would apply to such project site. 
 11.
Continuation of Rights. 
 11.1 Generally. Except as set forth herein, this Agreement will survive any change
of control, bankruptcy, insolvency, or winding up of either Party. In the event of any insolvency or winding up of either Party-licensor, each Party-licensee would have any and all possible rights to maintain and continue to exercise its rights and
licenses granted hereunder, including, with respect to Licensee as the Party-licensee, all rights to produce (or have produced), or to make (or have made) the Organisms and Organism Validated Improvements for the Kinross Facility, provided that such
Organisms and Organism Validated Improvements are used solely within the scope of the license granted in Section 2.1. 

11.2 Bankruptcy. All rights and licenses granted by either Party under or pursuant to this Agreement are, for all purposes of
Section 365(n) of Title 11 of the United States Code 

  
 28 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 (“Title 11”), licenses of rights to “intellectual
property” as defined in Title 11. Each Party-licensee agrees that, in the event of the commencement of bankruptcy proceedings by or against the other Party-licensor under Title 11, such Party-licensee, as licensee of such rights under this
Agreement, will retain and may fully exercise all of its rights under this Agreement and all of its rights and elections under Title 11; provided that nothing contained in this Section 11.2 or resulting from either Party’s bankruptcy will
limit either Party’s obligations or liabilities hereunder, or either Party’s rights or remedies in the event of any breach or delay in performing such obligations hereunder. 
 12. Dispute Resolution. 
 12.1 Mediation; Arbitration; Dispute
Resolution. Except (i) as necessary to enforce any arbitral award, (ii) as necessary to secure equitable relief or (iii) for disputes resolved pursuant to Section 4.5(e)(iv), any controversy or claim, whether based on
contract, tort, statute or other legal or equitable theory (including any claim of fraud, misrepresentation or fraudulent inducement or any question of validity or effect of this Agreement, including this Section 12.1) arising out of or
related to this Agreement, or the breach or termination of this Agreement (any such controversy or claim, a “Dispute”) will be resolved in accordance with the terms, conditions, rules and procedures set forth on Exhibit 12.1
attached hereto. The Parties acknowledge and agree that this Section 12.1 is intended to cover controversies and claims that could otherwise be resolved through litigation. 

12.2 Equitable Relief. Notwithstanding anything to the contrary, each of the Parties hereby acknowledges that a breach of their
respective obligations under this Agreement may cause irreparable harm and that the remedy or remedies at law for any such breach may be inadequate. Each of the Parties hereby agrees that, in the event of any such breach, in addition to all other
available remedies hereunder, the non-breaching Party will have the right to seek equitable relief to enforce the provisions of this Agreement. 
 12.3 Tolling. The Parties agree that all applicable statutes of limitation and time-based defenses (such as estoppel and laches) will be tolled while the dispute resolution procedures set forth in
this Section 12 are pending, and the Parties will cooperate in taking all actions reasonably necessary to achieve such a result. 
 13.
Insurance. Each Party will purchase and maintain, at its sole cost and expense, insurance meeting the requirements of, and shall otherwise comply with the provisions of, Exhibit 13.  

14. Miscellaneous Provisions. 
 14.1 Assignment; Binding Effect. This Agreement may not be assigned or otherwise transferred by either Party, without the written consent of the other Party (such consent not to be unreasonably
withheld, conditioned or delayed); provided, however, that either Party may, without such consent, assign this Agreement to a successor or purchaser of all or substantially all of its business or assets to which this Agreement relates, whether in a
merger, sale of stock, sale of assets or other similar transaction (other than, in the case of Licensee, a Mascoma Competitor (as defined in Exhibit 1.14A)). No assignment shall be valid until the assignee has assumed the


  
 29 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 rights and obligations of the assignor under this Agreement. The rights and
obligations of the parties under this Agreement will be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement will be void. 

14.2 Notices. Any notice, request, demand other communication required or permitted hereunder will be in writing and will be
deemed to have been given (a) if delivered or sent by facsimile transmission, upon acknowledgment of receipt by the recipient, (b) if sent by a nationally recognized overnight courier, properly addressed with postage prepaid, on the next
business day (or Saturday if sent for Saturday delivery) or (c) if sent by registered or certified mail, upon the sooner of receipt or the expiration of three (3) days after deposit in United States post office facilities properly
addressed with postage prepaid. All notices will be sent to the addresses set forth below or to such other address as such Party may designate by notice to each other Party hereunder: 
 If to Mascoma: 
 Mascoma Corporation 

[Address] 

Attention: [            ] 

Facsimile: [            ] 

With a copy to: 
 Legal Department [at the same address above] 
 If to Licensee: 

[Address] 

Attention:              

Facsimile: (            )
            -             
 With a copy to: 
 [Address] 

Attention:              

Facsimile: (            )
            -             
 14.3 Governing Law. The validity, construction and performance of this Agreement will be governed by and construed in accordance with the substantive laws of the State of Delaware excluding any
conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction, provided that any dispute relating to the scope, validity, enforceability or
infringement of any Patents will be governed by, and construed and enforced in accordance with, the substantive laws of the jurisdiction in which such Patents apply. 

  
 30 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 14.4 Severability. If any term or other provision of
this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of this Agreement will nevertheless remain in full force and effect. Upon such determination that any term or
other provision is invalid, illegal or incapable of being enforced, the Parties hereto will negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner to the end
that the transactions contemplated hereby are fulfilled to the fullest extent possible. 
 14.5 Relationship of Parties.
Nothing in this Agreement is intended or will be deemed to constitute a partnership, agency, employer-employee or joint venture relationship between the Parties. No Party will incur any debts or make any commitments for the other, except to the
extent, if at all, specifically provided therein. Nothing in this Agreement, express or implied, is intended to confer on any person other than the Parties, as applicable, and their respective successors and assigns, any rights or remedies under or
by virtue of this Agreement, and there are no express or implied third party beneficiaries hereunder (in each case, except for Mascoma Indemnitees and Licensee Indemnitees for purposes of Section 9). 

14.6 Entire Agreement. This Agreement is the sole agreement with respect to the subject matter hereof and supersedes all other
agreements and understandings between the Parties with respect to same. 
 14.7 Amendment and Waiver. This Agreement may
not be amended or modified, nor may compliance with any condition or covenant set forth herein be waived, except by a writing duly and validly executed by each of the Parties, or, in the case of a waiver, the Party waiving compliance. No delay on
the part of any Party in exercising any right, power or privilege hereunder will operate as a waiver thereof, nor will any waiver on the part of any Party of any such right, power or privilege, or any single or partial exercise of any such right,
power or privilege, preclude any further exercise thereof or the exercise of any other such right, power or privilege. 
 14.8
Cumulative Remedies. All rights and remedies of the Parties hereunder will be cumulative and in addition to all other rights and remedies provided hereunder or available by agreement, at law or otherwise. 

14.9 Force Majeure. Neither Party will be held liable or responsible to the other Party nor be deemed to have defaulted under or
breached this Agreement for failure or delay in fulfilling or performing any term, other than an obligation to make payments hereunder, when such failure or delay is caused by or results from fire, floods, embargoes, government regulations,
prohibitions or interventions, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, acts of God or any other cause beyond the reasonable control of the affected Party to anticipate, prevent, avoid or mitigate (a
“Force Majeure Event”). 
 14.10 Further Assurances. Each Party agrees to perform such acts, execute such
further instruments, documents or certificates, and to provide such cooperation in proceedings and actions as may be reasonably requested by the other Party in order to carry out the intent and purpose of this Agreement. 

  
 31 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 14.11 Expenses. Except as otherwise expressly provided
in this Agreement, each Party will be responsible for the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of
this Agreement. 
 14.12 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in
connection with the review, drafting and negotiation of this Agreement. Accordingly, each Party hereto agrees that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party will not be applied in the
construction or interpretation of this Agreement. 
 14.13 Counterparts; Facsimiles. This Agreement may be executed in
one or more counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. Facsimile or PDF execution and delivery of this Agreement by either Party will constitute a legal, valid
and binding execution and delivery of this Agreement by such Party 
 14.14 Headings. All headings in this Agreement are
for convenience only and will not affect the meaning of any provision hereof. 
 14.15 Interpretation. Whenever any
provision of this Agreement uses the term “including” (or “includes”), such term will be deemed to mean “including without limitation” (or “includes without limitations”). “Herein,”
“hereby,” “hereunder,” “hereof” and other equivalent words refer to this Agreement as an entirety and not solely to the particular portion of this Agreement in which any such word is used. All definitions set forth
herein will be deemed applicable whether the words defined are used herein in the singular or the plural. Unless otherwise provided, all references to Sections and Exhibits in this Agreement are to Sections and Exhibits of this Agreement. References
to any Sections include Sections and subsections that are part of the related Section. 
 [Remainder of this Page
Intentionally Left Blank] 

  
 32 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized officers as of the
Effective Date. 
  

			
	MASCOMA CORPORATION
		
	By:	 	 
		 	(Signature)
		
	 Name:
	 	 
		
	 Title:
	 	 
		
	 Date:
	 	 

  

			
	KINROSS CELLULOSIC ETHANOL LLC
		
	By:	 	 
		 	(Signature)
		
	 Name:
	 	 
		
	 Title:
	 	 
		
	 Date:
	 	 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

Exhibit 1.13 
 [***]








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

Exhibit 1.14 A 
 [***]








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 
  







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

Exhibit 1.14 B 
 [***]








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

Exhibit 1.18 

Description of Organisms 

[***] 

  








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

Exhibit 1.31 
 [***]


  








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 

  








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

CONFDENTIAL 
 Exhibit 2.3(d) 
  
 [***]








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

Exhibit 2.3(e) 
 [***]


  








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

CONFIDENTIAL 
  

[***] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
  
 Exhibit 12.1 
 Dispute Resolution 

1. Applicability. Any dispute to which this Exhibit 12.1 applies shall be subject to mediation as a condition precedent to
arbitration by either Party. 
 2. Mediation. The Parties shall attempt in good faith to resolve any dispute to which
this Exhibit 12.1 applies promptly by confidential mediation under the then current CPR Mediation Procedure and this Exhibit 12.1 before resorting to arbitration. In the event of a conflict between the CPR Mediation Procedure and this
Exhibit 12.1, this Exhibit 12.1 will govern. Request for mediation shall be filed in writing with the other Party and with the regional office of the CPR Institute covering New York, New York. The request may be made concurrently with
the filing of a demand for arbitration, but, in such event, mediation shall proceed in advance of arbitration, which shall be stayed pending mediation for a period of sixty days from the commencement of the mediation proceedings, unless stayed for a
longer period by agreement of the Parties. The Parties shall share the mediator’s fee and any filing fees equally. The mediation shall be held in New York, New York, unless another location is mutually agreed upon. Agreements reached in
mediation shall be enforceable as settlement agreements in any arbitration or court having jurisdiction thereof. 
 3.
Arbitration. Any dispute to which this Exhibit 12.1 applies which is not resolved by mediation in accordance with Section 2 of this Exhibit 12.1 shall be subject to arbitration in accordance with the then current CPR
Institute Rules for Non-Administered Arbitration of Business Disputes and this Exhibit 12.1. In the event of a conflict between the CPR Rules and this Exhibit 12.1, this Exhibit 12.1 will govern. The arbitration shall be
governed by the United States Arbitration Act, 9 U.S.C. §§ 1-16, to the exclusion of any provision of Applicable Law inconsistent therewith or which would produce a different result, and judgment upon the award rendered by the arbitrator
may be entered by any court having jurisdiction. Either Party may commence such arbitration by sending an Arbitration Notice with respect thereto to the other Party, with a copy thereof to the regional office of the CPR Institute covering New York,
New York. The Arbitration Notice shall contain a brief description of the nature of the dispute and the name of the arbitrator appointed by the Party sending such Arbitration Notice. 

3. Selection of Arbitrator. 
 (A) Within [***] after delivery of the Arbitration Notice, the other Party shall appoint an arbitrator in writing to the Party sending such Arbitration Notice, with a copy thereof to the regional office
of the CPR Institute covering New York, New York. The two arbitrators so appointed shall, within [***] after the second of them has been appointed, appoint a third arbitrator and such arbitrators shall constitute the arbitrator panel (the
“Arbitrator Panel”). If the two arbitrators initially appointed are unable to agree on the third arbitrator within such five-day period, either Party may request the regional office of the CPR Institute covering New York, New York
to designate the third arbitrator. If the regional office of the CPR Institute covering New York, New York has not designated an arbitrator within ten business days following delivery of a request from either Party, either Party may request in
writing the judge of the United States District Court for the Southern District of New York senior in term of service 

  








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 
to appoint the third arbitrator. If the Party receiving the Arbitration Notice fails to appoint an arbitrator as set forth above, the arbitrator appointed by the Party sending such Arbitration
Notice shall constitute the entire Arbitrator Panel. If any arbitrator so chosen shall die, resign or otherwise fail or becomes unable to serve as an arbitrator, the Party that appointed such arbitrator shall appoint a replacement arbitrator within
fifteen days after receiving notice of such arbitrator’s death, resignation or inability to serve. 
 (B) Each arbitrator
shall be qualified by his or her education, experience and training to resolve the disputed matters. None of the arbitrators may be a current or former employee of either Party or any Affiliate (as defined in the JV Agreement) thereof or otherwise
have a stake in the outcome of the Dispute. 
 4. Conduct of Arbitration. 

(A) Any arbitration hearing shall be held in New York, New York. The Arbitrator Panel shall fix a reasonable time and place for the
hearing and shall determine the matters submitted to it pursuant to the provisions of this Agreement in a timely manner; provided, however, if the Arbitrator Panel shall fail to conclude the hearing to determine the issue in dispute within six
months after the selection of the Arbitrator Panel, then either Party shall have the right to require a new Arbitrator Panel to be selected pursuant to this Exhibit 12.1 unless such Party’s action shall have substantially contributed to
the delay. 
 (B) Except as expressly provided to the contrary in this Agreement, the Arbitrator Panel shall have the reasonable
and necessary power (i) to gather such materials, information, testimony and evidence as it deems relevant to the dispute before it (and each Party will provide such materials, information, testimony and evidence reasonably requested by the
Arbitrator Panel, except to the extent any information so requested is subject to an attorney-client or other statutory or legally-recognized privilege), (ii) to grant injunctive relief and enforce specific performance, (iii) to issue or
cause to be issued subpoenas (including subpoenas directed to third parties) for the attendance of witnesses and for the production of books, records, documents and other evidence, and (iv) to administer oaths. Subpoenas so issued shall be
served, and upon application to the court by a party or the Arbitrator Panel, enforced, in the manner provided by Applicable Law for the service and enforcement of subpoenas in a civil action. 

(C) In advance of the arbitration hearing, the Parties may conduct discovery in accordance with the Federal Rules of Civil Procedure.
Such discovery may include, but is not limited to: (i) the taking of oral and videotaped depositions and depositions on written questions; (ii) serving interrogatories, document requests and requests for admission; and (iii) any other
form and/or method of discovery provided for under the Federal Rules of Civil Procedure. The Parties shall attempt in good faith to resolve any discovery disputes that may arise. If the Parties are unable to resolve any such disputes, the Parties
may present their objections to the Arbitrator Panel who shall resolve the objections in accordance with the Federal Rules of Civil Procedure. The Arbitrator Panel may, if requested by a Party, order that a trade secret or other confidential
research, development or commercial information not be revealed or be revealed only in a designated way. All discovery shall be completed at least [***] prior to the hearing commencement date. 

  








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 (D) The Parties may also retain, with the consent of the
Arbitrator Panel, one or more experts to assist the Arbitrator Panel in resolving the Dispute. The Parties may also retain one or more experts for their own account and at their sole respective cost. The Parties shall identify and produce a report
from any experts who will give testimony and/or evidence at the arbitration hearing at least [***] prior to the commencement of the hearing. Rebuttal experts shall be named at least [***] prior to the commencement of the hearing. Any testifying
experts identified shall be made available for deposition in advance of any arbitration hearing. 
 (E) At least [***] prior to
the commencement of the hearing, the Parties shall exchange witness lists containing the names, addresses and phone numbers of the witnesses the Party expects to call. Except for good cause, only those individuals who appear on a witness list may be
called as a witness. 
 (F) The Parties shall exchange copies of exhibits and designated deposition testimony at least seven
business days prior to the commencement of the hearing. 
 (G) The Arbitrator Panel shall render a written decision within [***]
of the conclusion of the hearing. The Arbitrator Panel shall have jurisdiction and authority to interpret and apply the provisions of this Agreement only insofar as shall be necessary in the determination of the matter in dispute, but the Arbitrator
Panel shall not have jurisdiction or authority to add to or alter in any way the provisions of this Agreement. The Arbitrator Panel’s decision shall govern and shall be final, nonappealable (except to the extent provided in the Federal
Arbitration Act) and binding on the Parties hereto pursuant to the United States Arbitration Act and the Arbitrator Panel’s written decision may be entered in any court having appropriate jurisdiction. THE ARBITRATOR PANEL AND ANY COURT
ENFORCING THE AWARD OF THE ARBITRATOR PANEL SHALL NOT HAVE THE RIGHT OR AUTHORITY TO AWARD CONSEQUENTIAL, INDIRECT, PUNITIVE, INCIDENTAL OR SPECIAL DAMAGES, LOSS OF PROFITS OR GOODWILL OR EXEMPLARY DAMAGES TO EITHER PARTY EXCEPT TO THE EXTENT
EXPRESSLY PERMITTED IN THIS AGREEMENT. 
 (H) The responsibility for paying the costs and expenses of the arbitration, including
compensation to the Arbitrator Panel, shall be allocated between the Parties in a manner determined by the Arbitrator Panel to be fair and reasonable under the circumstances. Each Party shall be responsible for the fees and expenses of its
respective counsel, consultants and witnesses, unless the Arbitrator Panel determines that compelling reasons exist for allocating all or a portion of such costs and expenses otherwise. 

  








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

TECHNOLOGY LICENSE AND SUPPLY AGREEMENT 

 
 Exhibit 13 

Insurance Requirements 

[***] 

  








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

EXHIBIT C 
 FORM OF
WARRANT PURCHASE AGREEMENT 

  
 Exhibit C









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

WARRANT PURCHASE AGREEMENT 
 This WARRANT PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of
[            ], 2012, by and among Mascoma Corporation, a Delaware corporation (the “Company”), and Diamond Alternative Energy, LLC (the
“Investor”). 
 A. WHEREAS, the Investor and Frontier Renewable Resources LLC
(“Frontier”) have entered into the Kinross Cellulosic Ethanol LLC (“Kinross”) Limited Liability Company Agreement (the “LLC Agreement ”), in connection with the
development and operation of an integrated facility in Kinross Charter Township, Michigan that includes a commercial scale cellulosic fuel production facility (the “Kinross Facility”). 

B. WHEREAS, the Investor is making certain cash contributions to Kinross, as set forth in the LLC Agreement. In consideration for such
contributions, the Company wishes to issue to the Investor certain Warrants (as defined below). 
 NOW, THEREFORE, in
consideration of the mutual covenants herein contained and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 

SECTION 1. 
 ISSUANCE OF WARRANTS 
 1.1 Issuance of Warrants. The Company shall
issue two warrants in substantially the form attached hereto as Exhibit A-1 and Exhibit A-2 (the “Tranche 2-A Warrant” and the “Tranche 2-B Warrant,”
respectively, and more generally, the “Warrant” or the “Warrants”) to the Investor to purchase certain shares of Common Stock, par value $0.001 of the Company (the
“Common Stock”), in accordance with the following terms: 
 (a) The Tranche 2-A
Warrant will be exercisable for 3,164,557 shares of Common Stock at an exercise price of $3.16 per share. 
 (b) The Tranche 2-B
Warrant will be exercisable for 5,333,333 shares of Common Stock at an exercise price of $3.75 per share. 
 (c) The Tranche
2-A Warrant will be issued pursuant to this Agreement on the date hereof (“Tranche 2-A Warrant Issuance Date”). 

(d) The Tranche 2-B Warrant will be issued pursuant to this Agreement on the date (the “Tranche 2-B
Warrant Issuance Date” and together with the Tranche 2-A Warrant Issuance Date, the “Issuance Dates”) that is thirty (30) days after the earlier of: 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

(i) The date of Start-up of the Phase I Project (as defined in the LLC Agreement); and 

(ii) The date that the Nonreimbursable Investor Kinross Project Contribution Amount (as defined below), as mutually determined by
the Company and the Investor pursuant to Section 1.2, equals one-hundred and eighty-seven million dollars ($187 million) (the “Tranche 2-B Warrant Contribution Amount”). 

Notwithstanding anything to the contrary, if not previously issued pursuant to this Section 1.1(d), the Tranche 2-B Warrant will be issued pursuant
to this Agreement immediately prior to the consummation of a Change of Control and the Tranche 2-B Warrant Issuance Date shall be such date; provided, however, that the Tranche 2-B Warrant will not be issued in connection with a Change of Control if
either Member (as defined in the LLC Agreement) has exercised its Exit Election (as defined in the LLC Agreement) in accordance with Section 10.9(b) or Section 10.9(c) of the LLC Agreement and in which event, the Company shall have no
further obligation to issue the Tranche 2 B Warrant to the Investor. 
 As used herein: (a) the term
“Nonreimbursable Investor Kinross Project Contribution Amount” shall mean actual cash contributions made by the Investor to Kinross to fund hard and soft costs of developing and commencing operations of the
Phase I Project (after receipt of, and reimbursement from, the proceeds of the Grant Amount) which are not subject to potential future reimbursement from proceeds of the Grant Amount (including, without limitation, to the extent that no further
funding of the Grant Amount is available due to expiration or termination of the underlying grant agreements without extension by the applicable grant awarding authorities); and (b) the term “Grant Amount”
shall have the meaning ascribed to it in the LLC Agreement. 
 1.2 Certain Mechanics Related to Tranche 2-B Warrant. The
Investor shall notify the Company in writing if the Investor asserts that one of the conditions in Section 1.1(d) have been satisfied, and shall provide the Company with supporting materials reasonably satisfactory to the Company for the
Company to determine whether and when one of the conditions in Section 1.1(d) have been satisfied. The Company shall have the right to inspect or audit Kinross’ books and records as reasonably requested by the Company to confirm the
Nonreimbursable Investor Kinross Project Contribution Amount; provided that (a) if the Company intends to conduct any such inspection or audit it shall provide written notice to the Investor of such intent within five (5) days of the
Investor’s notice that one or more of the conditions have been satisfied and shall conclude such inspection or audit within seven (7) days of the Investor s notice, and (b) the Tranche 2-B Warrant Issuance Date will be not later than
ten (10) days after the later of the expiration of such five (5) day period and the conclusion of such inspection or audit. 

  
 2 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

SECTION 2. 
 CONDITIONS TO THE PARTIES’ OBLIGATIONS AND COVENANTS OF THE COMPANY 
 2.1 Conditions to the Investor’s Obligations. The obligations of the Investor under this Agreement are subject to the fulfillment or waiver, on or before the Tranche 2-A Warrant Issuance Date, of
each of the following conditions: 
 (a) Representations and Warranties. Each of the representations and warranties of
the Company set forth in Article III hereof shall be true in all material respects on the date of the Tranche 2-A Warrant Issuance Date. 
 (b) Performance by the Company. The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or
complied with by it on or before the Tranche 2-A Warrant Issuance Date and shall have obtained all approvals, consents and qualifications necessary to complete the purchase and sale described herein. 

2.2 Condition to the Company’s Obligations. The obligation of the Company to issue the Tranche 2-A Warrant or Tranche 2-B Warrant,
as applicable, to the Investor is subject to the fulfillment or waiver of the following conditions on or before the applicable Issuance Date: 
 (a) Representations and Warranties. Each of the representations and warranties of the Investor set forth in Article IV hereof shall be true in all material respects as of such Issuance Date.

 (b) Performance by the Investor. The Investor shall have performed and complied with all agreements, obligations and
conditions contained in this Agreement that are required to be performed or complied with by it on or before such Issuance Date and shall have obtained all approvals, consents and qualifications necessary to complete the purchase and sale described
herein. 
 (c) Lock-up. The Investor agrees, if requested by the Company, and an underwriter of Common Stock or other
securities of the Company, not to sell or otherwise transfer or dispose of any of the Securities during a period of up to 180 days following the effective date of a registration statement of the Company filed under the Securities Act (as defined
below); provided, however, that (a) such agreement only applies to the first such registration statement of the Company including securities to be sold on its behalf to the public in an underwritten offering; and (b) all
holders of registration rights with respect to securities of the Company, all officers and directors of the Company and all persons including Securities in such offering enter into similar agreements. The Company may impose stop-transfer
instructions with respect to the Securities (or other securities) subject to the foregoing restriction until the end of such period 
 2.3 Covenants of the Company. 

  
 3 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

(a) Amendment to the Restated Charter. Immediately prior to the Tranche 2-A Warrant Issuance Date, the Company shall have filed
with the Secretary of State of the State of Delaware (the “Secretary” ) a Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation of the Company, as amended from time to time
(the Company s Certificate of Incorporation, as amended to the date hereof including the above referenced Certificate of Amendment, the “Restated Charter”), to duly reserve the shares of Common Stock issuable
upon exercise of the Warrants (the “Warrant Shares”, and together with the Warrants, the “Securities”). The form of such Certificate of Amendment is attached hereto as
Exhibit C. 
 (b) Anti-Dilution Waiver. As may be required from time to time, the holders of the Preferred Stock (as
defined below) shall have waived the application of the anti-dilution rights of the Preferred Stock contained in the Restated Charter, with respect to the issuance of the Warrants in addition to the Warrant Shares. 

(c) Registration Rights. The Company and the parties thereto shall have amended the Company’s Third Amended and Restated
Registration Rights Agreement, dated August 31, 2010, as amended, so that the Warrant Shares are included within the definition of “Registrable Securities” within such agreement. 

SECTION 3. 
 REPRESENTATIONS AND WARRANTIES OF THE COMPANY 
 The Company
represents and warrants to the Investor as follows, each of which representation and warranty is true and correct as of the Tranche 2-A Warrant Issuance Date: 
 3.1 Organization. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to own and
lease its properties, to carry on its business as currently conducted and as proposed to be conducted and to carry out the transactions contemplated hereby and the Warrants. Except as set forth in Section 3.01 of the Disclosure Schedule
attached hereto as Exhibit B, the Company is duly qualified as a foreign corporation and is in good standing in all such other jurisdictions (which jurisdictions are listed in Section 3.01 of the Disclosure Schedule) in which the conduct
of its business or its ownership or leasing of property requires such qualification and in which the failure so to qualify or so to be in good standing would have a materially adverse effect on the Company’s operations or financial condition.

 3.2 Authorization. 
 (a) The execution, delivery and performance by the Company of this Agreement has been duly authorized by all requisite corporate action. This Agreement has been duly executed and delivered on behalf of
the Company and constitutes the valid and binding obligations of the Company, enforceable in accordance with its terms. This 

  
 4 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


Agreement and the Securities, when executed and delivered by the Company, will constitute valid and binding obligations of the Company, enforceable in accordance with their respective terms. The
execution, delivery and performance of this Agreement, the issuance and delivery of the Warrant and compliance with the provisions hereof and thereof by the Company (including the issuance of the Warrant Shares), do not and will not, with or without
the passage of time or the giving of notice or both, (a) violate any provision of current law, statute, rule, regulation, ordinance or any ruling, writ, injunction, order, judgment or decree of any court, administrative agency or other
governmental body binding upon the Company or (b) conflict with or result in any breach of any of the terms, conditions or provisions of, or constitute a default (or give rise to any right of termination, cancellation or acceleration) under, or
result in the creation of any lien, security interest, charge or encumbrance upon any of the properties or assets of the Company, or under the Restated Charter, the Company’s by-laws or any note, indenture, mortgage, lease, contract, purchase
order or other instrument, document or agreement to which the Company is a party or by which it or any of its property is bound or affected. 
 (b) The issuance and delivery by the Company of the Warrants and the Warrant Shares have been duly authorized by all requisite corporate action of the Company, and the Warrant Shares have been duly
reserved for issuance upon exercise of the Warrants, and when so issued and delivered upon exercise of the Warrants, will be validly issued and outstanding, fully paid and nonassessable, with no personal liability attaching to the ownership thereof,
and not subject to preemptive or any other similar rights of the stockholders of the Company or others. The Warrants are not subject to preemptive or any other similar rights of the stockholders of the Company or others. 

3.3 [NOTE: Capitalization to be updated upon execution of the Warrant Purchase Agreement.] Capitalization. The entire authorized
capital stock of the Company, immediately prior to the Tranche 2-A Warrant Issuance Date, consists of: 
 (a)
[                    ] shares of Common Stock, of which (i) 7,751,725 shares have been duly and validly issued and are outstanding, fully paid and
nonassessable, with no personal liability attaching to the ownership thereof; (ii) 5,000,000 shares have been reserved for issuance upon conversion of the Company’s Series A Preferred Stock, par value $0.001 per share (the
“Series A Preferred Stock”); (iii) 5,162,500 shares have been reserved for issuance upon exercise of the Company’s Series Al Preferred Stock, par value $0.001 per share (the
“Series A-1 Preferred Stock”); (iv) 11,498,128 shares have been reserved for issuance upon conversion of the Company’s Series B Preferred Stock, par value $0.001 per share (the
“Series B Preferred Stock”); (v) [9,988,356][NOTE: This number is subject to revision] These shares have been reserved for issuance upon conversion of the Company s Series C Preferred
Stock, par value $0.001 per share (the “Series C Preferred Stock”); (vi) 17,996,223 shares have been reserved for issuance upon conversion of the Company’s Series D Preferred
Stock, par value $0.001 per share (the “Series D Preferred Stock” and, together with the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the
Series C Preferred Stock, the “Preferred Stock”); (vii) 14,250,000 shares are reserved for issuance pursuant to the exercise of options that have or may be granted from time to time
under any Plan (as defined in the Stockholders Agreement); (viii) 1,000,000 shares 

  
 5 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


have been reserved for issuance upon the exercise of certain warrants issued in connection with a financing and a strategic acquisition; and (ix) 659,898 shares have been reserved for issuance
upon the exercise of certain warrants issued in connection with a debt financing; and 
 (b)
[                    ] shares of Preferred Stock, par value $0.001 per share, of which: (i) 5,000,000 shares have been designated shares of Series A
Preferred Stock and have been duly and validly issued and are outstanding, fully paid and nonassessable, with no personal liability attaching to the ownership thereof, (ii) 5,162,500 shares have been designated shares of Series Al Preferred Stock,
of which, (A) 5,000,000 shares have been duly and validly issued and are outstanding, fully paid and nonassessable, with no personal liability attaching to the ownership thereof, and (B) 162,500 shares have been reserved for issuance upon exercise
of a certain warrant issued in connection with a debt financing, (iii) 11,498,128 shares have been designated shares of Series B Preferred Stock of which, (A) 11,235,955 shares have been duly and validly issued and are outstanding, fully paid and
nonassessable, with no personal liability attaching to the ownership thereof, and (B) 262,173 shares have been reserved for issuance upon exercise of a certain warrant issued in connection with a debt financing; (v) [9,988,356][NOTE: This number is
subject to revision] shares have been designated shares of Series C Preferred Stock, of which, (A) 9,777,418 shares have been duly and validly issued and are outstanding, fully paid and non-assessable, with no personal liability attaching to the
ownership thereof, and (B) 210,938 shares have been reserved for issuance upon exercise of a certain warrant issued in connection with a debt financing; and (vi) 17,996,223 shares have been designated shares of Series D Preferred Stock, of which,
(A) 16,638,417 shares have been issued and are outstanding, and (B) 1,357,806 shares have been reserved for issuance upon exercise of certain warrants issued in connection with a financing. 

Section 3.03 of the Disclosure Schedule contains a list of all holders of Common Stock, Preferred Stock and options, warrants or
rights to purchase Common Stock and Preferred Stock, in each case including the number of shares of Common Stock and Preferred Stock held by, or subject to purchase pursuant to the exercise of any option, warrant or right held by, each such holder.
Except as set forth in Section 3.03 of the Disclosure Schedule or as being issued pursuant to this Agreement, there are no outstanding shares of capital stock of the Company or warrants, options, agreements, convertible securities or other
commitments pursuant to which the Company is or may become obligated to issue any shares of its capital stock or other securities of the Company. Except as set forth in Section 3.03 of the Disclosure Schedule, the number of shares of capital
stock, if any, reserved for issuance or issuable upon conversion of the Preferred Stock is not subject to adjustment by reason of the issuance of the Warrants or the shares issuable upon exercise thereof. Except as set forth in Section 3.03 of
the Disclosure Schedule and except as set forth in the Third Amended and Restated Stockholders Agreement, dated as of August 31, 2010, by and among the Company and the other parties thereto, as amended, or that certain Third Amended and
Restated Voting Agreement, dated as of August 31, 2010, by and among the Company and the other parties thereto, as amended, there are no preemptive or similar rights to purchase or otherwise acquire shares of capital stock of the Company
pursuant to any provision of 

  
 6 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


law, the Restated Charter or the By-laws or any agreement to which the Company is a party, or otherwise, and there is no agreement, restriction or encumbrance with respect to the sale or voting
of any shares of the Company’s capital stock (whether outstanding or issuable upon conversion or exercise of outstanding securities). The Company has not violated the Securities Act of 1933, as amended (the
“Securities Act”), or any state blue sky or securities law in connection with the issuance of any shares of Common Stock or other securities prior to the date hereof. 

3.4 Litigation. There is no action, suit, claim, proceeding or investigation pending (or that the Company intends to initiate) or, to the
Company’s knowledge, threatened against the Company or any of its properties, at law or in equity, or before or by any Federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or
foreign that challenges the validity or enforceability of, or seeks the enjoin the performance of this Agreement or the transactions contemplated hereby, and to the Company’s knowledge there is no reasonable basis for any action, suit, claim,
proceeding, or investigation which if decided against the Company would have a materially adverse effect on the Company. 
 3.5
Complete Disclosure. To the Company’s knowledge, neither the Agreement, as qualified by the Disclosure Schedule, nor any other documents or certificates furnished or to be furnished in connection herewith, when taken as a whole, contains any
untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances under which they were made. 

SECTION 4. 

REPRESENTATIONS AND WARRANTIES OF THE INVESTOR 
 The Investor represents and warrants to the Company that: (a) it has full power and authority to enter into and perform this Agreement in accordance with its terms, and it was not organized for the
specific purpose of acquiring the Securities; (b) it has sufficient knowledge and experience in investing in companies similar to the Company in terms of the Company’s stage of development so as to be able to evaluate the risks and merits of
its investment in the Company and it is able financially to bear the risks thereof; (c) in connection with the acquisition of the Warrants, it has made an investigation of the Company and its business as it deemed necessary and has had an
opportunity to discuss and review the Company’s business, management and financial affairs with the Company’s management as it deemed necessary; (d) the Securities being purchased by it are being acquired for its own account for the
purpose of investment and not with a view to the public resale or distribution thereof within the meaning of the Securities Act; (e) it understands that (i) the Securities have not been registered under the Securities Act by reason of their issuance
in a transaction exempt from the registration requirements of the Securities Act pursuant to Section 4(2) thereof or Rule 504, 505 or 506 promulgated under the Securities Act, (ii) under the Securities Act and applicable regulations thereunder the
Securities may be resold without registration under the Securities Act only 

  
 7 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


in certain limited circumstances, (iii) the certificates evidencing the Securities will bear a legend substantially similar to that set forth below: 

 

					
		  	 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES
LAWS, PURSUANT TO REGISTRATION UNDER SUCH LAWS OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF
THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS.
	  	

 and (iv) the Company will make a notation on its transfer books to such effect; (f) this Agreement has been
duly executed and delivered by it and constitutes the legal, valid and binding obligation of it, enforceable in accordance with the terms of the Agreement; and (g) it is an “accredited investor” as that term is defined in Rule 501
promulgated under the Securities Act. 
 SECTION 5. 
 MISCELLANEOUS 
 5.1 No Waiver; Cumulative Remedies. No failure or delay on the
part of any party to this Agreement in exercising any right, power or remedy hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or
the exercise of any other right, power or remedy hereunder. The remedies herein provided are cumulative and not exclusive of any remedies provided by law. 
 5.2 Amendments, Waivers and Consents. Except as otherwise provided herein, this Agreement may be amended, and compliance with any provision of this Agreement may be omitted or waived, only by the written
agreement of the Company and the Investor. A waiver or omission on one occasion shall not constitute a waiver or omission on any further occasion. 
 5.3 Addresses for Notices, etc. Any notice or communication given pursuant to this Agreement by any party to any other party shall be in writing and shall be sufficiently given if personally delivered,
sent by facsimile, sent by mail, postage prepaid, or sent by overnight courier, delivery charges prepaid, to the parties at the following 

  
 8 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


addresses or to such other address as either party may hereafter designate to the others by like notice: 
  

			
	 (a)
	  	if to the Company, to:
		
		  	Mascoma Corporation
		  	67 Etna Road, Suite 300
		  	Lebanon, NH 03766
		  	Attention: President
		  	Telephone: 603-676-3320
		  	Telecopy: 603-676-3321
		
		  	with a copy to:
		
		  	William J. Schnoor, Jr. and
		  	Jocelyn Arel
		  	Goodwin Procter LLP
		  	53 State Street
		  	Boston, Massachusetts 02109
		  	Telephone: (617) 570-1000
		  	Telecopy: (617) 523-1231
		
	 (b)
	  	if to the Investor:
		
		  	Diamond Alternative Energy, LLC
		  	One Valero Way
		  	San Antonio, Texas 78249
		  	Telephone: (210) 345-2306
		  	Telecopy: (210) 345-2270
		  	Attn: Robert Buchek
		
		  	with a copy to, which shall not constitute notice to the Investor:
		
		  	David Giles
		  	Valero Energy Corporation
		  	One Valero Way
		  	San Antonio, Texas 78249
		  	Telephone: (210) 345-2468
		  	Telecopy: (210) 345-2988

 5.4 Binding Effect; Assignment. The terms and conditions of this Agreement shall be binding upon and
inure to the benefit of the Company and the Investor and their respective heirs, successors and assigns. 
 5.5 Headings;
Interpretation. In this Agreement, (i) the meaning of defined terms shall be equally applicable to both the singular and plural forms of the terms defined; (ii) the captions and headings are used only for convenience and are not to be
considered in construing or interpreting this Agreement and (iii) the words “including,” 

  
 9 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


“includes” and “include” shall be deemed to be followed by the words “without limitation”. All references in this Agreement to sections, paragraphs, exhibits and
schedules shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits and schedules attached hereto, all of which exhibits and schedules are incorporated herein by this reference. 

5.6 No Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s or broker’s fee or
commission in connection with the transactions contemplated by this Agreement. The Investor agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder’s or broker’s
fee (and any asserted liability) for which the Investor or any of its directors, officers, partners, members, employees or representatives is responsible. The Company agrees to indemnify and hold harmless the Investor from any liability for any
commission or compensation in the nature of a finder’s or broker’s fee (and any asserted liability) for which the Company or any of its directors, officers, employees or representatives is responsible. 

5.7 Survival of Representations and Warranties. The representations and warranties of the Company and the Investor contained herein shall
survive the Tranche 2-A Warrant Issuance Date. Each of the Investor and the Company may rely on such representations and warranties irrespective of any investigation made, or notice or knowledge held by, it or any other person. 

5.8 Prior Agreements. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and
supersedes any other prior understandings or agreements concerning the subject matter hereof. 
 5.9 Severability. The
invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. 
 5.10 Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the substantive laws of the State of Delaware without regard to its principles of conflicts of laws.

 5.11 Payment of Fees. Each of the Company and the Investor shall pay its own legal and financial advisory fees. 

5.12 Counterpart; Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed an
original, but all of which taken together shall constitute one and the same instrument, and any of the parties hereto may execute this Agreement by signing any such counterpart. This Agreement may be executed and delivered by facsimile, or by e-mail
in portable document format (.pdf) and delivery of the signature page by such method will be deemed to have the same effect as if the original signature had been delivered to the other parties. 

5.13 Entire Agreement. This Agreement, together with all exhibits hereto and the Warrants, constitute the entire agreement and
understanding of the parties with respect to the subject matter hereof and supersede any and all prior negotiations, 

  
 10 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


correspondence, agreements, understandings duties or obligations between the parties with respect to the subject matter hereof. 

5.14 Further Assurances. From and after the date of this Agreement, upon the request of the Investor or the Company, the Company and the
Investor shall execute and deliver such instruments, documents or other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement. 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 11 









 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day, month and year first above written. 

 

			
	MASCOMA CORPORATION
		
	By:	 	  

		 	Name:
		 	Title:


 [SIGNATURE PAGE TO WARRANT
PURCHASE AGREEMENT] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day, month and year first above written. 

 

			
	DIAMOND ALTERNATIVE ENERGY, LLC
		
	By:	 	  

		 	Name:
		 	Title:


 [SIGNATURE PAGE TO WARRANT
PURCHASE AGREEMENT] 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

EXHIBIT A-1 
 Form of Tranche 2-A Warrant 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION
UNDER SUCH LAWS OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN
OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS. 

WARRANT TO PURCHASE COMMON STOCK 
 (TRANCHE 2-A) 
  

			
	No.            	  	            , 2012


THIS CERTIFIES THAT, for value received, Diamond Alternative Energy,
LLC, with its principal office at One Valero Way, San Antonio, Texas 78249, or its assigns (the “Holder”), is entitled to subscribe for and purchase from MASCOMA CORPORATION, a Delaware
corporation (the “Company”), with its principal office at 67 Etna Road, Suite 300, Lebanon, NH 03766, 3,164,557 shares of the Company’s Common Stock, par value $0.001 per share (the “Common
Stock”) (such number of shares, as adjusted pursuant to the provisions hereof, the “Shares”) at the Exercise Price (as defined below) (the “Warrant”). 

This Warrant is being issued in connection with the Warrant Purchase Agreement, by and between the Holder and the Company (the
“Warrant Purchase Agreement”). Capitalized terms used herein but not defined herein shall have the meanings ascribed to them in the Warrant Purchase Agreement. 

1. DEFINITIONS. As used herein, the following terms shall have the following respective meanings: 

(a) “Exercise Period” shall mean the period commencing on the date hereof and ending on the Expiration Date.

 (b) “Exercise Price” shall mean $3.16 per share, subject to adjustment pursuant to Section 6
below. 
 2. Expiration Date. This Warrant shall terminate and will have no further force as of June 30, 2012 (the
“Expiration Date”). 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

3. EXERCISE OF WARRANT. The rights represented by this Warrant may be exercised in
whole or in part at any time during the Exercise Period, by delivery of the following to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder): 

(a) An executed Notice of Exercise in the form attached hereto (the “Notice of Exercise”); 

(b) Payment of the Exercise Price either (i) in cash or by check or wire transfer, or (ii) by cancellation of
indebtedness; and 
 (c) This Warrant. 
 Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Shares so purchased, registered in the name of the Holder or persons affiliated with the Holder, if the
Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised. 
 If, prior to the Expiration Date, the Holder exercises this Warrant for less than all of the Shares, the Company, upon receipt of this Warrant for cancellation, shall issue a new Warrant to Holder
representing the balance of the Shares. 
 The person in whose name any certificate or certificates for Shares are to be issued
upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate
or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next
succeeding date (which date shall be not more than seven (7) days after the date of such surrender and payment) on which the stock transfer books are open. 
 4. COVENANTS OF THE COMPANY. 
 4.1 Covenants as to Shares. The Company covenants and agrees that all Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued
and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the Company will at all times during the Exercise Period, have authorized
and reserved, free from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant. If at any time during the Exercise Period the number of authorized but unissued shares of
Common Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of
shares as shall be sufficient for such purposes. 
 4.2 No Impairment. Except and to the extent as waived or consented to
by the Holder, the Company will not, by amendment of its certificate of incorporation or through 

  
 2 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any
of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Warrant and in the taking of all such action as may be necessary or appropriate in order
to protect the exercise rights of the Holder against impairment. 
 4.3 Notices of Record Date. In the event of
any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in
previous quarters) or other distribution, the Company shall mail to the Holder, at least ten (10) days prior to such record date, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or
distribution. 
 5. REPRESENTATIONS OF HOLDER. 

5.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that
it is acquiring the Warrant and the Shares solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Shares or any part thereof. The Holder also represents that the entire legal and beneficial
interests of the Warrant and Shares the Holder is acquiring is being acquired for, and will be held for, its account only. The Holder further represents that it is an “Accredited Investor” as defined in Rule 501(a) of Regulation D under
the Securities Act of 1933, as amended (the “Act” ). 
 5.2 Securities Are Not
Registered. 
 (a) The Holder understands that the Warrant and the Shares have not been registered under the Act on
the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its representations, the Holder has a present intention of
acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities. The Holder has no such present intention.

 (b) The Holder recognizes that the Warrant and the Shares must be held indefinitely unless they are subsequently
registered under the Act or an exemption from such registration is available. The Holder recognizes that, except as contemplated by the Third Amended and Restated Registration Rights Agreement, dated as of August 31, 2010, by and among the
Company and the other parties thereto, as amended, the Company has no obligation to register the Warrant or the Shares of the Company, or to comply with any exemption from such registration. 

(c) The Holder is aware that neither the Warrant nor the Shares may be sold pursuant to Rule 144 adopted under the Act unless
certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of certain current public information about the Company, the resale following the required holding period under Rule 144 and
the number of shares being sold during any three month period not 

  
 3 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


exceeding specified limitations. Holder is aware that the conditions for resale set forth in Rule 144 have not been satisfied. 

5.3 Disposition of Warrant and Shares. 
 (a) The Holder further agrees not to make any disposition of all or any part of the Warrant or Shares in any event unless and until: 

(i) The Company shall have received a letter secured by the Holder from the Securities and Exchange Commission (the
“Commission”) stating that no action will be recommended to the Commission with respect to the proposed disposition; 
 (ii) There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with said registration statement; or 

(iii) The Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a
reasonably detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, for
the Holder to the effect that such disposition will not require registration of such Warrant or Shares under the Act or any applicable state securities laws. 
 Notwithstanding the provisions of paragraphs (i), (ii) and (iii) above, no such registration statement or opinion of counsel shall be necessary for a transfer by a Holder that is (A) a partnership
transferring to its partners or former partners in accordance with partnership interests or to an affiliate of such partnership, (B) a corporation transferring to a wholly-owned subsidiary or a parent corporation that owns all of the capital stock
of the Holder, (C) a limited liability company transferring to its members or former members in accordance with their interest in the limited liability company or to an affiliate of such limited liability company, or (D) an individual transferring
to the Holder’s family member or trust for the benefit of an individual Holder; provided that in each case the transferee will be subject to the terms of this Warrant to the same extent as if it were an original Holder hereunder.

 (b) The Holder understands and agrees that all certificates evidencing the shares to be issued to the Holder may bear
the following legend: 
 “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE
SECURITIES LAWS, PURSUANT TO REGISTRATION UNDER SUCH LAWS OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE
ISSUER OF THESE SECURITIES MAY REQUIRE AN 

  
 4 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ALL APPLICABLE STATE SECURITIES
LAWS.” 
 6. Adjustments. Subject to the expiration of this Warrant pursuant to Section 2, the number
and kind of shares purchasable hereunder and the Exercise Price therefor are subject to adjustment from time to time, as follows: 
 (a) Merger or Reorganization. If at any time there shall be any reorganization, recapitalization, merger or consolidation (a “Reorganization”) involving
the Company in which shares of the Company’s stock are converted into or exchanged for securities, cash or other property, then, as a part of such Reorganization, lawful provision shall be made so that the Holder shall thereafter be entitled to
receive upon exercise of this Warrant, the kind and amount of securities, cash or other property of the successor corporation resulting from such Reorganization, equivalent in value to that which a holder of the Shares deliverable upon exercise of
this Warrant would have been entitled in such Reorganization if the right to purchase the Shares hereunder had been exercised immediately prior to such Reorganization, and appropriate adjustment shall be made to the Exercise Price. In any such case,
appropriate adjustment (as determined in good faith by the board of directors of the successor corporation) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder after such
Reorganization to the end that the provisions of this Warrant shall be applicable after the event, as near as reasonably may be, in relation to any shares or other securities deliverable after that event upon the exercise of this Warrant. The
Company will give Holder at least five (5) business days prior notice of the record date for any such Reorganization and at least five (5) business days prior notice of the closing of such Reorganization. 

(b) Reclassification of Shares. If the securities issuable upon exercise of this Warrant are changed into the same
or a different number of securities of any other class or classes by reclassification, capital reorganization, conversion of all outstanding shares of the relevant class or series or otherwise (a “Reclassification”), then, in
any such event, in lieu of the number of Shares which the Holder would otherwise have been entitled to receive, the Holder shall have the right thereafter to exercise this Warrant for a number of shares of such other class or classes of stock that a
holder of the number of securities deliverable upon exercise of this Warrant immediately before that change would have been entitled to receive in such Reclassification and appropriate adjustment shall be made to the Exercise Price, all subject to
further adjustment as provided herein with respect to such other shares. The Company will give Holder at least five (5) business days prior notice of the record date for any such Reclassification and at least five (5) business days prior
notice of the closing of any such Reclassification. 
 (c) Subdivisions and Combinations. In the event that
the outstanding shares of Common Stock are subdivided (by stock split, by payment of a stock dividend or otherwise) into a greater number of shares of such securities, the number of Shares issuable upon exercise of the rights under this Warrant
immediately prior to such subdivision shall, concurrently with the effectiveness of such subdivision, be proportionately increased, and the Exercise Price shall be proportionately decreased, and in the event that the outstanding shares of Common
Stock are combined (by reclassification or otherwise) into a lesser number of shares of 

  
 5 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


such securities, the number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such combination shall, concurrently with the effectiveness of such combination,
be proportionately decreased, and the Exercise Price shall be proportionately increased. 
 (d) Notice of
Adjustments. Upon any adjustment in accordance with this Section 6, the Company shall give notice thereof to the Holder, which notice shall state the event giving rise to the adjustment, the Exercise Price as adjusted and the type and
number of securities or other property purchasable upon the exercise of the rights under this Warrant, setting forth in reasonable detail the method of calculation of each. The Company shall, upon the written request of any Holder, furnish or cause
to be furnished to such Holder a certificate setting forth (i) such adjustments, (ii) the Exercise Price at the time in effect and (iii) the type and number of securities and the amount, if any, of other property that at the time
would be received upon exercise of this Warrant. 
 7. FRACTIONAL SHARES. No fractional
shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise
would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such
fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of a Share by such fraction. 
 8. NO STOCKHOLDER RIGHTS. This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a stockholder of the
Company. 
 9. TRANSFER OF WARRANT. Subject to applicable laws and the
restriction on transfer set forth in this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of assignment attached hereto to any
transferee designated by Holder. The transferee shall sign an investment letter in form and substance reasonably satisfactory to the Company. 
 10. LOST, STOLEN, MUTILATED OR DESTROYED WARRANT. If this Warrant is lost, stolen, mutilated or destroyed,
the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost,
stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.

 NOTICES, ETC. All notices required or permitted hereunder shall be in writing and shall
be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five (5) days after
having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification
of receipt. 

  
 6 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

All communications shall be sent to the Company or to Holder at its address listed on the first page of this Warrant or at such other address as the
Company or Holder may designate by ten (10) days advance written notice to the other parties hereto. The Company’s fax number is (603) 676-3321, and the Investor’s fax number is (210) 345-2270. 

11. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the
terms and conditions contained herein. 
 12. AMENDMENT AND WAIVER. Any term
of this Warrant may be amended or waived with the written consent of the Company and the Holder. 
 13.
GOVERNING LAW. This Warrant and all rights, obligations and liabilities hereunder shall be governed by, and construed and enforced in accordance with, the substantive laws of the State of Delaware without regard to
its principles of conflicts of laws. 
 [SIGNATURE PAGE FOLLOWS] 

  
 7 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly
authorized officer as of the date first written above. 
  

	
	MASCOMA CORPORATION
	
	By:                             
                                         
                   
	Name:                             
                                         
              
	Title:                            
                                         
                 


 
	
	
	DIAMOND ALTERNATIVE ENERGY, LLC
	
	By:                             
                                         
                   
	Name:                             
                                         
              
	Title:                            
                                         
                 


 SIGNATURE PAGE TO WARRANT








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

 
 NOTICE OF EXERCISE 

(1)      ̈    The undersigned hereby elects
to purchase             shares of Common Stock (the “Shares” ) of Mascoma Corporation (the
“Company” ) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. 

(2)    Please issue a certificate or certificates representing said shares of the Shares in the name of the
undersigned or in such other name as is specified below: 
  

					
		 	 	 	
		 	(Name)	 	
			
		 	 	 	
			
		 	 	 	
		 	(Address)	 	

 (3)    The undersigned represents that (i) the aforesaid Shares are being
acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the
undersigned is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) the
undersigned is experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the
undersigned’s own interests; (iv) the undersigned understands that the Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities
Act ”), by reason of a specific exemption from the registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such
securities have not been registered under the Securities Act, they must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the
aforesaid Shares may not be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met and until the undersigned has held the shares for the period prescribed by Rule 144, that among the conditions for use of the
Rule is the availability of current information to the public about the Company; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid Shares unless and until there is then in effect a registration
statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or, if reasonably requested by the Company, the undersigned has provided the Company with an opinion
of counsel reasonably satisfactory to the Company, stating that such registration is not required. 
  

					
			
	 	 		 	 
	(Date)	 		 	(Signature)
			
		 		 	 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

(Print name) 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

ASSIGNMENT FORM 
  

					
		  	(To assign the foregoing Warrant, execute this form
		  	and supply required information. Do not use this
		  	form to purchase shares.)

 FOR VALUE RECEIVED, the foregoing Warrant and all
rights evidenced thereby are hereby assigned to 
  

			
	 Name:
	  	   

	 	  	(Please Print)
		
	Address:	  	 
		
		  	(Please Print)

 Dated:
                                    ,
20         
 Holder’s 
 Signature:
                                         
                                         
     
 Holder’s 
 Address:
                                         
                                         
       
 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the
face of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

EXHIBIT A-2 
 Form of Tranche 2-B Warrant 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

 
 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER
THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION UNDER SUCH LAWS OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN
INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ALL APPLICABLE STATE
SECURITIES LAWS. 
 WARRANT TO PURCHASE COMMON STOCK 

(TRANCHE 2-B) 
  

			
	NO.__	 	                ___,2012


THIS CERTIFIES THAT, for value received, Diamond Alternative Energy, LLC, with its
principal office at One Valero Way, San Antonio, Texas 78249, or its assigns (the “Holder”), is entitled to subscribe for and purchase from MASCOMA CORPORATION, a Delaware corporation (the “Company” ),
with its principal office at 67 Etna Road, Suite 300, Lebanon, NH 03766, 5,333,333 shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”) (such number of shares, as adjusted pursuant to the
provisions hereof, the “Shares”) at the Exercise Price (as defined below) (the “Warrant”). 
 This Warrant is being issued in connection with the Warrant Purchase Agreement, by and between the Holder and the Company (the “Warrant Purchase Agreement”). Capitalized terms used
herein but not defined herein shall have the meanings ascribed to them in the Warrant Purchase Agreement. 

1.    DEFINITIONS. As used herein, the following terms shall have the following respective
meanings: 
 (a)     “Change of Control” shall mean (i) any
consolidation or merger of the Company with another corporation, which is effected such that the Company’s stockholders as of immediately preceding such transaction or series of related transactions own less than 50% of the voting securities of
the surviving entity immediately after such transaction or transactions (provided that this shall exclude any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by the Company or any
successor (including, without limitation, the offering currently contemplated by the Company) or indebtedness of the 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


Company is cancelled or converted, any joint ventures involving the Company, any transaction to change the Company’s jurisdiction of incorporation or similar transactions, or a combination
thereof), or (ii) the sale of all or substantially all of its assets to another corporation, whether in one transaction or a series of related transactions. 
 (b)    “Exercise Period” shall mean the period commencing on the date hereof and ending on the Expiration Date. 

(c)    “Exercise Price” shall mean $3.75 per share, subject to adjustment pursuant to
Section 6 below. 
 2.    EXPIRATION DATE. This Warrant shall
terminate and will have no further force or effect on the earlier of (i) the fifth-year anniversary of the date hereof, or (ii) the consummation of a Change of Control (the “Expiration Date”). 

3.    EXERCISE OF WARRANT. The rights represented by this Warrant
may be exercised in whole or in part at any time during the Exercise Period, by delivery of the following to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder): 

(a)    An executed Notice of Exercise in the form attached hereto (the “Notice of
Exercise”); 
 (b)    Payment of the Exercise Price either (i) in cash or by check
or wire transfer, (ii) by cancellation of indebtedness; or (iii) by net exercise pursuant to Section 3.1 and 

(c)    This Warrant. 
 Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Shares so purchased, registered in the name of the Holder or persons affiliated with the Holder, if the
Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised. 
 If, prior to the Expiration Date, the Holder exercises this Warrant for less than all of the Shares, the Company, upon receipt of this Warrant for cancellation, shall issue a new Warrant to Holder
representing the balance of the Shares. 
 The person in whose name any certificate or certificates for Shares are to be issued
upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate
or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next
succeeding date (which date shall be not more than seven (7) days after the date of such surrender and payment) on which the stock transfer books are open. 
 3.1    Net Exercise. Notwithstanding any provisions herein to the contrary, if the fair market value of one share of the Company’s Common Stock issuable hereunder is


  
 2 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  


greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may elect to receive shares equal to the value
(as determined below) of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Notice of Exercise in which event the Company shall issue to the
Holder a number of shares of Common Stock computed using the following formula: 
  

					
		
				  	X = Y (A-B)
		
				  	        A
		
	 	Where X =	  	  	the number of Shares to be issued to the Holder
		
	 	Y =	  	  	the number of shares of Common Stock purchasable under the Warrant or,
				  	if only a portion of the Warrant is being exercised, the portion of the
				  	Warrant being canceled (at the date of such calculation)
		
	 	A =	  	  	the fair market value of one share of the Company’s Common Stock
				  	purchasable under the Warrant (at the date of such calculation)
		
	 	B =	  	  	Exercise Price (as adjusted to the date of such calculation)

 For purposes of the above calculation, the fair market value per share of Common Stock shall be the average
of the closing prices of the Common Stock, on the securities exchange on which such Common Stock is traded following the Securities Act of 1933, as amended (the “Act”) (the
“Initial Public Offering”), for five trading days immediately prior to the exercise date. If the Common Stock is not then traded on a securities exchange, then the fair market value per share of
Common Stock shall be determined in good faith by the Company’s Board of Directors. 

4.     COVENANTS OF THE COMPANY. 

4.1 Covenants as to Shares. The Company covenants and agrees that all Shares that may be issued upon the exercise of the rights
represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the
Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant. If at any time
during the Exercise Period the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to
increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes. 

4.2 No Impairment. Except and to the extent as waived or consented to by the Holder, the Company will not, by amendment of its
certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Warrant and in the taking of all 

  
 3 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

such action as may be necessary or appropriate in order to protect the exercise rights of the Holder against impairment. 

4.3     Notices of Record Date. In the event of any taking by the Company of a record of the holders of any
class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarters) or other distribution, the Company shall mail
to the Holder, at least ten (10) days prior to such record date, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution. 

5.    REPRESENTATIONS OF HOLDER. 

5.1    Acquisition of Warrant for Personal Account. The Holder represents and warrants that it is acquiring
the Warrant and the Shares solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Shares or any part thereof. The Holder also represents that the entire legal and beneficial interests of the
Warrant and Shares the Holder is acquiring is being acquired for, and will be held for, its account only. The Holder further represents that it is an “Accredited Investor” as defined in Rule 501(a) of Regulation D under the Act.

 5.2    Securities Are Not Registered. 

    (a)     The Holder understands that the Warrant and the Shares have not been
registered under the Act on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its representations, the Holder
has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities. The Holder has
no such present intention. 
     (b)    The Holder recognizes that the Warrant
and the Shares must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The Holder recognizes that, except as contemplated by the Third Amended and Restated Registration
Rights Agreement, dated as of August 31, 2010, by and among the Company and the other parties thereto, as amended, the Company has no obligation to register the Warrant or the Shares of the Company, or to comply with any exemption from such
registration. 
     (c)    The Holder is aware that neither the Warrant nor the
Shares may be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of certain current public information about the
Company, the resale following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations. Holder is aware that the conditions for resale set forth in Rule 144 have
not been satisfied. 
 5.3    Disposition of Warrant and Shares. 

  
 4 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

(a)    The Holder further agrees not to make any disposition of all or any part of the Warrant or Shares in
any event unless and until: 
 (i)    The Company shall have received a letter secured by the Holder
from the Securities and Exchange Commission (the “Commission”) stating that no action will be recommended to the Commission with respect to the proposed disposition; 

(ii)    There is then in effect a registration statement under the Act covering such proposed disposition and
such disposition is made in accordance with said registration statement; or 
 (iii)    The Holder
shall have notified the Company of the proposed disposition and shall have furnished the Company with a reasonably detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder
shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, for the Holder to the effect that such disposition will not require registration of such Warrant or Shares under the Act or any applicable state
securities laws. 
 Notwithstanding the provisions of paragraphs (i), (ii) and (iii) above, no such registration statement or opinion
of counsel shall be necessary for a transfer by a Holder that is (A) a partnership transferring to its partners or former partners in accordance with partnership interests or to an affiliate of such partnership, (B) a corporation
transferring to a wholly-owned subsidiary or a parent corporation that owns all of the capital stock of the Holder, (C) a limited liability company transferring to its members or former members in accordance with their interest in the limited
liability company or to an affiliate of such limited liability company, or (D) an individual transferring to the Holder’s family member or trust for the benefit of an individual Holder; provided that in
each case the transferee will be subject to the terms of this Warrant to the same extent as if it were an original Holder hereunder. 
 (b)    The Holder understands and agrees that all certificates evidencing the shares to be issued to the Holder may bear the following legend: 

“THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION
UNDER SUCH LAWS OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN
OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS.” 

  
 5 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

6.    Adjustments. Subject to the expiration of this Warrant pursuant to Section 2, the number and kind of
shares purchasable hereunder and the Exercise Price therefor are subject to adjustment from time to time, as follows: 
 (a)
Merger or Reorganization. If at any time there shall be any reorganization, recapitalization, merger or consolidation (a “Reorganization”) involving the Company (other than as otherwise provided for herein
or as would cause the expiration of this Warrant pursuant to Section 2) in which shares of the Company’s stock are converted into or exchanged for securities, cash or other property, then, as a part of such Reorganization, lawful provision
shall be made so that the Holder shall thereafter be entitled to receive upon exercise of this Warrant, the kind and amount of securities, cash or other property of the successor corporation resulting from such Reorganization, equivalent in value to
that which a holder of the Shares deliverable upon exercise of this Warrant would have been entitled in such Reorganization if the right to purchase the Shares hereunder had been exercised immediately prior to such Reorganization, and appropriate
adjustment shall be made to the Exercise Price. In any such case, appropriate adjustment (as determined in good faith by the board of directors of the successor corporation) shall be made in the application of the provisions of this Warrant with
respect to the rights and interests of the Holder after such Reorganization to the end that the provisions of this Warrant shall be applicable after the event, as near as reasonably may be, in relation to any shares or other securities deliverable
after that event upon the exercise of this Warrant. The Company will give Holder at least five (5) business days prior notice of the record date for any such Reorganization and at least five (5) business days prior notice of the closing of
such Reorganization. 
 (b) Reclassification of Shares. If the securities issuable upon exercise of this
Warrant are changed into the same or a different number of securities of any other class or classes by reclassification, capital reorganization, conversion of all outstanding shares of the relevant class or series or otherwise (other than as
otherwise provided for herein or as would cause the expiration of this Warrant pursuant to Section 2) (a “Reclassification”), then, in any such event, in lieu of the number of Shares which the Holder would otherwise have
been entitled to receive, the Holder shall have the right thereafter to exercise this Warrant for a number of shares of such other class or classes of stock that a holder of the number of securities deliverable upon exercise of this Warrant
immediately before that change would have been entitled to receive in such Reclassification and appropriate adjustment shall be made to the Exercise Price, all subject to further adjustment as provided herein with respect to such other shares. The
Company will give Holder at least five (5) business days prior notice of the record date for any such Reclassification and at least five (5) business days prior notice of the closing of any such Reclassification. 

(c) Subdivisions and Combinations. In the event that the outstanding shares of Common Stock are subdivided (by
stock split, by payment of a stock dividend or otherwise) into a greater number of shares of such securities, the number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such subdivision shall, concurrently with
the effectiveness of such subdivision, be proportionately increased, and the Exercise Price shall be proportionately decreased, and in the event that the outstanding shares of Common Stock are combined (by reclassification or otherwise) into a
lesser number of shares of such securities, the number of Shares issuable upon exercise of the rights under this Warrant 

  
 6 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

immediately prior to such combination shall, concurrently with the effectiveness of such combination, be proportionately decreased, and the Exercise Price
shall be proportionately increased. 
 (d)    Notice of Adjustments. Upon any
adjustment in accordance with this Section 6, the Company shall give notice thereof to the Holder, which notice shall state the event giving rise to the adjustment, the Exercise Price as adjusted and the type and number of securities or other
property purchasable upon the exercise of the rights under this Warrant, setting forth in reasonable detail the method of calculation of each. The Company shall, upon the written request of any Holder, furnish or cause to be furnished to such Holder
a certificate setting forth (i) such adjustments, (ii) the Exercise Price at the time in effect and (iii) the type and number of securities and the amount, if any, of other property that at the time would be received upon exercise of
this Warrant. 
 7.    TREATMENT OF WARRANT ON
CHANGE OF CONTROL. Notwithstanding anything to the contrary contained herein, to the extent this Warrant is not previously exercised, and if the fair market value of one share of Common Stock is
greater than the Exercise Price then in effect, this Warrant shall be deemed automatically exercised (even if not surrendered) pursuant to Section 3.1 immediately prior to the consummation of a Change of Control. Otherwise, if the Warrant is
not deemed automatically exercised pursuant to this provision, the Warrant will expire upon the consummation of such Change of Control. To the extent this Warrant or any portion thereof is deemed automatically exercised prior to a Change of Control,
the Company agrees to promptly notify the Holder of the number of shares of Common Stock or other consideration in connection with any such Change of Control, if any, the Holder is to receive by reason of such automatic exercise. For the avoidance
of doubt, the order of actions upon a Change of Control in reference to the phrase “immediately prior to the consummation of a Change of Control” herein and in the Warrant Purchase Agreement means the issuance of this Warrant pursuant to
the Warrant Purchase Agreement and immediately thereafter the exercise of this Warrant pursuant to this Section 7. 

8.    FRACTIONAL SHARES. No fractional shares shall be issued upon the exercise
of this Warrant as a consequence of any adjustment pursuant hereto. All Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of any
fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the
product resulting from multiplying the then current fair market value of a Share by such fraction. 

9.    NO STOCKHOLDER RIGHTS. This Warrant in and
of itself shall not entitle the Holder to any voting rights or other rights as a stockholder of the Company. 

10.    TRANSFER OF WARRANT. Subject to applicable laws and the
restriction on transfer set forth in this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of assignment attached hereto to any
transferee designated by Holder. The transferee shall sign an investment letter in form and substance reasonably satisfactory to the Company. 

  
 7 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

11.    LOST, STOLEN, MUTILATED OR
DESTROYED WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant,
include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the
allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 
 NOTICES,
ETC. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by facsimile if sent during
normal business hours of the recipient, if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after
deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company or to Holder at its address listed on the first page of this Warrant or at
such other address as the Company or Holder may designate by ten (10) days advance written notice to the other parties hereto. The Company’s fax number is (603) 676-3321, and the Investor’s fax number is (210) 345-2270.

 12.    ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute
acceptance of and agreement to all of the terms and conditions contained herein. 

13.    AMENDMENT AND WAIVER. Any term of this Warrant may be
amended or waived with the written consent of the Company and the Holder. 

14.    GOVERNING LAW. This Warrant and all rights, obligations and liabilities
hereunder shall be governed by, and construed and enforced in accordance with, the substantive laws of the State of Delaware without regard to its principles of conflicts of laws. 

[SIGNATURE PAGE FOLLOWS] 

  
 8 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly
authorized officer as of the date first written above. 
  

			
	MASCOMA CORPORATION
		
	 By:
	 	 
		
	 Name:
	 	 
		
	 Title:
	 	 


  

			
	DIAMOND ALTERNATIVE ENERGY, LLC
		
	 By:
	 	 
		
	 Name:
	 	 
		
	 Title:
	 	 


 SIGNATURE PAGE TO WARRANT








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

NOTICE OF EXERCISE 
 (1)      ̈    The undersigned hereby elects to purchase
        shares of Common Stock (the “Shares”) of Mascoma Corporation (the “Company”) pursuant to the terms of the attached Warrant, and
tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. 

           ̈    The
undersigned hereby elects to purchase         Shares of the Company pursuant to the terms of the net exercise provisions set forth in Section 3.1 of the attached Warrant, and shall tender payment
of all applicable transfer taxes, if any. 
 (2)     Please issue a certificate or certificates
representing said shares of the Shares in the name of the undersigned or in such other name as is specified below: 
  

					
		 	 	  	
		 	(Name)	  	
		 	 	  	
			
		 	 	  	
		 	(Address)	  	

 (3)     The undersigned represents that (i) the aforesaid Shares are
being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares;
(ii) the undersigned is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company;
(iii) the undersigned is experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting
the undersigned’s own interests; (iv) the undersigned understands that the Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”),
by reason of a specific exemption from the registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been
registered under the Securities Act, they must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the aforesaid Shares may not be
sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met and until the undersigned has held the shares for the period prescribed by Rule 144, that among the conditions for use of the Rule is the availability of
current information to the public about the Company; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid Shares unless and until there is then in effect a registration statement under the Securities
Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or, if reasonably requested by the Company, the undersigned has provided the Company with an opinion of counsel reasonably
satisfactory to the Company, stating that such registration is not required. 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

							
	 (Date)
	 		 	(Signature)
			
		 		 	
		 		 	(Print name)








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

ASSIGNMENT FORM 
  

					
		  	 (To assign the foregoing Warrant, execute this form
 and supply required information. Do not use this
 form to purchase shares.)


 FOR VALUE RECEIVED, the foregoing Warrant and all
rights evidenced thereby are hereby assigned to 
  

			
	Name:	  	
		  	(Please Print)
	Address:	  	
		  	(Please Print)

 Dated:                 ,
20     
  

			
	 Holder’s

Signature:                
                                         
           

		 	
	 Holder’s

Address:                 
                                         
          


 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the
Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant. 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

EXHIBIT B 
 Disclosure Schedule 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

EXHIBIT C 
 Amendment to Certificate of Incorporation 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

SECOND CERTIFICATE OF AMENDMENT 
 TO 
 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION 

OF 

MASCOMA CORPORATION 
 [            ], 2012 
 Mascoma
Corporation (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 

1.     Pursuant to Section 242 of the DGCL, this Second Certificate of Amendment to the Eighth Amended and
Restated Certificate of Incorporation (this “Amendment”) amends the provisions of the Eighth Amended and Restated Certificate of Incorporation of the Company, as previously amended on January 7, 2011 (the
“Certificate”). 
 2.     This Amendment has been approved and adopted by the
Company’s Board of Directors and written consent has been given in accordance with the provisions of Sections 228 and 242 of the DGCL, and the provisions of the Certificate. 

3.     The Certificate is hereby amended by striking out the first paragraph of Article Fourth thereof and by
substituting in lieu of said paragraph the following new paragraph: 
 “The total number of shares of all
classes of capital stock that the Corporation shall have authority to issue is (i) [            ] shares of Common Stock, $0.001 par value per share (“Common Stock”), and
(ii) [            ] shares of Preferred Stock, $0.001 par value per share (“Preferred Stock”), of which: (A) 5,000,000 of such shares of Preferred Stock are
designated as shares of Series A Preferred Stock (the “Series A Preferred”), (B) 5,162,500 of such shares of Preferred Stock are designated as shares of Series A1 Preferred Stock (the “Series A1 Preferred”),
(C) 11,498,128 of such shares of Preferred Stock are designated as shares of Series B Preferred Stock (the “Series B Preferred”), (D) [9,988,356][NOTE: This number is subject to revision] of such shares of Preferred Stock
are designated as shares of Series C Preferred Stock (the “Series C Preferred”) and (E) 17,996,223 of such shares of Preferred Stock are designated as shares of Series D Preferred Stock (the “Series D
Preferred”), each with the rights and preferences set forth below.” 
 4.     The Certificate
is hereby further amended as follows: 
 (a) The “and” prior to Article Fourth, Section B, Subsection 3(e)(i)(4)(L) is
hereby deleted, and the period after Article Fourth, Section B, Subsection 3(e)(i)(4)(L) is replaced with; “and”. 







 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

(b) The following is added as Article Fourth, Section B, Subsection 3(e)(i)(4)(M) of the Certificate: 

 

	 	“(L)	Shares issuable upon exercise of the following warrants issued to Diamond Alternative Energy, LLC (“DAE”) pursuant to a Warrant Purchase Agreement by
and between the Corporation and DAE: (i) Warrant to Purchase Common Stock exercisable for up to 3,164,557 shares of Common Stock (subject to adjustment as provided in therein) and (ii) Warrant to Purchase Common Stock exercisable for up to
5,333,333 shares of Common Stock (subject to adjustment as provided in therein).” 

 5.
      This Second Certificate of Amendment to the Amended and Restated Certificate of Incorporation herein certified has been duly adopted and written consent has been given in accordance with the provisions of Sections
228 and 242 of the General Corporation Law of the State of Delaware. 

  
 2 








 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION
PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 
  

 
 Signed
on                    , 2012 
  

	
	MASCOMA CORPORATION
	
	  
	Name: William J. Brady
	Title: President and Chief Executive Officer